{"questions": [{"id": "6402c910201352f04a00000c", "type": "yesno", "body": "Can losartan reduce brain atrophy in Alzheimer's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31026619", "http://www.ncbi.nlm.nih.gov/pubmed/20838622", "http://www.ncbi.nlm.nih.gov/pubmed/34687634", "http://www.ncbi.nlm.nih.gov/pubmed/29226862", "http://www.ncbi.nlm.nih.gov/pubmed/31135048", "http://www.ncbi.nlm.nih.gov/pubmed/19416949", "http://www.ncbi.nlm.nih.gov/pubmed/8915036", "http://www.ncbi.nlm.nih.gov/pubmed/34927073", "http://www.ncbi.nlm.nih.gov/pubmed/21512418", "http://www.ncbi.nlm.nih.gov/pubmed/20620665", "http://www.ncbi.nlm.nih.gov/pubmed/27389178", "http://www.ncbi.nlm.nih.gov/pubmed/31219516", "http://www.ncbi.nlm.nih.gov/pubmed/34842769", "http://www.ncbi.nlm.nih.gov/pubmed/34948942", "http://www.ncbi.nlm.nih.gov/pubmed/21174483", "http://www.ncbi.nlm.nih.gov/pubmed/12477704", "http://www.ncbi.nlm.nih.gov/pubmed/17347250", "http://www.ncbi.nlm.nih.gov/pubmed/32176777", "http://www.ncbi.nlm.nih.gov/pubmed/33150361"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34687634", "text": "INTERPRETATION\n12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease.", "offsetInBeginSection": 2590, "offsetInEndSection": 2740, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31026619", "text": "It is currently unknown whether brain atrophy subtypes defined in Alzheimer's disease are clinically relevant during aging. We investigated participan", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29226862", "text": "ing visits.\n\n\nCONCLUSION\nThis study will identify whether losartan is efficacious in the treatment of AD and whether definitive Phase III trials are w", "offsetInBeginSection": 1846, "offsetInEndSection": 1996, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12477704", "text": "Patients with Alzheimer's disease have higher plasma homocysteine levels than controls, but it is uncertain whether higher plasma homocysteine levels are involved in the early pathogenesis of the disease.", "offsetInBeginSection": 72, "offsetInEndSection": 222, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20620665", "text": "ging initiative (ADNI) dataset to assess if adjusting for baseline characteristics can reduce sample sizes. Controls (n = 199), patients with mild cog", "offsetInBeginSection": 142, "offsetInEndSection": 292, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34842769", "text": "Since brain atrophy leads to irreversible cognitive decline and dementia, an optimal nutritional solution should be able to not only enhance cognitive function during aging but also reduce irreversible brain atrophy.", "offsetInBeginSection": 960, "offsetInEndSection": 1110, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31135048", "text": "Medial temporal sparing in non-amnestic Alzheimer's disease may thus be due in part to later onset of medial temporal degeneration than in amnestic patients rather than different rates of atrophy over time.", "offsetInBeginSection": 2293, "offsetInEndSection": 2449, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20838622", "text": " mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitiv", "offsetInBeginSection": 1933, "offsetInEndSection": 2083, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20620665", "text": "Treatment trials in AD should consider the effects of normal aging; adjusting for baseline characteristics can significantly reduce required sample sizes.", "offsetInBeginSection": 1248, "offsetInEndSection": 1398, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34927073", "text": "However, the relative contribution of these pathological hallmarks to cortical atrophy, a widely used MRI biomarker in Alzheimer's disease, is yet to be defined.", "offsetInBeginSection": 166, "offsetInEndSection": 318, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34687634", "text": "lacebo daily for 12 months. Randomisation, minimised by age and baseline medial temporal lobe atrophy score, was undertaken online or via pin-access s", "offsetInBeginSection": 1078, "offsetInEndSection": 1228, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32176777", "text": "ex neurological symptoms in patients with focal brain lesions localize to brain networks. Here, we use a new technique termed 'atrophy network mapping", "offsetInBeginSection": 390, "offsetInEndSection": 540, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31135048", "text": "However, it is unclear whether such models are applicable in non-amnestic Alzheimer's disease, which is associated with domain-specific cognitive deficits and relatively spared episodic memory.", "offsetInBeginSection": 172, "offsetInEndSection": 322, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34687634", "text": "We investigated whether the angiotensin II receptor antagonist losartan, compared with placebo, could reduce brain volume loss, as a measure of disease progression, in clinically diagnosed mild-to-moderate Alzheimer's disease.", "offsetInBeginSection": 185, "offsetInEndSection": 335, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17347250", "text": "oth significantly greater than the DLB group. There was no significant difference in the rates of atrophy between the Alzheimer's disease, mixed Alzhe", "offsetInBeginSection": 1899, "offsetInEndSection": 2049, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21512418", "text": " Vitamin B supplements, such as folate, may help prevent homocysteine-related atrophy in Alzheimer's disease by possibly reducing homocysteine levels.", "offsetInBeginSection": 604, "offsetInEndSection": 754, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12477704", "text": "These results support the hypothesis that higher plasma homocysteine levels are associated with more atrophy of the hippocampus and cortical regions in elderly at risk of Alzheimer's disease.", "offsetInBeginSection": 1508, "offsetInEndSection": 1658, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33150361", "text": "in regions and whether there is evidence for protein-associated acceleration/deceleration of atrophy rates. We therefore aimed to model how these prot", "offsetInBeginSection": 811, "offsetInEndSection": 961, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8915036", "text": " This atrophy was similar in magnitude to that seen in Alzheimer's disease and is likely to be the anatomical substrate for the memory deficits found in each of these patients groups", "offsetInBeginSection": 427, "offsetInEndSection": 609, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33150361", "text": "The results suggest that TDP-43 and tau have different contributions to acceleration and deceleration of brain atrophy rates over time in both Alzheimer's disease and primary age-related tauopathy.", "offsetInBeginSection": 2612, "offsetInEndSection": 2762, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34948942", "text": "for Alzheimer's prevention. Even so, research has shown that we can take steps to reduce the risk of developing it. Prospective studies have found tha", "offsetInBeginSection": 1325, "offsetInEndSection": 1475, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19416949", "text": " Our results suggest that imaging-based spatial patterns of brain atrophy of Alzheimer's disease, evaluated with sophisticated pattern analysis and recognition methods, may be useful in discriminating among CN individuals who are likely to be stable versus those who will show cognitive decline", "offsetInBeginSection": 1767, "offsetInEndSection": 2061, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27389178", "text": "ncoupling response to sensory stimulation. The cognitive deficits of A/T mice were not restored by losartan nor were the increased brain levels of sol", "offsetInBeginSection": 683, "offsetInEndSection": 833, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21174483", "text": "Since the hippocampus is a plastic structure and atrophy of this structure is closely related to the pathophysiology of Alzheimer's disease, if we could control blood pressure, regulate blood sugar, treat behavioural and psychological symptoms, achieve satisfactory lipid lowering and maintain a seizure-free state in patients with Alzheimer's disease, this may not only improve disease control but could also potentially affect the rate of disease progression.", "offsetInBeginSection": 3430, "offsetInEndSection": 3640, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20838622", "text": "ive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins.\n\n\nOBJECTIVE\nTo determine wh", "offsetInBeginSection": 193, "offsetInEndSection": 343, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31219516", "text": "osterior cortical atrophy, the syndrome can provide important insights into selective vulnerability and phenotypic diversity. The present study descri", "offsetInBeginSection": 293, "offsetInEndSection": 443, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31026619", "text": " significant predictive factors. As a possible surrogate of confined tauopathy and early Alzheimer's disease pathology, future studies should consider", "offsetInBeginSection": 1070, "offsetInEndSection": 1220, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640f857d201352f04a00002b", "type": "factoid", "body": "What is CHARMS with respect to medical review of predictive modeling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33364802", "http://www.ncbi.nlm.nih.gov/pubmed/36149932", "http://www.ncbi.nlm.nih.gov/pubmed/35878479", "http://www.ncbi.nlm.nih.gov/pubmed/35073384", "http://www.ncbi.nlm.nih.gov/pubmed/35493941", "http://www.ncbi.nlm.nih.gov/pubmed/31441567", "http://www.ncbi.nlm.nih.gov/pubmed/34757383", "http://www.ncbi.nlm.nih.gov/pubmed/33594834", "http://www.ncbi.nlm.nih.gov/pubmed/32583899", "http://www.ncbi.nlm.nih.gov/pubmed/31762119", "http://www.ncbi.nlm.nih.gov/pubmed/31090660", "http://www.ncbi.nlm.nih.gov/pubmed/33492724", "http://www.ncbi.nlm.nih.gov/pubmed/32914178", "http://www.ncbi.nlm.nih.gov/pubmed/31439598"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/31762119", "text": "However, these models should be developed appropriately (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies [CHARMS] and Prediction model Risk Of Bias ASsessment Tool [PROBAST] statements).", "offsetInBeginSection": 116, "offsetInEndSection": 266, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31439598", "text": "Data was extracted following the Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.", "offsetInBeginSection": 690, "offsetInEndSection": 840, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35878479", "text": "We aim to assess how functioning, depressive symptoms, and psychotic symptoms are associated with different numbers of Clinical High At-Risk Mental State (CHARMS) categories.", "offsetInBeginSection": 61, "offsetInEndSection": 211, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33492724", "text": "We followed the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information from its 11 domains (Source of data, Participants, etc).", "offsetInBeginSection": 405, "offsetInEndSection": 555, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32583899", "text": "The CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist was created to provide methodological appraisals of predictive models, based on the best available scientific evidence and through systematic reviews.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660", "text": "Studies were assessed using the checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist.", "offsetInBeginSection": 389, "offsetInEndSection": 539, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35493941", "text": "We used the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS) checklist for the risk of bias assessment.", "offsetInBeginSection": 864, "offsetInEndSection": 1014, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33594834", "text": "tems from the CHEERS checklist for economic evaluations and the CHARMS checklist for evaluation of prediction studies.\n\n\nRESULTS\nFrom 38 selected stud", "offsetInBeginSection": 960, "offsetInEndSection": 1110, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33364802", "text": "A checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) and the prediction model risk of bias assessment tool (PROBAST) were used for the data extraction process and critical appraisal.", "offsetInBeginSection": 517, "offsetInEndSection": 667, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36149932", "text": "Two authors independently assessed studies for inclusion and undertook data extraction following recommendations of the CHARMS checklist, while quality assessment was performed using the PROBAST tool.", "offsetInBeginSection": 1027, "offsetInEndSection": 1177, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31441567", "text": "For each model, we analysed (domains of CHARMS, Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) the following: source of data, participants, outcome to be predicted, candidate predictors, sample size, missing data, model development, model performance, model evaluation, results and interpretation and discussion.", "offsetInBeginSection": 461, "offsetInEndSection": 611, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32914178", "text": "ng to treatments (predictive) in mental disorders.\n\n\nMETHODS\nPRISMA/RIGHT/CHARMS-compliant systematic review of the Web of Science, Cochrane Central R", "offsetInBeginSection": 314, "offsetInEndSection": 464, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35073384", "text": "ssing medical researchers. The aim of this review was to assess the current level of knowledge with regard to regression modeling contained in such st", "offsetInBeginSection": 564, "offsetInEndSection": 714, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34757383", "text": "s with 35 models for evaluation. Models focused on surgical (22), medical (5), or both (8) populations. Eighteen models were internally validated, 10 ", "offsetInBeginSection": 901, "offsetInEndSection": 1051, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410eb95201352f04a00002e", "type": "list", "body": "Which splicing factors have been associated with alternative splicing in PLN R14del hearts?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36375644", "http://www.ncbi.nlm.nih.gov/pubmed/35191471", "http://www.ncbi.nlm.nih.gov/pubmed/34383135"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36375644", "text": "Bioinformatical analysis pointed to the tissue-specific splicing factors Srrm4 and Nova1 as likely upstream regulators of the observed splicing changes in the PLN-R14del cardiomyocytes.", "offsetInBeginSection": 1271, "offsetInEndSection": 1421, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35191471", "text": "Challenge of ex vivo hearts with isoproterenol and rapid pacing unmasked higher propensity for sustained ventricular tachycardia (VT) in hPLN-R14del relative to hPLN-WT.", "offsetInBeginSection": 914, "offsetInEndSection": 1064, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34383135", "text": "ternative splicing subtype. Splicing factors that differentially expressed and alternatively spliced could result in global alternative splicing. Glob", "offsetInBeginSection": 803, "offsetInEndSection": 953, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64162fb0690f196b5100001a", "type": "list", "body": "What are the most common mutation types in Duchenne muscular Dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29581631", "http://www.ncbi.nlm.nih.gov/pubmed/10422002", "http://www.ncbi.nlm.nih.gov/pubmed/33741226", "http://www.ncbi.nlm.nih.gov/pubmed/19555515", "http://www.ncbi.nlm.nih.gov/pubmed/23620649", "http://www.ncbi.nlm.nih.gov/pubmed/33039804"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33741226", "text": "ssociated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder. These have been observed with higher freq", "offsetInBeginSection": 135, "offsetInEndSection": 285, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23620649", "text": "The Duchenne Muscular dystrophy (DMD) is the most frequent muscle disorder in childhood caused by mutations in the Xlinked dystrophin gene (about 65% deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations).", "offsetInBeginSection": 115, "offsetInEndSection": 265, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33039804", "text": "in children and is clinically characterized by progressive muscle degeneration and severe cardiomyopathy. In this study, renal epithelial cells were o", "offsetInBeginSection": 134, "offsetInEndSection": 284, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19555515", "text": "d wasting. The most common are Duchenne muscular dystrophy and Becker muscular dystrophy, which result from mutations within the gene encoding dystrop", "offsetInBeginSection": 116, "offsetInEndSection": 266, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10422002", "text": "ivity were found in both diseases. Spontaneous activity--bizarre and fibrillation potentials, as well as sharp waves are more common for Duchenne type", "offsetInBeginSection": 773, "offsetInEndSection": 923, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29581631", "text": "BACKGROUND\nNonsense mutations in the dystrophin gene usually result in a severe Duchenne muscular dystrophy phenotype.\n\n\nFINDINGS\nWe describe a 7-year", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eef3ebf36125a42600000a", "type": "factoid", "body": "What is the target of Litifilimab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21160809", "http://www.ncbi.nlm.nih.gov/pubmed/23099046", "http://www.ncbi.nlm.nih.gov/pubmed/36069871", "http://www.ncbi.nlm.nih.gov/pubmed/35939578", "http://www.ncbi.nlm.nih.gov/pubmed/1477416", "http://www.ncbi.nlm.nih.gov/pubmed/26670814", "http://www.ncbi.nlm.nih.gov/pubmed/22110496"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36069871", "text": "4, 8, 12, 16, and 20, with the primary end point of evaluating cutaneous lupus activity. The trial design was subsequently modified; adults with SLE, ", "offsetInBeginSection": 686, "offsetInEndSection": 836, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939578", "text": "ne the effect and safety of litifilimab for the treatment of cutaneous lupus erythematosus. (Funded by Biogen; LILAC ClinicalTrials.gov number, NCT028", "offsetInBeginSection": 2523, "offsetInEndSection": 2673, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1477416", "text": "ctivate already activated T cells remains unclear. Assuming that the T lymphocyte is the target site for CS, local therapy reaches only a small fracti", "offsetInBeginSection": 997, "offsetInEndSection": 1147, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26670814", "text": "Thus, recent data suggest that avoiding hyperpyrexia, rather than cooling \"per se,\" may be considered the main therapeutic target to avoid secondary brain damage after out-of-hospital cardiac arrest.", "offsetInBeginSection": 487, "offsetInEndSection": 637, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36069871", "text": "uired to determine the safety and efficacy of litifilimab for the treatment of SLE. (Funded by Biogen; LILAC ClinicalTrials.gov number, NCT02847598.).", "offsetInBeginSection": 2468, "offsetInEndSection": 2618, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36069871", "text": "CONCLUSIONS\nIn a phase 2 trial involving participants with SLE, litifilimab was associated with a greater reduction from baseline in the number of swollen and tender joints than placebo over a period of 24 weeks.", "offsetInBeginSection": 2287, "offsetInEndSection": 2437, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939578", "text": "CONCLUSIONS\nIn a phase 2 trial involving participants with cutaneous lupus erythematosus, treatment with litifilimab was superior to placebo with regard to a measure of skin disease activity over a period of 16 weeks.", "offsetInBeginSection": 2355, "offsetInEndSection": 2505, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939578", "text": "Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.", "offsetInBeginSection": 260, "offsetInEndSection": 410, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22110496", "text": "Recent publications suggest that target end-tidal carbon dioxide concentrations should be higher than values currently considered as acceptable. This ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21160809", "text": "In this review we aim to explore the therapeutic potential and benefit of target therapy in the management of gastrointestinal soft tissue sarcoma and the possible complications or pitfalls of such an approach.", "offsetInBeginSection": 571, "offsetInEndSection": 721, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23099046", "text": "Based on this methodological motivation, the current experiments tested if the shape of a fixation target can be used to reduce eye movements during fixation.", "offsetInBeginSection": 651, "offsetInEndSection": 801, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64136fbf201352f04a00003d", "type": "factoid", "body": "What is AUROC in context of predictive modeling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32930711", "http://www.ncbi.nlm.nih.gov/pubmed/34865209", "http://www.ncbi.nlm.nih.gov/pubmed/32666900", "http://www.ncbi.nlm.nih.gov/pubmed/35879562", "http://www.ncbi.nlm.nih.gov/pubmed/32689629", "http://www.ncbi.nlm.nih.gov/pubmed/31093546", "http://www.ncbi.nlm.nih.gov/pubmed/28323524", "http://www.ncbi.nlm.nih.gov/pubmed/31304302", "http://www.ncbi.nlm.nih.gov/pubmed/25885260", "http://www.ncbi.nlm.nih.gov/pubmed/36329470", "http://www.ncbi.nlm.nih.gov/pubmed/30815109", "http://www.ncbi.nlm.nih.gov/pubmed/28292743", "http://www.ncbi.nlm.nih.gov/pubmed/34154565", "http://www.ncbi.nlm.nih.gov/pubmed/36447416", "http://www.ncbi.nlm.nih.gov/pubmed/33932935", "http://www.ncbi.nlm.nih.gov/pubmed/27829179", "http://www.ncbi.nlm.nih.gov/pubmed/35353054", "http://www.ncbi.nlm.nih.gov/pubmed/31807867", "http://www.ncbi.nlm.nih.gov/pubmed/31509205", "http://www.ncbi.nlm.nih.gov/pubmed/33026357", "http://www.ncbi.nlm.nih.gov/pubmed/33203588", "http://www.ncbi.nlm.nih.gov/pubmed/35509018", "http://www.ncbi.nlm.nih.gov/pubmed/25958031", "http://www.ncbi.nlm.nih.gov/pubmed/35505048"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35879562", "text": "The predictive accuracy of an individual biomarker on cognitive impairment was evaluated using area under the receiver operating characteristic curve (AUROC), and multivariate logistic regression was applied to evaluate predictive accuracy of biomarkers on cognitive impairment; 178 subjects (41 PD, 31 VaD and 106 normal controls) were included.", "offsetInBeginSection": 360, "offsetInEndSection": 510, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25885260", "text": "Accuracy in prediction of outcome (AC), sensitivity (SN), specificity (SP), and area under receiver-operating curve (AUROC) were compared between 3 models: KCC (INR, creatinine, coma grade, pH), CART analysis using only KCC variables (KCC-CART) and a CART model using new variables (NEW-CART).", "offsetInBeginSection": 652, "offsetInEndSection": 802, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32930711", "text": "RESULTS\nFor logistic regression, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81.15%) and pancreatic cancer (80.53%) tasks.", "offsetInBeginSection": 1005, "offsetInEndSection": 1155, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32689629", "text": "7 Comprehensive Stroke Centers using the area under the receiver operating characteristic curve (AUROC).\n\n\nRESULTS\nIn the derivation group, 448 patien", "offsetInBeginSection": 782, "offsetInEndSection": 932, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25958031", "text": "ndings). Sensitivity, specificity, predictive values and area under receiving operating curves (AUROC) of RBUS for VCUG abnormalities were determined.", "offsetInBeginSection": 1325, "offsetInEndSection": 1475, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34865209", "text": "s). Model performance was assessed using area under the receiver operator characteristic curve (AUROC). Pre-N8-GP prophylaxis models learned from data", "offsetInBeginSection": 598, "offsetInEndSection": 748, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34154565", "text": "iagnostic threshold were evaluated using area under the receiver operating characteristic curve (AUROC). Stratification analysis by age and MP-IgM tit", "offsetInBeginSection": 536, "offsetInEndSection": 686, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35505048", "text": " learning algorithms was assessed by the area under the receiver operating characteristic curve (AUROC). The conventional scoring models had various p", "offsetInBeginSection": 543, "offsetInEndSection": 693, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31509205", "text": " (NPVs), positive predictive values (PPVs), and area under the receiver operating characteristic curve (AUROC), of machine learning models when predic", "offsetInBeginSection": 1023, "offsetInEndSection": 1173, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28292743", "text": "ted from existing clinical data, and the area under the receiver operator characteristic curve (AUROC) compared.\n\n\nSETTING\nUK tertiary referral childr", "offsetInBeginSection": 202, "offsetInEndSection": 352, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27829179", "text": "nd standard (full-version) SOFA score using area under the receiver operating characteristic (AUROC) curve and Brier score.\n\n\nRESULTS\nOf the 2322 pati", "offsetInBeginSection": 477, "offsetInEndSection": 627, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33203588", "text": "sing PubMed, MEDLINE, and Scopus databases. Papers with area under the receiver operating curve (AUROC) scores reported were included in the analysis.", "offsetInBeginSection": 471, "offsetInEndSection": 621, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36329470", "text": "onstruct the prediction model. Finally, the area under the receiver operating characteristic (AUROC) curve was used to compare the model performance.\n", "offsetInBeginSection": 837, "offsetInEndSection": 987, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33026357", "text": "and at home hospitalization discharge, respectively; the AUROC (sensitivity/specificity) values for in-hospital admission were 0.71 (0.67/0.64) and 0.", "offsetInBeginSection": 1359, "offsetInEndSection": 1509, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31304302", "text": "Deep learning models achieved high accuracy for tasks such as predicting: in-hospital mortality (area under the receiver operator curve [AUROC] across sites 0.93-0.94), 30-day unplanned readmission (AUROC 0.75-0.76), prolonged length of stay (AUROC 0.85-0.86), and all of a patient's final discharge diagnoses (frequency-weighted AUROC 0.90).", "offsetInBeginSection": 1029, "offsetInEndSection": 1179, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35509018", "text": "Evaluation metrics methods specifically confusion matrix, accuracy, precision, recall, F1 score, and Area under the\u00a0Receiver Operating Characteristics (AUROC) were used to evaluate the performance of predictive models.", "offsetInBeginSection": 846, "offsetInEndSection": 996, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31093546", "text": "Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive performance ability.", "offsetInBeginSection": 112, "offsetInEndSection": 262, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32666900", "text": "2-VASc and C2HEST score was estimated by area under the receiver operating characteristic curve (AUROC).\n\n\nRESULTS\nThe AUROC for CHA2DS2-VASc score in", "offsetInBeginSection": 386, "offsetInEndSection": 536, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31807867", "text": "RESULTS\nA training set (n\u2009=\u2009200) was used to develop predictive models of the EGFR mutation status (Model 1: area under the receiver operating characteristic curve [AUROC]\u2009=\u20090.910, 95% CI 0.861-0.945; Model 2: AUROC\u2009=\u20090.859, 95% CI 0.803-0.904; Model 3: AUROC\u2009=\u20090.711, 95% CI 0.643-0.773).", "offsetInBeginSection": 652, "offsetInEndSection": 802, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33932935", "text": "Prediction performance of the models was measured by computing areas under the receiver operating characteristic curve (AUROCs), calibration, and confusion matrix metrics (positive predictive value, sensitivity, and specificity) and was subjected to internal bootstrap validation.", "offsetInBeginSection": 1273, "offsetInEndSection": 1423, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35509018", "text": "Evaluation metrics methods specifically confusion matrix, accuracy, precision, recall, F1 score, and Area under the\u00a0Receiver Operating Characteristics (AUROC) were used to evaluate the performance of predictive models.", "offsetInBeginSection": 838, "offsetInEndSection": 988, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36447416", "text": "red to the test set. The model with the highest area under the receiver operating curve (AUROC) was chosen, and important features in the model were i", "offsetInBeginSection": 1064, "offsetInEndSection": 1214, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28323524", "text": "Performance of prediction, accuracy of discrimination (area under the receiver operating characteristic curve [AUROC]), calibration, and validity of the two predictive models were investigated.", "offsetInBeginSection": 645, "offsetInEndSection": 795, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25885260", "text": "D, lactate, coma grade) offered predictive AC 86%, SP 91%, SN 46%, AUROC 0.73.\n\n\nCONCLUSION\nCARTs offer simple prognostic models for APAP-ALF patients", "offsetInBeginSection": 1413, "offsetInEndSection": 1563, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28292743", "text": "demonstrated better overall predictive performance with an AUROC of 0.87 or greater. Comparing each system with the highest performing PEWS with Bonfe", "offsetInBeginSection": 1030, "offsetInEndSection": 1180, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35879562", "text": "n/A\u03b240 (AUROC\u2009=\u20090.749) were significant individual predictors of cognitive impairment. In multivariate logistic regression, full model of combined bio", "offsetInBeginSection": 1276, "offsetInEndSection": 1426, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30815109", "text": " level, heparin administration) and 27 of them had AUROC values of greater than 0.7. These results are encouraging considering the high variation in i", "offsetInBeginSection": 506, "offsetInEndSection": 656, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31509205", "text": "g machine learning models predicted normal results with an AUROC of 0.90 or greater for 12 stand-alone laboratory tests (eg, sodium AUROC, 0.92 [95% C", "offsetInBeginSection": 1810, "offsetInEndSection": 1960, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35353054", "text": "ks, and recursive partitioning (RP). The area under the receiver operating characteristic curve (AUROC) indicated the performance of the models. The m", "offsetInBeginSection": 956, "offsetInEndSection": 1106, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33026357", "text": " area under the receiver operating characteristic curve (AUROC; sensitivity/specificity) for the prediction of mortality were 0.88 (0.81/0.76) and 0.8", "offsetInBeginSection": 1186, "offsetInEndSection": 1336, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63fa13da201352f04a000001", "type": "yesno", "body": "Is PRP-40 regulation of microexons a conserved phenomenon?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30833759", "http://www.ncbi.nlm.nih.gov/pubmed/30404949", "http://www.ncbi.nlm.nih.gov/pubmed/1765104", "http://www.ncbi.nlm.nih.gov/pubmed/19129193", "http://www.ncbi.nlm.nih.gov/pubmed/34346508", "http://www.ncbi.nlm.nih.gov/pubmed/33482885", "http://www.ncbi.nlm.nih.gov/pubmed/9301433", "http://www.ncbi.nlm.nih.gov/pubmed/25525873", "http://www.ncbi.nlm.nih.gov/pubmed/12043842", "http://www.ncbi.nlm.nih.gov/pubmed/32535349", "http://www.ncbi.nlm.nih.gov/pubmed/19451655", "http://www.ncbi.nlm.nih.gov/pubmed/19278297", "http://www.ncbi.nlm.nih.gov/pubmed/34348142", "http://www.ncbi.nlm.nih.gov/pubmed/33621242"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33621242", "text": "Microexons are extremely small exons (3-27 nucleotides long) that are highly evolutionarily conserved and play critical roles in promoting neuronal differentiation and development.", "offsetInBeginSection": 133, "offsetInEndSection": 283, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9301433", "text": "Results from the present study might indicate seasonal variation in the regulation of constitutive nitric oxide synthetase in women with PRP, which may contribute to new therapeutic approaches.", "offsetInBeginSection": 1464, "offsetInEndSection": 1614, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142", "text": "d dysregulation of microexons but not conventionally sized exons. PRP-40 regulation of neuronal microexons is therefore a widely conserved phenomenon.", "offsetInBeginSection": 945, "offsetInEndSection": 1095, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33482885", "text": "BACKGROUND\nMicroexons, exons that are \u2264\u200930 nucleotides, are a highly conserved and dynamically regulated set of cassette exons. They have key roles in", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19129193", "text": "The action of these factors on the PrP promoter is haplotype-specific, leading us to propose that the prion protein expression pattern and, with it, the distribution of TSE infectivity may be associated with PrP promoter genotype.", "offsetInBeginSection": 1458, "offsetInEndSection": 1608, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30404949", "text": "These data highlight microexon skipping as a mechanism to spatially restrict signaling and provide a mechanistic link between RTK-initiated phosphoinositide microdomains and Arf6 during signal transduction and cancer cell migration.", "offsetInBeginSection": 928, "offsetInEndSection": 1078, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25525873", "text": "ssociated with reduced levels of nSR100. The results thus reveal a highly conserved program of dynamic microexon regulation associated with the remode", "offsetInBeginSection": 858, "offsetInEndSection": 1008, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142", "text": "f neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dependen", "offsetInBeginSection": 532, "offsetInEndSection": 682, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12043842", "text": "egenerative diseases in humans and animals. Although PrP is highly conserved evolutionarily, there is some sequence divergence among species; as a con", "offsetInBeginSection": 131, "offsetInEndSection": 281, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19278297", "text": "Altogether, our data uncover evolutionarily conserved roles of PrP in cell communication, which ultimately impinge on the stability of adherens cell junctions during embryonic development.", "offsetInBeginSection": 1265, "offsetInEndSection": 1415, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508", "text": "pectrum disorder. However, little is known of the patterns, regulatory mechanisms and roles of microexon splicing in cancer. We here examined the tran", "offsetInBeginSection": 114, "offsetInEndSection": 264, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1765104", "text": "evealed that only two regions from positions -650 bp - -30 bp were highly conserved in all other PRP genes, PRP boxes 1 and 2. Box 1 at positions -112", "offsetInBeginSection": 510, "offsetInEndSection": 660, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30833759", "text": "Neuronal microexons represent the most conserved class of alternative splicing in vertebrates, and are critical for proper brain development and function.", "offsetInBeginSection": 75, "offsetInEndSection": 225, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30404949", "text": "nce of microexons and their contribution to signaling diversity is poorly understood. The Met receptor tyrosine kinase (RTK) modulates invasive growth", "offsetInBeginSection": 150, "offsetInEndSection": 300, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32535349", "text": "The discovery and characterization of a network of highly conserved neuronal microexons has provided fundamental new insight into mechanisms underlying nervous system development and function, as well as an important basis for pathway convergence in autism spectrum disorder.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33482885", "text": " that are not present in mouse transcript annotation databases. Unsupervised clustering of microexons based on their inclusion patterns segregates bra", "offsetInBeginSection": 845, "offsetInEndSection": 995, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19278297", "text": "mRNAs can partially rescue this knockdown phenotype, indicating conserved PrP functions. Using zebrafish, mouse, and Drosophila cells, we show that Pr", "offsetInBeginSection": 348, "offsetInEndSection": 498, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19451655", "text": "poorly understood phenomenon by expressing fusion proteins of sheep prion protein and green fluorescent protein ((GFP)PrP) in N2a cells, with variable sequence context surrounding the start codon Met(1). (GFP)PrP expressed with the wild-type sequence was transported normally through the secretory pathway to the cell surface with acquisition of N-glycan groups, but two N-terminal fragments of (GFP)PrP were detected intracellularly, starting in frame from Met(17). When (GFP)PrP was expressed with a compromised Kozak sequence ((GFP)PrP*), dispersed intracellular fluorescence was observed. A similar switch from pericellular to intracellular PrP localization was seen when analogous constructs of sheep PrP, without inserted GFP, were expressed, showing that this phenomenon is not caused by the GFP tag", "offsetInBeginSection": 133, "offsetInEndSection": 939, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19451655", "text": ", without inserted GFP, were expressed, showing that this phenomenon is not caused by the GFP tag. Western blotting revealed a reduction in glycosylat", "offsetInBeginSection": 842, "offsetInEndSection": 992, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e15690f196b51000020", "type": "yesno", "body": "Is casimersen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34909800", "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "http://www.ncbi.nlm.nih.gov/pubmed/26136844", "http://www.ncbi.nlm.nih.gov/pubmed/29066903", "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "http://www.ncbi.nlm.nih.gov/pubmed/30171533", "http://www.ncbi.nlm.nih.gov/pubmed/21171099", "http://www.ncbi.nlm.nih.gov/pubmed/34553378", "http://www.ncbi.nlm.nih.gov/pubmed/17846262", "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "http://www.ncbi.nlm.nih.gov/pubmed/34064562", "http://www.ncbi.nlm.nih.gov/pubmed/19517771", "http://www.ncbi.nlm.nih.gov/pubmed/34105177", "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "http://www.ncbi.nlm.nih.gov/pubmed/35213020", "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "http://www.ncbi.nlm.nih.gov/pubmed/36401026", "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "http://www.ncbi.nlm.nih.gov/pubmed/33012180"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19517771", "text": "ing gene transfer strategies have been conducted, but no effective treatment has been established. Two plausible ways have been proposed. One is the i", "offsetInBeginSection": 294, "offsetInEndSection": 444, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34553378", "text": "uscular dystrophy (DMD) is a degenerative muscle disease with no effective drug treatment. This study investigated the positive effects of fenofibrate", "offsetInBeginSection": 33, "offsetInEndSection": 183, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "r dystrophy is a lethal neuromuscular disease that currently has no effective therapy. Transgenic overexpression of the alpha7 integrin in mdx/utrn(-/", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "se of mortality among Duchenne muscular dystrophy patients and lacks effective therapies. Phosphodiesterase type 5 is implicated in dystrophic patholo", "offsetInBeginSection": 42, "offsetInEndSection": 192, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "es, most commonly as limb-girdle muscular dystrophy 2I. There is no effective therapy available. Glucocorticoid steroids have become the standard trea", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29066903", "text": "easures of fat embolism have been proposed; however, so far, there is no efficient therapy. The prevention, early diagnosis and adequate symptomatic t", "offsetInBeginSection": 1190, "offsetInEndSection": 1340, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "text": "dystrophin, a 427-kDa cytoskeletal protein, but the effective therapeutic drug is presently unavailable. We previously reported that a trypsin-like pr", "offsetInBeginSection": 73, "offsetInEndSection": 223, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34105177", "text": "etic parameters were similar at weeks 7 and 60.\n\n\nDISCUSSION\nCasimersen was well tolerated in participants with DMD amenable to exon 45 skipping. Most", "offsetInBeginSection": 1417, "offsetInEndSection": 1567, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "text": "ith Duchenne muscular dystrophy experienced severe acute heart failure triggered by pneumonia. Levosimendan was effective in improving heart function.", "offsetInBeginSection": 264, "offsetInEndSection": 414, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34105177", "text": "Our primary study objective was to evaluate safety and tolerability of casimersen; the secondary objective was to characterize the plasma pharmacokinetics.", "offsetInBeginSection": 321, "offsetInEndSection": 471, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": "ive degeneration of skeletal and cardiac muscles. Currently, there is no effective therapy for this disorder. However, the technology of cell reprogra", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26136844", "text": "essive pediatric muscle disorder. For decades, research has been conducted to find an effective therapy. This review presents current therapeutic meth", "offsetInBeginSection": 99, "offsetInEndSection": 249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35213020", "text": "Several exon skipping antisense oligonucleotides (eteplirsen, golodirsen, viltolarsen, and casimersen) have been approved for the treatment of Duchenne muscular dystrophy, but many more are in development targeting an array of different DMD exons.", "offsetInBeginSection": 37, "offsetInEndSection": 187, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30171533", "text": "Antisense-mediated exon skipping is most extensively studied in Duchenne muscular dystrophy (DMD) and has developed from in vitro proof-of-concept studies to clinical trials targeting various single exons such as exon 45 (casimersen), exon 53 (NS-065/NCNP-01, golodirsen), and exon 51 (eteplirsen).", "offsetInBeginSection": 492, "offsetInEndSection": 642, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "r levels of activated Akt in their muscles. Thus, VPA has important biological effects that may be applicable for the treatment of muscular dystrophy.", "offsetInBeginSection": 1056, "offsetInEndSection": 1206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21171099", "text": "evel of serum creatine kinase. At the doses tested, C-EPO is not an effective therapeutic for the treatment of a mouse model of Duchenne muscular dyst", "offsetInBeginSection": 825, "offsetInEndSection": 975, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "text": "ost common muscle disease found in male children. Currently, there is no effective therapy available for Duchenne muscular dystrophy patients. Therefo", "offsetInBeginSection": 36, "offsetInEndSection": 186, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "text": "From this review, it is clear that until a definitive treatment for Duchenne muscular dystrophy is available, the use of deflazacort and prednisone with judicious dietary control and close clinical monitoring for side effects seems the best intervention for interim preservation of function in such a common devastating disorder of young growing boys.", "offsetInBeginSection": 847, "offsetInEndSection": 997, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29066903", "text": "Several clinical trials have established both the beneficial effect of steroids in Duchenne muscular dystrophy and the well-known risk of side effects associated with their daily use.", "offsetInBeginSection": 37, "offsetInEndSection": 187, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17846262", "text": "reatment options. We examined the possibility of moving forward with gene therapy, an approach that demonstrates promise for treating Duchenne muscula", "offsetInBeginSection": 77, "offsetInEndSection": 227, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "text": "We concluded that embryo analysis using associated techniques of PCR and array CGH seems to be safe for embryo selection in cases of X-linked disorders, such as Duchenne muscular dystrophy.", "offsetInBeginSection": 1251, "offsetInEndSection": 1401, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401026", "text": "The canine X-linked muscular dystrophy in Japan (CXMDj), a dog model of DMD, produces no dystrophin and exhibits a severe phenotype similar to human patients from early childhood.", "offsetInBeginSection": 620, "offsetInEndSection": 770, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33012180", "text": "icoids and the limited evidence of bone-protective therapies, clinical trials are needed. We conducted surveys to obtain the opinion of young people w", "offsetInBeginSection": 114, "offsetInEndSection": 264, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "These results, for the\u00a0first time, demonstrate the efficacy and feasibility of this alliance treatment of the two drugs for fukutin-related protein-muscular dystrophy.", "offsetInBeginSection": 1484, "offsetInEndSection": 1634, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34909800", "text": "ent population. The continued approval of this drug will be dependent on satisfactory clinical results from an ongoing phase III trial. This article s", "offsetInBeginSection": 806, "offsetInEndSection": 956, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33012180", "text": "e unwilling to enrol their patients in such a trial. Our finding is relevant for the design of bone-protective studies in Duchenne muscular dystrophy.", "offsetInBeginSection": 2218, "offsetInEndSection": 2368, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "Consequently, phosphodiesterase type 5 inhibition is a candidate therapy for slowing the development of cardiomyopathy in Duchenne muscular dystrophy patients.", "offsetInBeginSection": 1663, "offsetInEndSection": 1813, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34064562", "text": "ed in a rehabilitation program and awaits the approval of the genetic treatment in Korea. This is the first report of an infantile presymptomatic Duch", "offsetInBeginSection": 1076, "offsetInEndSection": 1226, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34553378", "text": "CONCLUSIONS AND IMPLICATIONS\nFenofibrate substantially slows muscle dystrophy by promoting the degradation of myostatin protein, which may indicate a new therapeutic focus for patients with Duchenne muscular dystrophy.", "offsetInBeginSection": 897, "offsetInEndSection": 1047, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34553378", "text": "CONCLUSIONS AND IMPLICATIONS\nFenofibrate substantially slows muscle dystrophy by promoting the degradation of myostatin protein, which may indicate a new therapeutic focus for patients with Duchenne muscular dystrophy.", "offsetInBeginSection": 1663, "offsetInEndSection": 1813, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f02ceaf36125a426000015", "type": "summary", "body": "Which are the targets of Tirzepatide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35468321", "http://www.ncbi.nlm.nih.gov/pubmed/35767712", "http://www.ncbi.nlm.nih.gov/pubmed/36375235", "http://www.ncbi.nlm.nih.gov/pubmed/31984598", "http://www.ncbi.nlm.nih.gov/pubmed/34608929", "http://www.ncbi.nlm.nih.gov/pubmed/35355921", "http://www.ncbi.nlm.nih.gov/pubmed/34681215", "http://www.ncbi.nlm.nih.gov/pubmed/36157450", "http://www.ncbi.nlm.nih.gov/pubmed/32730231", "http://www.ncbi.nlm.nih.gov/pubmed/35921984", "http://www.ncbi.nlm.nih.gov/pubmed/33778934", "http://www.ncbi.nlm.nih.gov/pubmed/36050763", "http://www.ncbi.nlm.nih.gov/pubmed/34370970", "http://www.ncbi.nlm.nih.gov/pubmed/36004653", "http://www.ncbi.nlm.nih.gov/pubmed/35674880", "http://www.ncbi.nlm.nih.gov/pubmed/35579691", "http://www.ncbi.nlm.nih.gov/pubmed/34984793", "http://www.ncbi.nlm.nih.gov/pubmed/35333651", "http://www.ncbi.nlm.nih.gov/pubmed/35210595", "http://www.ncbi.nlm.nih.gov/pubmed/35830001", "http://www.ncbi.nlm.nih.gov/pubmed/35914543", "http://www.ncbi.nlm.nih.gov/pubmed/35468325", "http://www.ncbi.nlm.nih.gov/pubmed/34186022"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35210595", "text": "ptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. Its association with cardiovascular outcomes requires ev", "offsetInBeginSection": 56, "offsetInEndSection": 206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34984793", "text": "The development of high-dose GLP-1 RAs and the dual GLP-1/glucose-dependent insulinotropic peptide RA tirzepatide resulted in increasing numbers of people reaching HbA1c and body weight targets, with up to 62% attaining normoglycaemia with 15-mg tirzepatide.", "offsetInBeginSection": 1479, "offsetInEndSection": 1629, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35767712", "text": "M. This first-in-class agent serves as a coagonist for both the GLP-1 and GIP receptors. In this review, we report on the pharmacologic mechanism of G", "offsetInBeginSection": 897, "offsetInEndSection": 1047, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35468321", "text": "The secondary outcomes were to compare tirzepatide (5 mg, 10 mg, and 15 mg) versus insulin degludec for the proportion and duration of time in tight target range at 24 and 52 weeks.", "offsetInBeginSection": 1783, "offsetInEndSection": 1933, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35830001", "text": "Tirzepatide is in phase III development for heart failure, obesity and cardiovascular disorders in T2DM, and in phase II development for non-alcoholic steatohepatitis.", "offsetInBeginSection": 819, "offsetInEndSection": 969, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34186022", "text": "At 40 weeks, all tirzepatide doses were superior to placebo for changes from baseline in HbA1c, fasting serum glucose, bodyweight, and HbA1c targets of less than 7\u00b70% (<53 mmol/mol) and less than 5\u00b77% (<39 mmol/mol).", "offsetInBeginSection": 1695, "offsetInEndSection": 1845, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35674880", "text": "nder development for long-term weight management, heart failure with preserved ejection fraction, and nonalcoholic steatohepatitis. This study evaluat", "offsetInBeginSection": 221, "offsetInEndSection": 371, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36050763", "text": "Certainly, the apparent advantage of tirzepatide, a dual incretin agonist, over GLP-1RA will spark renewed interest in the therapeutic potential of GIP in type 2 diabetes, obesity and related co-morbidities.", "offsetInBeginSection": 2516, "offsetInEndSection": 2666, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36004653", "text": "Tirzepatide is a unimolecular dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which is developed as once-weekly injection for the treatment of type 2 diabetes.", "offsetInBeginSection": 24, "offsetInEndSection": 174, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35468321", "text": "These new data provide additional evidence to the effect of tirzepatide and potential for achieving glycaemic targets without increase of hypoglycaemic risk compared with a basal insulin.", "offsetInBeginSection": 3278, "offsetInEndSection": 3428, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33778934", "text": "eveloped for once-weekly treatment of type 2 diabetes (T2D), weight management, and nonalcoholic steatohepatitis, was evaluated in subjects with renal", "offsetInBeginSection": 195, "offsetInEndSection": 345, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32730231", "text": "Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis.", "offsetInBeginSection": 66, "offsetInEndSection": 216, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35468321", "text": " 15 mg 25% [14-35], p<0\u00b70001). Participants assigned to tirzepatide 10 mg and 15 mg, but not to tirzepatide 5 mg, spent significantly more time in tig", "offsetInBeginSection": 2755, "offsetInEndSection": 2905, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35914543", "text": "Participants were randomly assigned (1:1:1:1) to receive tirzepatide (5, 10, or 15 mg) or dulaglutide (0\u00b775 mg) once per week using a computer-generated random sequence with an Interactive Web Response System.", "offsetInBeginSection": 601, "offsetInEndSection": 751, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36157450", "text": "Tirzepatide, a dual agonist of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide 1 (GLP-1) receptors, improved glucose control and reduced body weight in different therapeutic approaches.", "offsetInBeginSection": 4, "offsetInEndSection": 154, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35579691", "text": "ody weight reduction was evident with tirzepatide vs placebo, GLP-1 RAs and basal insulin. Tirzepatide did not increase the odds of hypoglycaemia but ", "offsetInBeginSection": 2728, "offsetInEndSection": 2878, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36375235", "text": "ent of type 2 diabetes. Tirzepatide is a novel once-weekly dual GIP and GLP-1 receptor agonist which has been studied in the SURPASS clinical trials i", "offsetInBeginSection": 126, "offsetInEndSection": 276, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34608929", "text": "ulated a cluster of metabolites and lipids associated with IR, obesity, and future T2D risk. Branched-chain amino acids, direct catabolic products glu", "offsetInBeginSection": 1083, "offsetInEndSection": 1233, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35468325", "text": "The aim of this substudy was to characterise the changes in liver fat content (LFC), volume of visceral adipose tissue (VAT), and abdominal subcutaneous adipose tissue (ASAT) in response to tirzepatide or insulin degludec in a subpopulation of the SURPASS-3 study.", "offsetInBeginSection": 233, "offsetInEndSection": 383, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35914543", "text": "in the tirzepatide 5 mg treatment group. For the tirzepatide 10 and 15 mg treatment groups, increases by 2\u00b75 mg occurred once every 4 weeks until the ", "offsetInBeginSection": 1139, "offsetInEndSection": 1289, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35830001", "text": "Tirzepatide (Mounjaro\u2122) is a single molecule that combines dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35914543", "text": "rzepatide was superior compared with dulaglutide for glycaemic control and reduction in bodyweight. The safety profile of tirzepatide was consistent w", "offsetInBeginSection": 3123, "offsetInEndSection": 3273, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35921984", "text": "RESULTS\nTreatment with tirzepatide stimulated catabolism of BCAAs/BCKAs in BAT, as demonstrated by increased labeling of BCKA-derived metabolites, and increases in levels of byproducts of BCAA breakdown, including glutamate, alanine, and 3-hydroxyisobutyric acid (3-HIB).", "offsetInBeginSection": 1111, "offsetInEndSection": 1261, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35355921", "text": "A1c. Secondary outcomes were to evaluate alterations in blood-glucose, glycemic targets, weight, lipids, and adverse events.\n\n\nResults\nFrom 34 article", "offsetInBeginSection": 430, "offsetInEndSection": 580, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35355921", "text": "5.31 to -3.55); P < 0.01; I 2 = 95%] as compared to dulaglutide, semaglutide, degludec, or glargine. Patients receiving tirzepatide had higher odds of", "offsetInBeginSection": 1239, "offsetInEndSection": 1389, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36050763", "text": "Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin secretion that are also expressed in regions of the brain that regulate food intake.", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31984598", "text": " treatment using three different dose-escalation regimens in patients with type 2 diabetes.\n\n\nMATERIALS AND METHODS\nIn this double-blind, placebo-cont", "offsetInBeginSection": 58, "offsetInEndSection": 208, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34681215", "text": "Tirzepatide significantly improved glycemic control and body weight and had an acceptable safety profile, indicating that it is an effective therapeutic option for glucose-lowering in patients with type 2 diabetes mellitus.", "offsetInBeginSection": 1402, "offsetInEndSection": 1552, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35333651", "text": "SignificanceTirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), which are incretin receptors that regulate carbohydrate metabolism.", "offsetInBeginSection": 29, "offsetInEndSection": 179, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34370970", "text": "INTERPRETATION\nIn patients with type 2 diabetes, tirzepatide (5, 10, and 15 mg) was superior to titrated insulin degludec, with greater reductions in HbA1c and bodyweight at week 52 and a lower risk of hypoglycaemia.", "offsetInBeginSection": 4374, "offsetInEndSection": 4524, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640e2616201352f04a00002a", "type": "yesno", "body": "Is medical hydrology the same as Spa therapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12110784", "http://www.ncbi.nlm.nih.gov/pubmed/21563002", "http://www.ncbi.nlm.nih.gov/pubmed/21563001", "http://www.ncbi.nlm.nih.gov/pubmed/29455296", "http://www.ncbi.nlm.nih.gov/pubmed/12831346", "http://www.ncbi.nlm.nih.gov/pubmed/12406431", "http://www.ncbi.nlm.nih.gov/pubmed/18829219", "http://www.ncbi.nlm.nih.gov/pubmed/33866427", "http://www.ncbi.nlm.nih.gov/pubmed/10868019", "http://www.ncbi.nlm.nih.gov/pubmed/12463465"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/12110784", "text": "Within conservative approaches, spa hydrotherapy is popular among patients with venous disorders in Europe, but whether the practice is associated with health or social benefits remains controversial.", "offsetInBeginSection": 159, "offsetInEndSection": 309, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29455296", "text": "PubMed/Medline, Embase, and Cochrane Library were searched for relevant articles in English or Italian about studies involving healthy and sub-healthy subjects or patients with a diagnosed disease about effects of balneotherapy, mud/peloid therapy, and spa therapy on serum and salivary cortisol levels.", "offsetInBeginSection": 67, "offsetInEndSection": 269, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12831346", "text": "liximab and etanercept are approved in Europe. The situation in SpA is different to RA because there is an unmet medical need, especially in AS, since", "offsetInBeginSection": 675, "offsetInEndSection": 825, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18829219", "text": "y to administer physical therapy for CVD in France, but its efficacy has not been evaluated yet. This study aimed to assess the efficacy of balneother", "offsetInBeginSection": 169, "offsetInEndSection": 319, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12463465", "text": "dence that treatment seems to be as effective as in adults. Risks are likely to be the same as in patients suffering from other forms of juvenile idio", "offsetInBeginSection": 1224, "offsetInEndSection": 1374, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21563002", "text": "This article argues that the seemingly contradictory systems (markets and medicine) coexist much in the same way that magic, religion and medicine coexisted in the old water sites.", "offsetInBeginSection": 1638, "offsetInEndSection": 1788, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29455296", "text": "Spa therapy with or without included mud/peloid therapy demonstrated the same potential to influence cortisol levels also in sub-healthy subjects and in patients with a diagnosed disease.", "offsetInBeginSection": 1399, "offsetInEndSection": 1585, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10868019", "text": "therapy of SpA. The same is true for the knowledge on course, prognostic factors, and the socioeconomic consequences of these diseases. Furthermore, o", "offsetInBeginSection": 408, "offsetInEndSection": 558, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12406431", "text": " the treatment of RA in Europe and in the USA. The situation in SpA is different from RA because there is an unmet medical need, especially in AS, bec", "offsetInBeginSection": 640, "offsetInEndSection": 790, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33866427", "text": "Overall, retrieved scientific evidence suggests that spa therapy is beneficial for patients affected by some specific musculoskeletal conditions, with improvements potentially lasting up to 9 months.", "offsetInBeginSection": 619, "offsetInEndSection": 769, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21563001", "text": " In the Portuguese context this model is highly medicalized; in the Brazilian case, spa treatments are viewed as 'alternative' or 'complementary' therapy and are also related to religious philosophies", "offsetInBeginSection": 325, "offsetInEndSection": 525, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410fa66201352f04a000034", "type": "summary", "body": "How does CYP1A2 relate to coffee consumption and apetite?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34564706", "http://www.ncbi.nlm.nih.gov/pubmed/21357676", "http://www.ncbi.nlm.nih.gov/pubmed/19451835", "http://www.ncbi.nlm.nih.gov/pubmed/12925300", "http://www.ncbi.nlm.nih.gov/pubmed/35905656", "http://www.ncbi.nlm.nih.gov/pubmed/29976226", "http://www.ncbi.nlm.nih.gov/pubmed/28135712", "http://www.ncbi.nlm.nih.gov/pubmed/21876539", "http://www.ncbi.nlm.nih.gov/pubmed/19520064", "http://www.ncbi.nlm.nih.gov/pubmed/20390257", "http://www.ncbi.nlm.nih.gov/pubmed/18157525", "http://www.ncbi.nlm.nih.gov/pubmed/18398030", "http://www.ncbi.nlm.nih.gov/pubmed/9110357", "http://www.ncbi.nlm.nih.gov/pubmed/27713762", "http://www.ncbi.nlm.nih.gov/pubmed/34391463", "http://www.ncbi.nlm.nih.gov/pubmed/25595320"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/9110357", "text": "5), coffee consumption (p = 0.05) and plasma lycopene (p = 0.06) were positively associated with CYP1A2 activity. After adjustment for these variables", "offsetInBeginSection": 1111, "offsetInEndSection": 1261, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34564706", "text": "Herein, we addressed the novel hypothesis that genetic variation in CYP1A2, a gene responsible for more than 95% of caffeine metabolism, differentially impacts the association of coffee consumption with appetite and BMI among individuals with different genetic predispositions to obesity.", "offsetInBeginSection": 278, "offsetInEndSection": 428, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18157525", "text": "erbs than in Swedes (P=0.0003).\n\n\nCONCLUSIONS\nHabitual heavy coffee consumption increases CYP1A2 activity. Polycyclic aromatic hydrocarbons formed dur", "offsetInBeginSection": 1326, "offsetInEndSection": 1476, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34564706", "text": "CONCLUSIONS\nCYP1A2 rs762551 polymorphism modifies the association of habitual coffee consumption with BMI, in part by influencing appetite, energy intake and circulating levels of the orexigenic hormone asprosin.", "offsetInBeginSection": 1986, "offsetInEndSection": 2136, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21357676", "text": "a day per allele was observed for both SNPs. CYP1A2 is the main caffeine metabolizing enzyme and is also involved in drug metabolism. AHR detects xeno", "offsetInBeginSection": 959, "offsetInEndSection": 1109, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18398030", "text": "CYP1A2 plays a key role in the metabolism of both estrogen and coffee. Women with higher coffee intake and the CYP1A2*1F A/A genotype have a ratio of ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27713762", "text": "CONCLUSIONS\nEstimated CYP1A2 enzyme activity, and thus speed of caffeine metabolism, was higher in our type-2 diabetes group; this was possibly due to higher intake of caffeine, a known inducer of CYP1A2 enzyme activity.", "offsetInBeginSection": 367, "offsetInEndSection": 517, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18157525", "text": "RESULTS\nDaily consumption of at least three cups of coffee significantly increased CYP1A2 enzyme activity in both Serbs (P=0.0002) and Swedes (P<0.0001).", "offsetInBeginSection": 602, "offsetInEndSection": 752, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21876539", "text": "t constituents of coffee, whereas CYP1A2 is involved in the primary metabolism of caffeine. Significant evidence of association was also detected at r", "offsetInBeginSection": 879, "offsetInEndSection": 1029, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19520064", "text": "eptor and DAT. The results demonstrate that caffeine alters the striatal CYP1A2, adenosine A(2A) receptor and DAT expressions in mice exposed to MPTP.", "offsetInBeginSection": 1388, "offsetInEndSection": 1538, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35905656", "text": "onally, we hypothesize that CYP1A2 genotype can modulate serum glucose concentrations and lipid profile. A total of 421 participants aged 20 to 40 yea", "offsetInBeginSection": 753, "offsetInEndSection": 903, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29976226", "text": "The urate-increasing GCKR, ABCG2, MLXIPL, and CYP1A2 alleles were associated with reduced daily coffee consumption, with the strongest associations for CYP1A2 (beta -0.30, P\u2009=\u00a08\u2009\u00d7\u200910-40), and MLXIPL (beta -0.17, P\u2009=\u00a03\u2009\u00d7\u200910-8), and weaker associations for GCKR (beta -0.07, P\u2009=\u00a03\u2009\u00d7\u200910-10) and ABCG2 (beta -0.09, P\u2009=\u00a02\u2009\u00d7\u200910-9).", "offsetInBeginSection": 1292, "offsetInEndSection": 1442, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25595320", "text": "ts screened for stage 1 hypertension and whether CYP1A2 polymorphism modulates this association. A total of 1,180 nondiabetic patients attending 17 ho", "offsetInBeginSection": 245, "offsetInEndSection": 395, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20390257", "text": "ted. Significant association of heavy coffee consumption with high CYP1A2 enzyme activity was observed only in carriers of -163 A/A. Increasing effect", "offsetInBeginSection": 968, "offsetInEndSection": 1118, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19451835", "text": "NCLUSION\nThese data show that the risk of hypertension associated with coffee intake varies according to CYP1A2 genotype. Carriers of slow *1F allele ", "offsetInBeginSection": 1502, "offsetInEndSection": 1652, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19520064", "text": "susceptibility to PD. Cytochrome P450 1A2 (CYP1A2) is involved in caffeine metabolism and its clearance. Caffeine, on the other hand, antagonizes aden", "offsetInBeginSection": 250, "offsetInEndSection": 400, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12925300", "text": "n cancer risk in several epidemiological studies. CYP1A2 is a key enzyme in the metabolism of coffee and in the activation of heterocyclic aromatic co", "offsetInBeginSection": 63, "offsetInEndSection": 213, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25595320", "text": "These data show that coffee consumption increases the risk of impaired fasting glucose in hypertension particularly among carriers of the slow CYP1A2 *1F allele.", "offsetInBeginSection": 1361, "offsetInEndSection": 1511, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35905656", "text": "This study suggests that CYP1A2 rs762551 polymorphism is associated with coffee intake and serum TG concentrations in healthy 20- to 40-year-old adults.", "offsetInBeginSection": 1434, "offsetInEndSection": 1584, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28135712", "text": "LUSION\nWe corroborated results from a previous report that described interactions between ADORA2A and CYP1A2 polymorphisms and coffee consumption. Our", "offsetInBeginSection": 1304, "offsetInEndSection": 1454, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28135712", "text": "tabolizes caffeine; thus, gene polymorphisms in ADORA2A and CYP1A2 may influence the effect coffee consumption has on PD risk.\n\n\nMETHODS\nIn a populati", "offsetInBeginSection": 291, "offsetInEndSection": 441, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34564706", "text": "C\u2009>\u2009A (rs762551) polymorphism of CYP1A2 as rapid (AA), intermediate (AC), or slow (CC) caffeine metabolizers.\n\n\nRESULTS\nCoffee consumption led to lowe", "offsetInBeginSection": 984, "offsetInEndSection": 1134, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28135712", "text": "ed results from a previous report that described interactions between ADORA2A and CYP1A2 polymorphisms and coffee consumption. Our results also sugges", "offsetInBeginSection": 1324, "offsetInEndSection": 1474, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34391463", "text": "0 1A2 (CYP1A2) single nucleotide polymorphism (SNP) is related to caffeine metabolism and the risk of CVD among coffee drinkers. CYP1A2 rs762551 influ", "offsetInBeginSection": 98, "offsetInEndSection": 248, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e73690f196b51000023", "type": "yesno", "body": "Is eteplirsen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29752304", "http://www.ncbi.nlm.nih.gov/pubmed/30801483", "http://www.ncbi.nlm.nih.gov/pubmed/31576784", "http://www.ncbi.nlm.nih.gov/pubmed/34420980", "http://www.ncbi.nlm.nih.gov/pubmed/28280301", "http://www.ncbi.nlm.nih.gov/pubmed/28865998", "http://www.ncbi.nlm.nih.gov/pubmed/28990648", "http://www.ncbi.nlm.nih.gov/pubmed/30556126", "http://www.ncbi.nlm.nih.gov/pubmed/31261494", "http://www.ncbi.nlm.nih.gov/pubmed/32691988", "http://www.ncbi.nlm.nih.gov/pubmed/34120909", "http://www.ncbi.nlm.nih.gov/pubmed/26573217", "http://www.ncbi.nlm.nih.gov/pubmed/30856119", "http://www.ncbi.nlm.nih.gov/pubmed/30396145", "http://www.ncbi.nlm.nih.gov/pubmed/32483212", "http://www.ncbi.nlm.nih.gov/pubmed/29254734", "http://www.ncbi.nlm.nih.gov/pubmed/30526286", "http://www.ncbi.nlm.nih.gov/pubmed/27807823", "http://www.ncbi.nlm.nih.gov/pubmed/35715998", "http://www.ncbi.nlm.nih.gov/pubmed/30171536", "http://www.ncbi.nlm.nih.gov/pubmed/30195785", "http://www.ncbi.nlm.nih.gov/pubmed/23907995", "http://www.ncbi.nlm.nih.gov/pubmed/34797383", "http://www.ncbi.nlm.nih.gov/pubmed/29278896"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/32691988", "text": "In this year's neuromuscular Year in Review, we focus on Duchenne muscular dystrophy (DMD), reviewing studies that evaluate the respiratory effect of eteplirsen, the cardiopulmonary effects of ataluren, and a study comparing the use of spironolactone with eplerenone for the treatment of DMD-related cardiomyopathy.", "offsetInBeginSection": 232, "offsetInEndSection": 382, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26573217", "text": "s remained relatively stable in eteplirsen-treated patients. Eteplirsen was well tolerated. Analysis of HC confirmed the previously observed change in", "offsetInBeginSection": 1183, "offsetInEndSection": 1333, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30801483", "text": "We review the development of exon 51 skipping therapy with eteplirsen for Duchenne muscular dystrophy, including the recent report of long-term, sustained dystrophin production.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28990648", "text": "The technical FDA evaluation team reasons supporting that the drug has not proven clinical benefit, the attitude of patient advocacy groups and the post-approval FDA requirements to the marketing authorization holder are discussed.", "offsetInBeginSection": 759, "offsetInEndSection": 909, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34120909", "text": "BackgroundEteplirsen received accelerated FDA approval for treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping,", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30396145", "text": "Shorter PMOs would make higher doses economically feasible, and high dosing would result in better drug uptake into muscle, induce higher levels of dystrophin restoration in DMD muscle, and, ultimately, increase the clinical efficacy.", "offsetInBeginSection": 1250, "offsetInEndSection": 1400, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212", "text": "earlier this year. Although promising, the efficacy of eteplirsen and AON sequence employed remain controversial. In addition, exon skipping faces cha", "offsetInBeginSection": 551, "offsetInEndSection": 701, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30195785", "text": "herapeutics for Duchenne muscular dystrophy patients. However, the limited efficacy of eteplirsen underscores the importance to improve systemic deliv", "offsetInBeginSection": 90, "offsetInEndSection": 240, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30526286", "text": "Eteplirsen was approved for the treatment of eligible patients with Duchenne muscular dystrophy (DMD) in September 2016 in one of the most, if not the most, controversial approvals ever made by the Food and Drug Administration of the United States.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212", "text": " promising, the efficacy of eteplirsen and AON sequence employed remain controversial. In addition, exon skipping faces challenges including the appli", "offsetInBeginSection": 578, "offsetInEndSection": 728, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34120909", "text": "Most frequent treatment-related adverse events were headache and vomiting; none led to treatment discontinuation.ConclusionsThis large, multicenter study contributes to the growing body of evidence for eteplirsen, confirming a positive treatment effect, favorable safety profile, and slowing of disease progression versus natural history.", "offsetInBeginSection": 1692, "offsetInEndSection": 1842, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26573217", "text": "OBJECTIVE\nTo continue evaluation of the long-term efficacy and safety of eteplirsen, a phosphorodiamidate morpholino oligomer designed to skip DMD exon 51 in patients with Duchenne muscular dystrophy (DMD).", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31261494", "text": "similar to those of the patients who remained ambulatory. Dystrophin production was confirmed following eteplirsen treatment.Despite the loss of ambul", "offsetInBeginSection": 1247, "offsetInEndSection": 1397, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34420980", "text": "BACKGROUND\nStudies 4658-201/202 (201/202) evaluated treatment effects of eteplirsen over 4 years in patients with Duchenne muscular dystrophy and confirmed exon-51 amenable genetic mutations.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34797383", "text": "ts pass away from heart failure or respiratory failure. Currently, there is no cure, though exon-skipping therapy including eteplirsen (brand name Exo", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29752304", "text": "equencing of newly formed slice junctions was used to confirm the mechanism of action of eteplirsen.\n\n\nRESULTS\nReverse transcription PCR analysis and ", "offsetInBeginSection": 914, "offsetInEndSection": 1064, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28280301", "text": " exon 51 in defective gene variants. Eteplirsen is applicable for approximately 14% of patients with DMD mutations. This article extensively reviews a", "offsetInBeginSection": 626, "offsetInEndSection": 776, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823", "text": " developed by Sarepta Therapeutics. Intravenous eteplirsen has received accelerated approval from the US FDA for the treatment of Duchenne muscular dy", "offsetInBeginSection": 99, "offsetInEndSection": 249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30856119", "text": "OBJECTIVE\nEvaluate the effects of eteplirsen on FVC% p annual change in 3 trials versus matched Cooperative International Neuromuscular Research Group Duchenne Natural History Study (CINRG DNHS) controls.", "offsetInBeginSection": 278, "offsetInEndSection": 428, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35715998", "text": "sue in patients with Duchenne muscular dystrophy (DMD). Eteplirsen is a United States-approved treatment for patients with DMD and exon 51 skip-amenab", "offsetInBeginSection": 49, "offsetInEndSection": 199, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30556126", "text": "Exon 51 skipping with eteplirsen demonstrated a structural and functional effect in a small group of patients and received restricted approval in the USA.", "offsetInBeginSection": 747, "offsetInEndSection": 897, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29278896", "text": "CONCLUSIONS\nWith eteplirsen treatment, deterioration of respiratory muscle function based on FVC% p was half of that seen in the UDP; MEP% p and MIP% p compared favorably with natural history.", "offsetInBeginSection": 1495, "offsetInEndSection": 1645, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29254734", "text": "OBJECTIVE\nThis study analysed the results of previous studies to assess the safety and efficacy of the eteplirsen, and is the first pooled-analysis of its kind.", "offsetInBeginSection": 477, "offsetInEndSection": 627, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28865998", "text": "ipping. Eteplirsen remains controversial with insufficient evidence of its therapeutic effect in patients. We recently developed an in\u00a0silico tool to ", "offsetInBeginSection": 512, "offsetInEndSection": 662, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31576784", "text": "ded promising results; the US Food and Drug Administration (FDA) approved eteplirsen (Exondys51) as the first exon-skipping drug for the treatment of ", "offsetInBeginSection": 713, "offsetInEndSection": 863, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30171536", "text": "ven to be powerful tools for treating neuromuscular diseases. The approval of Exondys 51 (eteplirsen) and Spinraza (nusinersen) for the treatment of p", "offsetInBeginSection": 60, "offsetInEndSection": 210, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23907995", "text": "OBJECTIVE\nIn prior open-label studies, eteplirsen, a phosphorodiamidate morpholino oligomer, enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic mutations amenable to skipping exon 51.", "offsetInBeginSection": 32, "offsetInEndSection": 182, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29254734", "text": "CONCLUSIONS\nWhether or not this increase in percentage dystrophin-positive fibres and distance walked is clinically significant is unclear, and there is therefore a need for more clinical trials.", "offsetInBeginSection": 1206, "offsetInEndSection": 1356, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29752304", "text": "METHODS\nClinical study 202 was an observational, open-label extension of the randomized, controlled study 201 assessing the safety and efficacy of eteplirsen in patients with DMD with a confirmed mutation in the DMD gene amenable to correction by skipping of exon 51.", "offsetInBeginSection": 226, "offsetInEndSection": 376, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29278896", "text": "Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO), is designed to skip exon 51, restore the reading frame, and induce production of internally shortened dystrophin in patients with mutations amenable to such treatment.", "offsetInBeginSection": 373, "offsetInEndSection": 599, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f03939f36125a42600001b", "type": "summary", "body": "What is the use of darolutamide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36087070", "http://www.ncbi.nlm.nih.gov/pubmed/32436836", "http://www.ncbi.nlm.nih.gov/pubmed/28490267", "http://www.ncbi.nlm.nih.gov/pubmed/32003293", "http://www.ncbi.nlm.nih.gov/pubmed/34797506", "http://www.ncbi.nlm.nih.gov/pubmed/34866168", "http://www.ncbi.nlm.nih.gov/pubmed/36028656", "http://www.ncbi.nlm.nih.gov/pubmed/31571146", "http://www.ncbi.nlm.nih.gov/pubmed/31695432", "http://www.ncbi.nlm.nih.gov/pubmed/35179323", "http://www.ncbi.nlm.nih.gov/pubmed/36297536", "http://www.ncbi.nlm.nih.gov/pubmed/30828788", "http://www.ncbi.nlm.nih.gov/pubmed/28801852", "http://www.ncbi.nlm.nih.gov/pubmed/32881669", "http://www.ncbi.nlm.nih.gov/pubmed/33237495", "http://www.ncbi.nlm.nih.gov/pubmed/31571095", "http://www.ncbi.nlm.nih.gov/pubmed/33135506", "http://www.ncbi.nlm.nih.gov/pubmed/34129460", "http://www.ncbi.nlm.nih.gov/pubmed/35552309", "http://www.ncbi.nlm.nih.gov/pubmed/32605736", "http://www.ncbi.nlm.nih.gov/pubmed/32905676", "http://www.ncbi.nlm.nih.gov/pubmed/33554636", "http://www.ncbi.nlm.nih.gov/pubmed/33226524", "http://www.ncbi.nlm.nih.gov/pubmed/32073798"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36028656", "text": "METHODS\nAll-cause grade\u2009\u2265\u20093 AEs with corresponding any-grade AEs reported among at least 10% of patients in any arm of the ARAMIS (darolutamide), SPARTAN (apalutamide), and PROSPER (enzalutamide) trials were selected for inclusion in the primary analyses.", "offsetInBeginSection": 612, "offsetInEndSection": 762, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33135506", "text": "alutamide, enzalutamide, and most recently, darolutamide (novel androgen receptor antagonists) have been approved for nonmetastatic castration-resista", "offsetInBeginSection": 183, "offsetInEndSection": 333, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32436836", "text": "D\nDarolutamide is recently approved for the treatment of non-metastatic castrate resistance prostate cancer. Hitherto, no stereoselective pharmacokine", "offsetInBeginSection": 9, "offsetInEndSection": 159, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32003293", "text": "1. Darolutamide is a novel selective androgen receptor antagonist consisting of two pharmacologically equipotent diastereoisomers. The absorption, dis", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32003293", "text": "reactions and glucuronidation. After intravenous administration, a relevant extent of the dose (20%) underwent extrabiliary excretion as darolutamide.", "offsetInBeginSection": 1243, "offsetInEndSection": 1393, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33226524", "text": "amide 600\u00a0mg twice daily or matched placebo while continuing androgen deprivation therapy. The primary endpoint was MFS.\n\n\nRESULTS\nIn Japan, 95 patien", "offsetInBeginSection": 526, "offsetInEndSection": 676, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34866168", "text": "BACKGROUND\nDarolutamide is a second-generation androgen receptor inhibitor approved for the treatment of nonmetastatic castration-resistant prostate cancer at a dosage of 600 mg orally twice daily.", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36087070", "text": "OBJECTIVE\nTo assess, the effect of darolutamide (a structurally distinct androgen receptor inhibitor) on urinary and bowel symptoms, using data from the phase III ARAMIS trial (NCT02200614) that showed darolutamide significantly reduced the risk of metastasis and death versus placebo.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32905676", "text": "eceptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phas", "offsetInBeginSection": 61, "offsetInEndSection": 211, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28490267", "text": "nical efficacy and safety of darolutamide for the treatment of advanced prostate cancer are reviewed. The design of two ongoing phase III trials (ARAM", "offsetInBeginSection": 739, "offsetInEndSection": 889, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34797506", "text": "INTRODUCTION\nApalutamide and darolutamide are next-generation androgen receptor inhibitors that have demonstrated superior efficacy compared to placebo in men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT).", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32073798", "text": "The results of a recent randomised phase 3 clinical trial show that the androgen receptor antagonist darolutamide improves metastasis-free survival in men with non-metastatic, castration-resistant prostate cancer, compared with placebo.", "offsetInBeginSection": 55, "offsetInEndSection": 205, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28801852", "text": " twice daily (Cohort 2) for 12\u00a0weeks. Primary endpoints: evaluate safety and pharmacokinetics of darolutamide.\n\n\nRESULTS\nOf 12 patients enrolled, 9 re", "offsetInBeginSection": 687, "offsetInEndSection": 837, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36297536", "text": "nistered in combination with darolutamide, which is considered not clinically meaningful. M1 exposures were similar with and without darolutamide admi", "offsetInBeginSection": 1057, "offsetInEndSection": 1207, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34797506", "text": "shed data from the ARAMIS study (darolutamide\u00a0+\u00a0ADT) for clinically relevant baseline measures. Hazard ratios (HR) and 95% credible intervals (CrI) we", "offsetInBeginSection": 620, "offsetInEndSection": 770, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35179323", "text": "BACKGROUND\nDarolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33237495", "text": "Given the efficacy and safety evidence from the final ARAMIS analysis and the key role of second-generation AR inhibitors in the management of nmCRPC, darolutamide +\u202fADT represents an important emerging option for the treatment of men with nmCRPC who are at high risk of developing metastatic prostate cancer.", "offsetInBeginSection": 1061, "offsetInEndSection": 1211, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35552309", "text": "SUMMARY\nPhase 3 trials and peer-reviewed literature demonstrate that enzalutamide, apalutamide, and darolutamide prolong overall survival (OS) in men with nmCRPC.", "offsetInBeginSection": 887, "offsetInEndSection": 1037, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31571146", "text": "BACKGROUND AND OBJECTIVES\nDarolutamide is a novel androgen receptor (AR) antagonist approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC).", "offsetInBeginSection": 57, "offsetInEndSection": 207, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32605736", "text": "ad similar and higher MFS rate in indirect comparison with darolutamide. In cases where AEs are concerning, darolutamide might be the preferred agent.", "offsetInBeginSection": 1745, "offsetInEndSection": 1895, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30828788", "text": "graft. Altogether, these results substantiate a unique antagonistic profile of darolutamide and support further development as a prostate cancer drug.", "offsetInBeginSection": 1482, "offsetInEndSection": 1632, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33237495", "text": "Oral darolutamide (Nubeqa\u2122) is a novel second-generation, nonsteroidal, selective androgen receptor (AR) inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).", "offsetInBeginSection": 90, "offsetInEndSection": 240, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28801852", "text": "PURPOSE\nThis trial assessed the safety, pharmacokinetics, and efficacy of darolutamide (ODM-201), a new-generation nonsteroidal androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer (mCRPC).", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34129460", "text": "al androgen inhibitor FDA approved for the treatment of castration-resistant non-metastatic prostate cancer (nmCRPC). After decades of offering androg", "offsetInBeginSection": 28, "offsetInEndSection": 178, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32436836", "text": "METHODS\nIn vitro (liver microsomes stability and protein binding) and in vivo experiments (oral/intravenous dosing to mice) were carried out using darolutamide, S,S-darolutamide and S,Rdarolutamide.", "offsetInBeginSection": 499, "offsetInEndSection": 649, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35179323", "text": "CONCLUSIONS\nIn this trial involving patients with metastatic, hormone-sensitive prostate cancer, overall survival was significantly longer with the combination of darolutamide, androgen-deprivation therapy, and docetaxel than with placebo plus androgen-deprivation therapy and docetaxel, and the addition of darolutamide led to improvement in key secondary end points.", "offsetInBeginSection": 1836, "offsetInEndSection": 2106, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31695432", "text": "inical studies and the potential of darolutamide for the treatment of advanced prostate cancer. To date, darolutamide efficacy and tolerability has be", "offsetInBeginSection": 842, "offsetInEndSection": 992, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31571095", "text": "BACKGROUND\nDarolutamide, an androgen receptor antagonist with a distinct molecular structure, significantly prolonged metastasis-free survival versus placebo in the phase III ARAMIS study in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32881669", "text": "Darolutamide has shown high potential in inhibiting the growth of MR49F (Enzalutamide resistant PC cells) and VCaP (Castration-resistant PC cells) cell lines and transcriptional activities of AR.", "offsetInBeginSection": 1214, "offsetInEndSection": 1368, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33554636", "text": "The trial showed that darolutamide in addition to hormone therapy increased the length of time that the trial participants were still alive for and lowered the risk of death by 31% compared with placebo (sugar pill) and hormone therapy.", "offsetInBeginSection": 723, "offsetInEndSection": 873, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64136664201352f04a00003b", "type": "list", "body": "What are the main clinical features of small-fiber neuropathy (SFN)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33802768", "http://www.ncbi.nlm.nih.gov/pubmed/31639840", "http://www.ncbi.nlm.nih.gov/pubmed/34075618", "http://www.ncbi.nlm.nih.gov/pubmed/33830702", "http://www.ncbi.nlm.nih.gov/pubmed/30316835", "http://www.ncbi.nlm.nih.gov/pubmed/17868250", "http://www.ncbi.nlm.nih.gov/pubmed/35130356", "http://www.ncbi.nlm.nih.gov/pubmed/25622669", "http://www.ncbi.nlm.nih.gov/pubmed/36331613", "http://www.ncbi.nlm.nih.gov/pubmed/31325646", "http://www.ncbi.nlm.nih.gov/pubmed/30968230", "http://www.ncbi.nlm.nih.gov/pubmed/26872938", "http://www.ncbi.nlm.nih.gov/pubmed/23304492", "http://www.ncbi.nlm.nih.gov/pubmed/20433606", "http://www.ncbi.nlm.nih.gov/pubmed/36005471", "http://www.ncbi.nlm.nih.gov/pubmed/23982054", "http://www.ncbi.nlm.nih.gov/pubmed/29809227", "http://www.ncbi.nlm.nih.gov/pubmed/24829596", "http://www.ncbi.nlm.nih.gov/pubmed/30636091", "http://www.ncbi.nlm.nih.gov/pubmed/31943276", "http://www.ncbi.nlm.nih.gov/pubmed/28410768", "http://www.ncbi.nlm.nih.gov/pubmed/22570215", "http://www.ncbi.nlm.nih.gov/pubmed/15546602", "http://www.ncbi.nlm.nih.gov/pubmed/25835646", "http://www.ncbi.nlm.nih.gov/pubmed/35366250"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35366250", "text": "op as a result of systemic immune-mediated inflammation. The most common symptoms of this complication were dysautonomia and mild sensory dysfunction.", "offsetInBeginSection": 1220, "offsetInEndSection": 1370, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17868250", "text": "Small-fiber neuropathy (SFN) is diagnosed on the basis of clinical features and specialized tests of small-fiber function because standard nerve conduction studies are normal.", "offsetInBeginSection": 25, "offsetInEndSection": 175, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30968230", "text": "The main clinical features include neuropathic pain and autonomic disturbance, which are occasionally disclaimed due to outstanding fatigue, daily performance decline, anxiety, and depression.", "offsetInBeginSection": 288, "offsetInEndSection": 438, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15546602", "text": "sis of the clinical features, normal nerve conduction studies (NCS) and abnormal specialized tests of small nerve fibers. Among others, these tests in", "offsetInBeginSection": 340, "offsetInEndSection": 490, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34075618", "text": "METHODS\nThis is a retrospective, observational study of sequential patients diagnosed with definite SFN (typical clinical features, normal nerve conduction studies, abnormal epidermal nerve fiber density) from the end of November 2016 to the middle of July 2019 at the Cantonal Hospital Lucerne, central Switzerland.", "offsetInBeginSection": 341, "offsetInEndSection": 491, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31943276", "text": " investigations, including quantitative sensory testing, intraepidermal nerve fiber density and confocal corneal microscopy. Knowledge of these disord", "offsetInBeginSection": 364, "offsetInEndSection": 514, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25622669", "text": "re the relationship between clinical features, electrophysiology and intraepidermal nerve fiber density (IENFD) in peripheral neuropathy with small fi", "offsetInBeginSection": 18, "offsetInEndSection": 168, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33802768", "text": "wn as SFN. This pathology may be the result of metabolic, toxic, immune-mediated, and/or genetic factors. Small fiber symptoms can be variable and inc", "offsetInBeginSection": 170, "offsetInEndSection": 320, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24829596", "text": "al factors in patients with seemingly idiopathic SFN, such as impaired glucose tolerance. However, idiopathic SFN in young to middle-aged Swedish pati", "offsetInBeginSection": 1512, "offsetInEndSection": 1662, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22570215", "text": "Small fiber neuropathy (SFN) is characterized by negative sensory symptoms (thermal and pinprick hypoesthesia) reflecting peripheral deafferentation and positive sensory symptoms and signs (burning pain, allodynia, hyperalgesia), which often dominate the clinical picture.", "offsetInBeginSection": 43, "offsetInEndSection": 193, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35130356", "text": "Though uniform diagnostic criteria are unavailable, most of them request typical clinical features and reduced intra-epidermal nerve fiber density on proximal or distal skin biopsy.", "offsetInBeginSection": 322, "offsetInEndSection": 472, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23982054", "text": "We conducted the current study to analyze the clinical, immunologic, and neurophysiologic features of primary Sj\u00f6gren syndrome (pSS)-associated sensory small fiber neuropathies (SFNs).", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23982054", "text": "Clinical symptoms included burning pains (90%), numbness (87.5%), tingling (82.5%), pins and needles (72.5%), electric discharges (70%), and allodynia (55%).", "offsetInBeginSection": 707, "offsetInEndSection": 857, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33830702", "text": "The symptoms of SFN usually are sensitive including paresthesia, dysesthesia or burning pain, and protopathic deficits, sometimes associated with dysautonomia.", "offsetInBeginSection": 138, "offsetInEndSection": 288, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36005471", "text": "3 autoantibodies. Demographics, clinical features, epidermal nerve fiber density, and Quantitative Sudomotor Axon Reflex Test results were analyzed. I", "offsetInBeginSection": 450, "offsetInEndSection": 600, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30316835", "text": "nel of two read-outs reflecting SFN in zebrafish, being nerve density and behavioral responses. Nerve density was studied using a transgenic line in w", "offsetInBeginSection": 457, "offsetInEndSection": 607, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34075618", "text": "valence rates of SFN in Switzerland. SFN can vary greatly in its symptoms and severity. Extensive work-up resulted in two thirds of the patients being", "offsetInBeginSection": 1239, "offsetInEndSection": 1389, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28410768", "text": " to channelopathies. Diagnostic management is based primarily on clinical examination and demonstration of small fiber dysfunction. Laser evoked poten", "offsetInBeginSection": 768, "offsetInEndSection": 918, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26872938", "text": "Etiological and clinical heterogeneity of small fiber neuropathy (SFN) precludes a unifying approach and necessitates reliance on recognizable clinical syndromes.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25835646", "text": "th duration of ERT (r=0.31, p=0.0495). Trends toward correlation with forced vital capacity and age at diagnosis were also present. Women had a higher", "offsetInBeginSection": 978, "offsetInEndSection": 1128, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29809227", "text": "Its clinical picture includes both negative and positive manifestations: sensory (pain/dysesthesias/pruritus) or combined sensory and autonomic complaints, associated with an almost entirely normal neurological examination.", "offsetInBeginSection": 498, "offsetInEndSection": 648, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31639840", "text": "esent, before the neuropathy evaluation. Etiology-specific treatment, lifestyle modification, and pain control are the key elements of SFN management.", "offsetInBeginSection": 512, "offsetInEndSection": 662, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30636091", "text": "CONCLUSION\nOur results suggest that idio-SFN more specifically involved small sensory fibers than pSS-SFN, in which subtle dysfunction of larger sensory fibers and damage of distal autonomic sudomotor innervation may occur.", "offsetInBeginSection": 816, "offsetInEndSection": 966, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35366250", "text": "tly understudied. This study aimed to identify the clinical and histological correlates of small fiber neuropathy in sarcoidosis patients. The study w", "offsetInBeginSection": 241, "offsetInEndSection": 391, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23304492", "text": "manifestations of the disease. SFN presents with peripheral pain and symptoms of autonomic dysfunction. The character of the pain can be burning or sh", "offsetInBeginSection": 121, "offsetInEndSection": 271, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31325646", "text": "PERSPECTIVE: This review provides a critical analysis of SFN associated with neurotoxic cancer treatments and the assessment tools for evaluating small fiber dysfunction in cancer patients.", "offsetInBeginSection": 1389, "offsetInEndSection": 1539, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36331613", "text": "n's syndrome. We did not observe any differences in SFN-defining sensory plus symptoms. Furthermore, intraepidermal nerve fiber densities (IENFD) were", "offsetInBeginSection": 695, "offsetInEndSection": 845, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20433606", "text": " evaluated 44 patients with SFN diagnosed in the presence of both symptoms and signs. Eleven were classified as non-length dependent SFN. Disease asso", "offsetInBeginSection": 190, "offsetInEndSection": 340, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31325646", "text": "PERSPECTIVE: This review provides a critical analysis of SFN associated with neurotoxic cancer treatments and the assessment tools for evaluating small fiber dysfunction in cancer patients.", "offsetInBeginSection": 561, "offsetInEndSection": 711, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35130356", "text": "rerequisites for treating SFN are an established diagnosis, knowledge about the symptoms and signs, and the etiology. Pain usually responds to oral/in", "offsetInBeginSection": 684, "offsetInEndSection": 834, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415c53e690f196b51000012", "type": "factoid", "body": "When was Keytruda approved by the FDA for the treatment of metastatic non-small cell lung cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25797684", "http://www.ncbi.nlm.nih.gov/pubmed/24573551", "http://www.ncbi.nlm.nih.gov/pubmed/33058106", "http://www.ncbi.nlm.nih.gov/pubmed/15962527", "http://www.ncbi.nlm.nih.gov/pubmed/27821604", "http://www.ncbi.nlm.nih.gov/pubmed/27920140", "http://www.ncbi.nlm.nih.gov/pubmed/27659911", "http://www.ncbi.nlm.nih.gov/pubmed/29019253", "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "http://www.ncbi.nlm.nih.gov/pubmed/27026676"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24573551", "text": "as granted on the basis of the high ORRs and durable responses. On November 20, 2013, crizotinib received full approval based on an improvement in pro", "offsetInBeginSection": 1086, "offsetInEndSection": 1236, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27659911", "text": "or patients with metastatic non-small cell lung cancer by the FDA in October, 2015. We present the first case, to the best of our knowledge, of a pati", "offsetInBeginSection": 547, "offsetInEndSection": 697, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27920140", "text": "andomized trials, the FDA approved the anti-PD-L1 agent atezolizumab in October. It is the first PD-L1 inhibitor approved for use in patients with met", "offsetInBeginSection": 49, "offsetInEndSection": 199, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27821604", "text": "In 2015, the FDA approved an unprecedented number of new therapies for non-small cell lung cancer (NSCLC), among them therapies addressing specific genomic tumor subsets in the setting of development of resistance to first-line targeted therapy.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27026676", "text": "UNLABELLED\n: On October 2, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab, a breakthrough therapy-de", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15962527", "text": "e cancer malignant pleural mesothelioma. Its accelerated approval for the second-line treatment of non-small-cell lung cancer followed in August 2004.", "offsetInBeginSection": 240, "offsetInEndSection": 390, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25797684", "text": "mphoma kinase rearranged metastatic non-small-cell lung cancer, on November 20, 2013. Crizotinib is a customized and improved therapeutic option for p", "offsetInBeginSection": 151, "offsetInEndSection": 301, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24573551", "text": "On August 26, 2011, the U.S. Food and Drug Administration (FDA) approved crizotinib (XALKORI Capsules, Pfizer Inc.) for treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "text": "On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treat", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29019253", "text": " remove its inhibitory effect and provoke an anti-tumor response. In October 2016, the Food and Drugs Administration (FDA) approved atezolizumab for t", "offsetInBeginSection": 260, "offsetInEndSection": 410, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33058106", "text": "The US FDA granted accelerated approval to pralsetinib for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6417949d690f196b51000035", "type": "list", "body": "Which gene therapies are under investigation for Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26140505", "http://www.ncbi.nlm.nih.gov/pubmed/30119719", "http://www.ncbi.nlm.nih.gov/pubmed/27340611", "http://www.ncbi.nlm.nih.gov/pubmed/28960187", "http://www.ncbi.nlm.nih.gov/pubmed/12206795", "http://www.ncbi.nlm.nih.gov/pubmed/7804468", "http://www.ncbi.nlm.nih.gov/pubmed/29936551", "http://www.ncbi.nlm.nih.gov/pubmed/23328943", "http://www.ncbi.nlm.nih.gov/pubmed/17217326", "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "http://www.ncbi.nlm.nih.gov/pubmed/30275245", "http://www.ncbi.nlm.nih.gov/pubmed/32591735", "http://www.ncbi.nlm.nih.gov/pubmed/27594988", "http://www.ncbi.nlm.nih.gov/pubmed/17846262", "http://www.ncbi.nlm.nih.gov/pubmed/31603849", "http://www.ncbi.nlm.nih.gov/pubmed/17885450", "http://www.ncbi.nlm.nih.gov/pubmed/2663627", "http://www.ncbi.nlm.nih.gov/pubmed/19555515", "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "http://www.ncbi.nlm.nih.gov/pubmed/32542436", "http://www.ncbi.nlm.nih.gov/pubmed/26754139", "http://www.ncbi.nlm.nih.gov/pubmed/23387802", "http://www.ncbi.nlm.nih.gov/pubmed/12206800", "http://www.ncbi.nlm.nih.gov/pubmed/19745732", "http://www.ncbi.nlm.nih.gov/pubmed/12206797"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30119719", "text": "Such translational research has led to the approval of two genetic therapies by the US Food and Drug Administration: eteplirsen for Duchenne muscular dystrophy and nusinersen for spinal muscular atrophy, which are both antisense oligonucleotides that modify pre-mRNA splicing.", "offsetInBeginSection": 420, "offsetInEndSection": 570, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32542436", "text": "nt years. Molecular therapies such as direct gene transfer or alternative processing of the disease-specific gene play an important role in this trans", "offsetInBeginSection": 235, "offsetInEndSection": 385, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32591735", "text": " dystrophy in China, mainly includes mRNA splicing modulators and adeno-associated virus mediated gene replacement. We hope to highlight some importan", "offsetInBeginSection": 547, "offsetInEndSection": 697, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": "In the present review, we describe current methods of induced pluripotent stem cell generation and discuss their implications for the study, modeling, and development of cell-based therapies for Duchenne muscular dystrophy.", "offsetInBeginSection": 600, "offsetInEndSection": 750, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12206800", "text": "In this study we have identified antisense oligoribonucleotides with which the skipping of 11 other Duchenne muscular dystrophy exons could be induced in cultured human muscle cells.", "offsetInBeginSection": 716, "offsetInEndSection": 866, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17217326", "text": "s Duchenne muscular dystrophy (DMD), which arises from defects in the dystrophin gene. Therapy specifically aimed at DMD is reviewed in the context of", "offsetInBeginSection": 333, "offsetInEndSection": 483, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7804468", "text": "A number of the viral vector systems, myoblast transfer, and direct injection techniques that are currently under investigation for the treatment of neuromuscular disorders are reviewed here.", "offsetInBeginSection": 240, "offsetInEndSection": 390, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17885450", "text": "Two more Phase I/IIa studies are underway in Duchenne muscular dystrophy, focused on the intramuscular administration of antisense oligonucleotides to induce exon skipping.", "offsetInBeginSection": 705, "offsetInEndSection": 855, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30275245", "text": "-specific strategies include nonsense readthrough, exon skipping, gene editing, utrophin modulation, and gene replacement. Other mechanisms include mu", "offsetInBeginSection": 749, "offsetInEndSection": 899, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26140505", "text": "e for the primary defect of this disease. These include dystrophin gene-replacement strategies, genetic modification techniques to restore dystrophin ", "offsetInBeginSection": 1307, "offsetInEndSection": 1457, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2663627", "text": "mmon forms of muscular dystrophy, Duchenne muscular dystrophy and myotonic dystrophy. 5. Supportive therapies for muscular dystrophy patients now incl", "offsetInBeginSection": 741, "offsetInEndSection": 891, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12206800", "text": "rophy gene which abort dystrophin synthesis. We have explored a gene correction therapy aimed at restoration of the reading frame in Duchenne muscular", "offsetInBeginSection": 107, "offsetInEndSection": 257, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "nhibition of protease content and activity. Consequently, phosphodiesterase type 5 inhibition is a candidate therapy for slowing the development of ca", "offsetInBeginSection": 1651, "offsetInEndSection": 1801, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19745732", "text": "gned to repair the primary genetic defect, called 'exon skipping' and 'nonsense codon suppression'.\n\n\nRECENT FINDINGS\nA drug, PTC124, was identified t", "offsetInBeginSection": 193, "offsetInEndSection": 343, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19555515", "text": "nclude gene therapy using adeno-associated viral, lentiviral and adenoviral vectors and nonviral vectors, such as plasmid DNA. Exon-skipping and cell-", "offsetInBeginSection": 663, "offsetInEndSection": 813, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19555515", "text": "g. These include gene therapy using adeno-associated viral, lentiviral and adenoviral vectors and nonviral vectors, such as plasmid DNA. Exon-skipping", "offsetInBeginSection": 653, "offsetInEndSection": 803, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26754139", "text": "oper care to patients according to published guidelines. With mutation-specific therapies under development for DMD, a correct diagnosis is now also i", "offsetInBeginSection": 296, "offsetInEndSection": 446, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28960187", "text": "In light of the positive results of these studies, genome engineering therapies are being enthusiastically explored for several genetic neuromuscular disorders.", "offsetInBeginSection": 980, "offsetInEndSection": 1130, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27594988", "text": "or DMD are currently available. In this review, we highlight the most advanced therapeutic strategies under investigation as potential DMD treatments.", "offsetInBeginSection": 478, "offsetInEndSection": 628, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19745732", "text": "ulting in premature stops. Two drugs developed for exon skipping, PRO051 and AVI-4658, result in the exclusion of exon 51 from mature mRNA. They can r", "offsetInBeginSection": 522, "offsetInEndSection": 672, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "Phosphodiesterase type 5 is implicated in dystrophic pathology, and the phosphodiesterase type 5 inhibitor tadalafil has recently been studied in a clinical trial for Duchenne muscular dystrophy.", "offsetInBeginSection": 168, "offsetInEndSection": 318, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26140505", "text": "These include manipulation of the expression of the gene or related genes, the splicing of the gene and its translation, and replacement of the gene using viral approaches.", "offsetInBeginSection": 395, "offsetInEndSection": 553, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23328943", "text": "at prolong ambulation and drugs to treat the cardiomyopathy. Multiple treatment strategies are under investigation and have shown promise for Duchenne", "offsetInBeginSection": 219, "offsetInEndSection": 369, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29936551", "text": "Treatment of the underlying pathobiology, such as micro-dystrophin gene replacement, exon skipping, stop codon read-through agents, and utrophin modulators showed variable success in animal and human studies.", "offsetInBeginSection": 261, "offsetInEndSection": 411, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12206797", "text": "Among the various approaches currently under investigation for dystrophin mutations that cause Duchenne muscular dystrophy is the use of chimeric RNA/DNA oligonucleotides (\"chimeraplasts\") to repair point mutations.", "offsetInBeginSection": 425, "offsetInEndSection": 575, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23387802", "text": "cement and gene/expression repair, including exon-skipping, vector-mediated gene therapy and cell therapy. Therapeutic strategies for different forms ", "offsetInBeginSection": 372, "offsetInEndSection": 522, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12206795", "text": "We are now conducting a phase I safety clinical trial which will pave the way for future therapeutic gene therapy trials for Duchenne muscular dystrophy.", "offsetInBeginSection": 776, "offsetInEndSection": 926, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31603849", "text": " pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration, etc. It is likely that an effective treatment for D", "offsetInBeginSection": 941, "offsetInEndSection": 1091, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27340611", "text": " Duchenne cardiomyopathy has been the primary focus of ongoing dystrophic cardiomyopathy gene therapy studies. Here, we use Duchenne cardiomyopathy ge", "offsetInBeginSection": 628, "offsetInEndSection": 778, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17846262", "text": "gene therapy, an approach that demonstrates promise for treating Duchenne muscular dystrophy. Gene therapy is not limited to replacement of defective genes but also includes strategies using surrogate genes with alternative but effective means of improving cellular function or repairing gene mutations", "offsetInBeginSection": 146, "offsetInEndSection": 448, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f02a82f36125a426000013", "type": "yesno", "body": "Does CIDEB mutation protect from liver disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35939579", "http://www.ncbi.nlm.nih.gov/pubmed/34646017", "http://www.ncbi.nlm.nih.gov/pubmed/19661960", "http://www.ncbi.nlm.nih.gov/pubmed/32553626", "http://www.ncbi.nlm.nih.gov/pubmed/21948526", "http://www.ncbi.nlm.nih.gov/pubmed/17646209", "http://www.ncbi.nlm.nih.gov/pubmed/32325343", "http://www.ncbi.nlm.nih.gov/pubmed/28585425", "http://www.ncbi.nlm.nih.gov/pubmed/24831470", "http://www.ncbi.nlm.nih.gov/pubmed/36070080", "http://www.ncbi.nlm.nih.gov/pubmed/33500241", "http://www.ncbi.nlm.nih.gov/pubmed/22661308", "http://www.ncbi.nlm.nih.gov/pubmed/20123130", "http://www.ncbi.nlm.nih.gov/pubmed/20551328", "http://www.ncbi.nlm.nih.gov/pubmed/28719542", "http://www.ncbi.nlm.nih.gov/pubmed/35489563", "http://www.ncbi.nlm.nih.gov/pubmed/35474605", "http://www.ncbi.nlm.nih.gov/pubmed/27207838", "http://www.ncbi.nlm.nih.gov/pubmed/19187774"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34646017", "text": "stinct hepatocyte clones per patient. CIDEB, which regulates lipid droplet metabolism in hepatocytes17-19, and GPAM, which produces storage triacylgly", "offsetInBeginSection": 911, "offsetInEndSection": 1061, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20551328", "text": "s by HepG2 cells, indicating that CideB is a critical mediator of stimulatory effects of PGC-1alpha on VLDL secretion. Collectively, these data sugges", "offsetInBeginSection": 1304, "offsetInEndSection": 1454, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939579", "text": "so found that variants in CIDEB, which encodes a structural protein found in hepatic lipid droplets, had a protective effect. The burden of rare predi", "offsetInBeginSection": 905, "offsetInEndSection": 1055, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939579", "text": " droplets.\n\n\nCONCLUSIONS\nRare germline mutations in CIDEB conferred substantial protection from liver disease. (Funded by Regeneron Pharmaceuticals.).", "offsetInBeginSection": 2112, "offsetInEndSection": 2262, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939579", "text": "h encodes a structural protein found in hepatic lipid droplets, had a protective effect. The burden of rare predicted loss-of-function variants plus m", "offsetInBeginSection": 942, "offsetInEndSection": 1092, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28585425", "text": "Our data showed that Cidea and Cidec were expressed at a high level in adipose tissue, and at a relatively high level in skeletal muscle, whereas Cideb was mainly expressed in the liver in both breeds of pig.", "offsetInBeginSection": 549, "offsetInEndSection": 699, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24831470", "text": "Cell death-inducing DFF45-like effector b (Cideb), an endoplasmic reticulum (ER)- and lipid droplet (LD)-associated protein, has been shown to play a critical role in maintaining hepatic lipid homeostasis by promoting the lipidation and maturation of VLDL particles.", "offsetInBeginSection": 89, "offsetInEndSection": 239, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36070080", "text": "Little, if any, is known about the association between the genotype and phenotype among children with telomere disease and whether the mutation we have described (r.95G>C) is predisposed to early severe hepatic involvement.", "offsetInBeginSection": 1285, "offsetInEndSection": 1435, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35474605", "text": "RESULTS\nThere was no evidence of association between rare germline variants or SNPs near five genes (ACVR2A, ALB, CIDEB, FOXO1 and TNRC6B) and risk or severity of liver disease.", "offsetInBeginSection": 919, "offsetInEndSection": 1087, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27207838", "text": "e CIDEa and CIDEc [3]. We therefore speculate that CIDEb may play a contrary role to the other CIDEs. The basic molecular information we provide here ", "offsetInBeginSection": 2104, "offsetInEndSection": 2254, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35474605", "text": "CONCLUSIONS\nDespite the acquisition of somatic mutations at these loci during progressive fatty liver disease, we did not find associations between germline variation and markers of liver disease, except in GPAM.", "offsetInBeginSection": 1508, "offsetInEndSection": 1658, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28719542", "text": "CONCLUSIONS\nOur data suggest that Cideb plays a protective role against the development of UC by reducing the lipid accumulation and oxidative damage in the colonic mucosa.", "offsetInBeginSection": 1482, "offsetInEndSection": 1632, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17646209", "text": "RESULTS\nCideb-null mice had lower levels of plasma triglycerides and free fatty acids and were resistant to high-fat diet-induced obesity and live steatosis.", "offsetInBeginSection": 879, "offsetInEndSection": 1029, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33500241", "text": "ion to steatohepatitis. Nevertheless, this mutation does not protect against HFHC diet-induced insulin resistance. The selective metabolic improvement", "offsetInBeginSection": 748, "offsetInEndSection": 898, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27207838", "text": "is under fasting and obese conditions, whereas CIDEb promotes lipid storage under normal diet conditions [1], and promotes the formation of triacylgly", "offsetInBeginSection": 295, "offsetInEndSection": 445, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19187774", "text": "Our data suggest that Cideb promotes the formation of triacylglycerol-enriched VLDL particles and provides a molecular insight into VLDL lipidation and maturation in hepatocytes.", "offsetInBeginSection": 883, "offsetInEndSection": 1033, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21948526", "text": "and lipid metabolism. However, the expression and function of Cideb in endocrine pancreas remain to be investigated.\n\n\nMETHODS\nBy using reverse transc", "offsetInBeginSection": 306, "offsetInEndSection": 456, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21948526", "text": "CONCLUSIONS\nThe present results suggest that increased Cideb expression upon palmitate exposure may be involved in beta cell lipoapoptosis through its influence on conversion of FFAs to lipid esters in lipid droplets.", "offsetInBeginSection": 1709, "offsetInEndSection": 1859, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35489563", "text": "role in hepatic lipid metabolism, participates in this process has not been reported. In the present study, we demonstrated that deficiency of cideb a", "offsetInBeginSection": 247, "offsetInEndSection": 397, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19661960", "text": "EC (r(2) = 0.32, P = 0.01) was strongly correlated with BMI, whereas CIDEB was not (r(2) = 0.01, P = 0.81). One year after surgery, CIDEC expression h", "offsetInBeginSection": 486, "offsetInEndSection": 636, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35474605", "text": "RESULTS\nThere was no evidence of association between rare germline variants or SNPs near five genes (ACVR2A, ALB, CIDEB, FOXO1 and TNRC6B) and risk or severity of liver disease.", "offsetInBeginSection": 889, "offsetInEndSection": 1039, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28585425", "text": "Finally, data from correlation analysis further found that CIDE mRNA expression was positively correlated with back fat thickness (BFT), abdominal fat mass (AFM), and the levels of NEFA, TAG, and glucose in the two breeds.", "offsetInBeginSection": 1752, "offsetInEndSection": 1902, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28585425", "text": "Collectively, these data revealed that the porcine CIDEs possibly modulated lipid metabolism and contributed to the development of fat deposition and obesity in Lantang pigs.", "offsetInBeginSection": 1902, "offsetInEndSection": 2052, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20123130", "text": "Cideb is a novel regulator in controlling cholesterol homeostasis in the liver. Therefore, Cideb could serve as an important therapeutical target for the treatment of atherosclerosis and cardiovascular diseases", "offsetInBeginSection": 1582, "offsetInEndSection": 1792, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24831470", "text": "nteract with ApoB48 in Caco-2 cells. Overall, these data revealed that Cideb plays an important role in controlling intestinal chylomicron lipidation.", "offsetInBeginSection": 1033, "offsetInEndSection": 1183, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22661308", "text": " Cideb, a member of cell death-inducing DFF45-like effector (CIDE) protein family, has been previously shown to promote VLDL lipidation and maturation", "offsetInBeginSection": 234, "offsetInEndSection": 384, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28719542", "text": " its roles in the pathogenesis of UC are still ill-defined.\n\n\nMETHODS\nAcute colitis was induced with DSS in Cideb-null and wild-type mice, and the inflammation and oxidative stress were evaluated in the colonic mucosa. Moreover, triglyceride accumulation and oxidative stress were further analyzed in polarized Caco-2 cells with overexpression of Cideb.\n\n\nRESULTS\nOur present data indicated that Cideb-null mice were more susceptible to DSS-induced colitis", "offsetInBeginSection": 397, "offsetInEndSection": 853, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32553626", "text": "ole in growth of lipid droplets. Of these, CIDEB and CIDEC2/FSP27B are abundant in the liver, and the steatotic livers, respectively. Hepatocyte nucle", "offsetInBeginSection": 139, "offsetInEndSection": 289, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32325343", "text": "nockout mice. Therefore, Cideb depletion could effectively attenuated TCDD or iron induced cell death related genes expression. In conclusion, our res", "offsetInBeginSection": 1082, "offsetInEndSection": 1232, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64089b21201352f04a000021", "type": "summary", "body": "Can you summarize the function of CDK9?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26083714", "http://www.ncbi.nlm.nih.gov/pubmed/21448926", "http://www.ncbi.nlm.nih.gov/pubmed/12037670", "http://www.ncbi.nlm.nih.gov/pubmed/21200140", "http://www.ncbi.nlm.nih.gov/pubmed/16720337", "http://www.ncbi.nlm.nih.gov/pubmed/32901849", "http://www.ncbi.nlm.nih.gov/pubmed/18473913", "http://www.ncbi.nlm.nih.gov/pubmed/30579871", "http://www.ncbi.nlm.nih.gov/pubmed/30726104", "http://www.ncbi.nlm.nih.gov/pubmed/34188177", "http://www.ncbi.nlm.nih.gov/pubmed/21143121", "http://www.ncbi.nlm.nih.gov/pubmed/27833949", "http://www.ncbi.nlm.nih.gov/pubmed/31758083", "http://www.ncbi.nlm.nih.gov/pubmed/32903585", "http://www.ncbi.nlm.nih.gov/pubmed/18753202", "http://www.ncbi.nlm.nih.gov/pubmed/34146121", "http://www.ncbi.nlm.nih.gov/pubmed/31594641", "http://www.ncbi.nlm.nih.gov/pubmed/34811514", "http://www.ncbi.nlm.nih.gov/pubmed/20930849", "http://www.ncbi.nlm.nih.gov/pubmed/17452463", "http://www.ncbi.nlm.nih.gov/pubmed/33631230"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20930849", "text": "er, CDK9 also forms a complex with cyclin K, the function of which is less clear. Using a synthetic lethal RNA interference screen in human cells, we ", "offsetInBeginSection": 205, "offsetInEndSection": 355, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32901849", "text": " pathogenic role in various types of cancer, little is known concerning its function in endometrial cancer. Our study was conducted to evaluate the ex", "offsetInBeginSection": 155, "offsetInEndSection": 305, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21200140", "text": "o binds to cyclin K but the function of this CDK9-cyclin K complex is less clear. We and others have recently shown that CDK9 functions directly in ma", "offsetInBeginSection": 302, "offsetInEndSection": 452, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34146121", "text": "coring the need to properly regulate CDK9. Here, I provide an overview of CDK9 function and regulation, with an emphasis on CDK9 dysregulation in huma", "offsetInBeginSection": 810, "offsetInEndSection": 960, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30726104", "text": " established pathogenic role in various cancers, its function in ovarian cancer remains poorly defined. The purpose of this study was to evaluate the ", "offsetInBeginSection": 173, "offsetInEndSection": 323, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31594641", "text": "Together, these findings highlight the importance of CDK9 in MB pathogenesis and suggest that it may serve as a promising therapeutic target for the treatment of MB.", "offsetInBeginSection": 1274, "offsetInEndSection": 1424, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18753202", "text": "The primary function of cdk9 and its partners, the cyclin T variants, is in the elongation of RNA transcripts, although functions related to the initiation and processing of transcripts have also been reported.", "offsetInBeginSection": 410, "offsetInEndSection": 560, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31594641", "text": "Although CDK9 plays a pathogenic role in various cancers, its function in MB remains unknown. Here, we show that CDK9 is highly expressed in MB tumors", "offsetInBeginSection": 341, "offsetInEndSection": 491, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12037670", "text": "pping within 101-161 aa of the bHLH region. Finally, cdk9 can phosphorylate MyoD in vitro, suggesting the possibility that cdk9/cycT2a regulation of m", "offsetInBeginSection": 1014, "offsetInEndSection": 1164, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21143121", "text": "The CDK9 inhibitory activity of the derivatives was measured in specific kinase assay and the CDK inhibitory profile of the best ones (IC(50) < 100 nM) was determined.", "offsetInBeginSection": 700, "offsetInEndSection": 850, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31758083", "text": "athological function of CDK9 in bacterial inflammatory diseases has never been explored. CDK9 inhibition or knock-down attenuated Porphyromonas gingiv", "offsetInBeginSection": 191, "offsetInEndSection": 341, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12037670", "text": "Unlike the other cdks, cdk9 is not serum- or cell cycle-regulated and is instead involved in the regulation of transcriptional elongation by phosphorylating the carboxyl-terminal domain (CTD) of RNA polymerase II.", "offsetInBeginSection": 281, "offsetInEndSection": 431, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26083714", "text": "nRNP to deliver to target genes and also enhances CDK9's activity and resistance to inhibition. Because the i-CDK9-induced MYC expression and binding ", "offsetInBeginSection": 720, "offsetInEndSection": 870, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34811514", "text": "In this review, we summarize the current knowledge on the role of CDK9 in transcriptional regulation, epigenetic regulation, and different cellular factor interactions, focusing on new advances.", "offsetInBeginSection": 943, "offsetInEndSection": 1093, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27833949", "text": "P II transcription complexes. The regulation of CDK9 function is an intricate network that includes post-translational modifications (phosphorylation/", "offsetInBeginSection": 1044, "offsetInEndSection": 1194, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21448926", "text": "t protein coding genes. Cdk9 kinase function is dependent upon phosphorylation of Thr186 in its T-loop. In this study, we examined kinases and signali", "offsetInBeginSection": 261, "offsetInEndSection": 411, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21143121", "text": "Among CDKs, CDK9 is a validated pathological target in HIV infection, inflammation and cardiac hypertrophy; however selective CDK9 inhibitors are still not available.", "offsetInBeginSection": 321, "offsetInEndSection": 471, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32903585", "text": "Among them, since the transcription-associated CDK9 represents the sentry of cell transcriptional homeostasis, it can be a valuable target for managing cancers in which the transcriptional machinery is dysregulated by tumor-driver oncogenes.", "offsetInBeginSection": 123, "offsetInEndSection": 273, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18753202", "text": "We conclude that cdk9 plays a critical role in the optimization of expression of genes regulated by ICP22 and that one function of cdk9 in HSV-1-infected cells may be to bring ICP22 into the RNA Pol II transcriptional complex.", "offsetInBeginSection": 1485, "offsetInEndSection": 1635, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27833949", "text": " synthesis and processing by eukaryotic RNA polymerase II. As a cyclin-dependent kinase, CDK9 activation in vivo depends upon its association with T-t", "offsetInBeginSection": 139, "offsetInEndSection": 289, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30579871", "text": "athogenesis of malignant tumors. However, the expression and function of CDK9 remain unknown in osteosarcomas. The purpose of this study is to assess ", "offsetInBeginSection": 101, "offsetInEndSection": 251, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33631230", "text": "emia. Recent studies have implicated cyclin-dependent kinase 9 (CDK9) in inflammatory responses and renal fibrosis. In this study, we explored a poten", "offsetInBeginSection": 86, "offsetInEndSection": 236, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30726104", "text": "rmation, and migration activity. Our results reveal CDK9 as a novel prognostic biomarker and a promising therapeutic target for preventing metastasis ", "offsetInBeginSection": 1145, "offsetInEndSection": 1295, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26083714", "text": "CDK9 is the kinase subunit of positive transcription elongation factor b (P-TEFb) that enables RNA polymerase (Pol) II's transition from promoter-proximal pausing to productive elongation.", "offsetInBeginSection": 29, "offsetInEndSection": 187, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34188177", "text": "Here, we demonstrate that CDK9 is closely associated with the progression of HCC and can serve as an HCC therapeutic target by modulating the recovery of wild-type p53 (wt-p53) function.", "offsetInBeginSection": 377, "offsetInEndSection": 537, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34811514", "text": "In this review, we summarize the current knowledge on the role of CDK9 in transcriptional regulation, epigenetic regulation, and different cellular factor interactions, focusing on new advances.", "offsetInBeginSection": 897, "offsetInEndSection": 1065, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18473913", "text": "/or transcriptional control. CDK9 is the catalytic subunit of positive transcription elongation factor b (P-TEFb). CDK9 is the kinase of the TAK compl", "offsetInBeginSection": 135, "offsetInEndSection": 285, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17452463", "text": "mplex is regulated by acetylation. We demonstrate that CDK9 is an acetylated protein in cells and can be acetylated by p300 in vitro. Through both in ", "offsetInBeginSection": 686, "offsetInEndSection": 836, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18473913", "text": " designed, and structural studies can add information in the understanding of this kinase. The major features related to CDK9 inhibition will be revie", "offsetInBeginSection": 1508, "offsetInEndSection": 1658, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16720337", "text": "This review primarily focuses on the mechanisms that modulate CDK9 activity and its recruitment to cellular genes, where it phosphorylates the C-terminal domain of RNA polymerase II (RNAPII) as well as negative elongation factors.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410eead201352f04a000030", "type": "summary", "body": "How does RBM24 control QT interval?", "documents": [], "snippets": []}, {"id": "64105502201352f04a00002d", "type": "yesno", "body": "Is North Star Ambulatory Assessment score a reliable clinical outcome for disease progression assessment in Duchenne Muscular Dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30319901", "http://www.ncbi.nlm.nih.gov/pubmed/31629611", "http://www.ncbi.nlm.nih.gov/pubmed/29167533", "http://www.ncbi.nlm.nih.gov/pubmed/35501714", "http://www.ncbi.nlm.nih.gov/pubmed/31479456", "http://www.ncbi.nlm.nih.gov/pubmed/35862363", "http://www.ncbi.nlm.nih.gov/pubmed/30868504", "http://www.ncbi.nlm.nih.gov/pubmed/35626905", "http://www.ncbi.nlm.nih.gov/pubmed/25447928", "http://www.ncbi.nlm.nih.gov/pubmed/23726376", "http://www.ncbi.nlm.nih.gov/pubmed/22404693", "http://www.ncbi.nlm.nih.gov/pubmed/21410696", "http://www.ncbi.nlm.nih.gov/pubmed/25454732", "http://www.ncbi.nlm.nih.gov/pubmed/25271887", "http://www.ncbi.nlm.nih.gov/pubmed/34170974", "http://www.ncbi.nlm.nih.gov/pubmed/33978227", "http://www.ncbi.nlm.nih.gov/pubmed/21954141", "http://www.ncbi.nlm.nih.gov/pubmed/20634072", "http://www.ncbi.nlm.nih.gov/pubmed/23909763", "http://www.ncbi.nlm.nih.gov/pubmed/34155911", "http://www.ncbi.nlm.nih.gov/pubmed/35932452", "http://www.ncbi.nlm.nih.gov/pubmed/28648683", "http://www.ncbi.nlm.nih.gov/pubmed/27494024"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23909763", "text": " However, in Duchenne muscular dystrophy (DMD), identifying changes in function is not straightforward. In this study, we use Rasch-transformed data t", "offsetInBeginSection": 184, "offsetInEndSection": 334, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21954141", "text": "ur study indicates that the North Star Ambulatory Assessment is practical and reliable. It takes only 10 minutes to perform and incorporates both univ", "offsetInBeginSection": 911, "offsetInEndSection": 1061, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33978227", "text": "INTRODUCTION\nThere is a need for reliable and properly validated outcome measures in Duchenne muscular dystrophy, both to monitor functional impairment and to assess the impact of new therapies.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35626905", "text": " (-12 months) to video assessment was 2.0 (2.8SD).\n\n\nCONCLUSION\nThe results from the study suggest that video NSAA is partially feasible and reliable.", "offsetInBeginSection": 1115, "offsetInEndSection": 1265, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31629611", "text": "Our results showed North Star Ambulatory Assessment scores progressively increased with age. The largest increase was observed between age 3 and 4 yea", "offsetInBeginSection": 381, "offsetInEndSection": 531, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20634072", "text": "n daily regimen. The scores on the North Star assessment ranged from 6/34 to 34/34. The distance on the 6-minute walk test ranged from 127 to 560.6 m.", "offsetInBeginSection": 723, "offsetInEndSection": 873, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23726376", "text": "l Motor Scale (HFMSE) and North Star Ambulatory Assessment (NSAA) may also be useful in this young DMD population. Clinical evaluators from the MDA-DM", "offsetInBeginSection": 348, "offsetInEndSection": 498, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28648683", "text": "North Star Ambulatory Assessment in Brazilian Portuguese is a reliable and valid instrument to measure functional capacity in boys with Duchenne muscular dystrophy.", "offsetInBeginSection": 1382, "offsetInEndSection": 1532, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23726376", "text": "2.2 \u00b1 0.4 years) showed a mean score of 12 \u00b1 5. Outcome assessments of young boys with DMD are feasible and in this multicenter study were best demons", "offsetInBeginSection": 1162, "offsetInEndSection": 1312, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29167533", "text": "n proposed as biomarker of disease progression in dystrophinopathies. Correlation with clinically meaningful outcome measures such as North Star Ambul", "offsetInBeginSection": 303, "offsetInEndSection": 453, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30868504", "text": "ly correlated with the overall mean T2 relaxation time. T2 mapping may prove clinically useful in monitoring muscle changes as a result of the disease", "offsetInBeginSection": 1292, "offsetInEndSection": 1442, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25454732", "text": "of the same age. Our findings suggest that the North Star Ambulatory Assessment can be reliably used at least from the age of 4 years. Longitudinal na", "offsetInBeginSection": 862, "offsetInEndSection": 1012, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35862363", "text": "The Motor Function Measure (general instrument), Duchenne Muscular Dystrophy Upper-limb Patient-reported Outcome Measure, North Star Ambulatory Assessment, and Myotonic Dystrophy Type 1 Activity and Participation Scale for Clinical Use (specific) are also recommended.", "offsetInBeginSection": 2182, "offsetInEndSection": 2332, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27494024", "text": "The application of the revised version of the scale to data collected in young DMD boys showed that very few of the DMD boys were able to complete with a full score all the age appropriate items.", "offsetInBeginSection": 1053, "offsetInEndSection": 1203, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35501714", "text": "the patients. Molecular diagnoses were confirmed by multiplex ligation-dependent probe amplification and next-generation sequencing tests.\n\n\nRESULTS\nA", "offsetInBeginSection": 713, "offsetInEndSection": 863, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25271887", "text": "n Duchenne muscular dystrophy. Our findings will help not only to have a better idea of the progression of the disorder but also provide reference dat", "offsetInBeginSection": 1302, "offsetInEndSection": 1452, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21410696", "text": "olutions for in future use of the NSAA. Importantly, our findings supported good clinical validity in that the hierarchy of items within the scale pro", "offsetInBeginSection": 1405, "offsetInEndSection": 1555, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34170974", "text": "bulant patients affected by Duchenne muscular dystrophy amenable to skip exons 44, 45, 51 or 53.\n\n\nMATERIALS AND METHODS\nWe included 101 patients, 34 ", "offsetInBeginSection": 134, "offsetInEndSection": 284, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30319901", "text": "Currently, the 6-minute walk test (6-MWT) and the North Star Ambulatory Assessment (NSAA) are the primary outcome measures in clinical trials, but they are severely limited by the subjective consciousness and mood of patients, and can only be used in older and ambulatory boys.", "offsetInBeginSection": 279, "offsetInEndSection": 429, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35932452", "text": "uscle weakness on motor function is similar. The NSAD is a reliable and valid ClinRO of motor performance for individuals with LGMD and is suitable fo", "offsetInBeginSection": 1923, "offsetInEndSection": 2073, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35501714", "text": "Clinical history, including the disease phenotype, steroid therapy, and the North Star Ambulatory Assessment (NSAA) score, was taken for all the patients.", "offsetInBeginSection": 609, "offsetInEndSection": 759, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31629611", "text": " of the gene (p\u00a0<\u00a00,001). Very few boys achieved the age appropriate maximum score. These results provide useful information for the assessment and co", "offsetInBeginSection": 1082, "offsetInEndSection": 1232, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22404693", "text": "AIM\nWe evaluated ambulatory patients with Duchenne muscular dystrophy from the cardiovascular standpoint and studied the correlation between the results of electrocardiographic (ECG) findings, left ventricular ejection fraction (LVEF), troponin T and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels and patients' North Star Ambulatory Assessment scores.", "offsetInBeginSection": 120, "offsetInEndSection": 364, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33978227", "text": "CONCLUSION\nOur study has resulted in a convenient and reliable instrument for the quantification of functional abilities in boys with Duchenne muscular dystrophy in Spain.", "offsetInBeginSection": 1474, "offsetInEndSection": 1624, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35932452", "text": "OBJECTIVE\nThe North Star Assessment for limb-girdle type muscular dystrophies (NSAD), a clinician-reported outcome measure (ClinRO) of motor performance, was initially developed and validated for use in dysferlinopathy, an autosomal recessive form of limb-girdle muscular dystrophy (LGMD R2/2B).", "offsetInBeginSection": 44, "offsetInEndSection": 194, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31479456", "text": "Functional variability among boys with Duchenne muscular dystrophy (DMD) is well recognised and complicates interpretation of clinical studies. We hypothesised that boys with DMD could be clustered into groups sharing similar trajectories of ambulatory function over time, as measured by the North Star Ambulatory Assessment (NSAA) total score.", "offsetInBeginSection": 0, "offsetInEndSection": 344, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21410696", "text": "st evidence to support such tools. The North Star Ambulatory Assessment (NSAA) is a promising, clinician-rated scale with potential uses spanning clin", "offsetInBeginSection": 222, "offsetInEndSection": 372, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34155911", "text": "Conclusion: The moderate correlation between functional tests, age and baseline MRI measures supports MRI as a biomarker in Duchenne muscular dystrophy clinical trials.", "offsetInBeginSection": 740, "offsetInEndSection": 896, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25447928", "text": " separately.\n\n\nCONCLUSIONS\nArithmetically derived composite scores can provide stronger correlations to functional measures than isolated biomarkers. ", "offsetInBeginSection": 1529, "offsetInEndSection": 1679, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35626905", "text": "The North Star Ambulatory Assessment (NSAA) is a validated 17-item functional rating scale and widely used to assess motor function in boys with Duchenne muscular dystrophy (DMD). The SARS-CoV-2 pandemic and subsequent Government 'lockdown' resulted in no face-to-face clinic visits hence the motor abilities were not monitored. The aim was to investigate whether the NSAA was feasible and reliable by video assessment", "offsetInBeginSection": 10, "offsetInEndSection": 428, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f032caf36125a42600001a", "type": "summary", "body": "What is the mechanism of action of rilzabrutinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34631841", "http://www.ncbi.nlm.nih.gov/pubmed/35417637", "http://www.ncbi.nlm.nih.gov/pubmed/27324312", "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "http://www.ncbi.nlm.nih.gov/pubmed/23089283", "http://www.ncbi.nlm.nih.gov/pubmed/6572387", "http://www.ncbi.nlm.nih.gov/pubmed/33674445", "http://www.ncbi.nlm.nih.gov/pubmed/33942286"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417637", "text": "nisms of action: decreased macrophage (Fc\u03b3 receptor)-mediated platelet destruction and reduced production of pathogenic autoantibodies.\n\n\nMETHODS\nIn a", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33942286", "text": "id clinical activity in pemphigus vulgaris. These data suggest that BTK inhibition may be a promising treatment strategy and support further investiga", "offsetInBeginSection": 1742, "offsetInEndSection": 1892, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33674445", "text": "ses. We examined the pharmacodynamic profile of rilzabrutinib and its preclinical mechanisms of action. In addition to potent and selective BTK enzyme", "offsetInBeginSection": 344, "offsetInEndSection": 494, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312", "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.", "offsetInBeginSection": 256, "offsetInEndSection": 406, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "text": "This study aimed to define the clinically relevant supratherapeutic dose of rilzabrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, and evaluate potential effects of therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects.", "offsetInBeginSection": 43, "offsetInEndSection": 193, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417637", "text": "\n\nCONCLUSIONS\nRilzabrutinib was active and associated with only low-level toxic effects at all dose levels. The dose of 400 mg twice daily was identif", "offsetInBeginSection": 1877, "offsetInEndSection": 2027, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33674445", "text": "Rilzabrutinib is characterized by reversible covalent BTK binding, long BTK residence time with low systemic exposure, and multiple mechanistic and biological effects on immune cells.", "offsetInBeginSection": 1465, "offsetInEndSection": 1615, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "text": ", or moxifloxacin (positive control). Primary objectives: part A - pharmacokinetics (PK) of rilzabrutinib \u00b1 ritonavir, safety, and optimal dose for Pa", "offsetInBeginSection": 660, "offsetInEndSection": 810, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34631841", "text": "\u03bcM). Conclusion: Remibrutinib and rilzabrutinib inhibit Btk-dependent pathways of platelet aggregation upon GPVI, VWF/GPIb, and Fc\u03b3RIIA activation. Re", "offsetInBeginSection": 1650, "offsetInEndSection": 1800, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33942286", "text": "zabrutinib alone, or with much lower CS doses than usual, was safe, with rapid clinical activity in pemphigus vulgaris. These data suggest that BTK in", "offsetInBeginSection": 1666, "offsetInEndSection": 1816, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "text": "trointestinal intolerance. In Part B, rilzabrutinib 400\u2009mg\u2009+\u2009ritonavir increased rilzabrutinib mean AUC0-\u221e from 454 to 3800\u2009ng\u2009h/mL and Cmax from 144 ", "offsetInBeginSection": 1259, "offsetInEndSection": 1409, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33674445", "text": "Rilzabrutinib is characterized by reversible covalent BTK binding, long BTK residence time with low systemic exposure, and multiple mechanistic and biological effects on immune cells.", "offsetInBeginSection": 1524, "offsetInEndSection": 1674, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283", "text": "The role of the mirror mechanism in cognition remains an intriguing and hotly debated topic in cognitive neuroscience. Since its discovery in the monk", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417637", "text": "ously treated patients with immune thrombocytopenia. We used intrapatient dose escalation of oral rilzabrutinib over a period of 24 weeks; the lowest ", "offsetInBeginSection": 458, "offsetInEndSection": 608, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33942286", "text": "tibodies. Rilzabrutinib is a new reversible, covalent BTK inhibitor demonstrating preclinical efficacy as monotherapy in canine pemphigus foliaceus.\n\n", "offsetInBeginSection": 202, "offsetInEndSection": 352, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6572387", "text": "enylate cyclase activities that are stimulated by human chorionic gonadotropin (hCG) and thyrotropin, respectively. Both cell types also respond to ch", "offsetInBeginSection": 96, "offsetInEndSection": 246, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34631841", "text": " platelet effects of two novel BTKi that exhibit a high (remibrutinib) or low (rilzabrutinib) selectivity for Btk over Tec. Methods and Results: Remib", "offsetInBeginSection": 524, "offsetInEndSection": 674, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641368ee201352f04a00003c", "type": "list", "body": "What are the  types/categories of adult diffuse gliomas.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35988090", "http://www.ncbi.nlm.nih.gov/pubmed/32640746", "http://www.ncbi.nlm.nih.gov/pubmed/34817712", "http://www.ncbi.nlm.nih.gov/pubmed/36428772", "http://www.ncbi.nlm.nih.gov/pubmed/35599404", "http://www.ncbi.nlm.nih.gov/pubmed/35562130", "http://www.ncbi.nlm.nih.gov/pubmed/26445861", "http://www.ncbi.nlm.nih.gov/pubmed/35098369", "http://www.ncbi.nlm.nih.gov/pubmed/1666470", "http://www.ncbi.nlm.nih.gov/pubmed/36299937", "http://www.ncbi.nlm.nih.gov/pubmed/34858308", "http://www.ncbi.nlm.nih.gov/pubmed/20708546", "http://www.ncbi.nlm.nih.gov/pubmed/33317715", "http://www.ncbi.nlm.nih.gov/pubmed/30937703", "http://www.ncbi.nlm.nih.gov/pubmed/35455749", "http://www.ncbi.nlm.nih.gov/pubmed/35578106", "http://www.ncbi.nlm.nih.gov/pubmed/35267601", "http://www.ncbi.nlm.nih.gov/pubmed/34405606", "http://www.ncbi.nlm.nih.gov/pubmed/36430704", "http://www.ncbi.nlm.nih.gov/pubmed/28201752", "http://www.ncbi.nlm.nih.gov/pubmed/35701666", "http://www.ncbi.nlm.nih.gov/pubmed/34729052", "http://www.ncbi.nlm.nih.gov/pubmed/16700618"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729052", "text": "The objectives of the current study were to assess the frequency of IDH mutation, ATRX expression loss, p53 overexpression, and 1p/19q co-deletion detection in adult diffuse gliomas (Grade II, III, and IV) and to correlate them with clinicopathological and histopathological features.", "offsetInBeginSection": 609, "offsetInEndSection": 759, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36430704", "text": "btypes of the adult-type diffuse gliomas, including astrocytoma, oligodendroglioma and glioblastoma. The novel data explain the inconsistencies in ear", "offsetInBeginSection": 933, "offsetInEndSection": 1083, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36299937", "text": "In the new WHO classification 2021, adult-type diffuse astrocytic gliomas subdivide into isocitrate dehydrogenase (IDH)-mutant astrocytoma, IDH-mutant and 1p/19q-codeleted oligodendroglioma, and IDH-wildtype glioblastoma.", "offsetInBeginSection": 198, "offsetInEndSection": 348, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35267601", "text": "The 2021 World Health Organization (WHO) classifies gliomas as adult-type diffuse gliomas or circumscribed astrocytic gliomas depending on their histology and molecular features.", "offsetInBeginSection": 160, "offsetInEndSection": 310, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35562130", "text": "This review briefly discusses two tumor types: astrocytoma, IDH-mutant, and oligodendroglioma, IDH-mutant and 1p/19q codeleted, with emphasis on relevant changes in their classification and defining molecular genetic alterations.", "offsetInBeginSection": 293, "offsetInEndSection": 443, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26445861", "text": "f IDH wild-type/BRAF V600E-mutated diffuse glioma, evolving from grade III to grade IV. The tumor displayed atypical exophytic growth and had unusual ", "offsetInBeginSection": 737, "offsetInEndSection": 887, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32640746", "text": "One of the most significant of these changes has been the division of adult astrocytomas into IDH-wildtype and IDH-mutant categories in addition to histologic grade as part of the main-line diagnosis, although a great deal of heterogeneity in the clinical outcome still remains to be explained within these categories.", "offsetInBeginSection": 494, "offsetInEndSection": 644, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20708546", "text": "current standard therapeutic methods, including maximal surgical resection, radiation, and chemotherapy. The pathogenesis of adult glioma is complex, ", "offsetInBeginSection": 71, "offsetInEndSection": 221, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30937703", "text": "eous group of tumors of the central nervous system that vary greatly in histology and prognosis. A significant advance during the last decade has been", "offsetInBeginSection": 38, "offsetInEndSection": 188, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35599404", "text": "In the 5th edition of WHO classification of central nervous system tumors published in the end of 2021, one of the most important revisions is the division of the classification into adult-type and pediatric-type diffuse gliomas, and the latter is further divided into pediatric-type diffuse low-grade gliomas and pediatric-type diffuse high-grade gliomas.", "offsetInBeginSection": 510, "offsetInEndSection": 660, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36428772", "text": "We explain how DNA methylation-based classification works and list the methylation-based tumour types and subclasses for adult and paediatric diffuse gliomas.", "offsetInBeginSection": 292, "offsetInEndSection": 442, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729052", "text": " which could be useful for the evaluation of prognosis, especially Grade III and II. Although the immunohistochemical approach does not replace geneti", "offsetInBeginSection": 1595, "offsetInEndSection": 1745, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35578106", "text": "Many tumors have also been reconceptualized into new \"supercategories,\" including adult-type diffuse gliomas, pediatric-type diffuse low- and high-grade gliomas, and circumscribed astrocytic gliomas.", "offsetInBeginSection": 446, "offsetInEndSection": 596, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35098369", "text": "cific patterns compared with other genetic alterations according to glioma subtypes. This mutation has variable impacts on patient outcomes in associa", "offsetInBeginSection": 113, "offsetInEndSection": 263, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34817712", "text": "In the new 2021 WHO CNS tumor classification scheme, diffuse gliomas will be classified as either adult-type diffuse gliomas, pediatric-type diffuse high-grade gliomas, or pediatric-type diffuse low-grade gliomas.", "offsetInBeginSection": 815, "offsetInEndSection": 965, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16700618", "text": "epresentatives in this subgroup are the diffuse astrocytic, oligodendroglial, and mixed oligo-astrocytic tumors. Especially in these diffuse gliomas, ", "offsetInBeginSection": 258, "offsetInEndSection": 408, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35701666", "text": "Adult-type diffuse gliomas and meningiomas are the most common primary intracranial tumors of the central nervous system. DNA methylation profiling is", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34858308", "text": "ily of adult types of diffuse gliomas under the insignia of \"glioblastoma, IDH-wildtype.\" Of note, glioblastomas still can be detected in children whe", "offsetInBeginSection": 542, "offsetInEndSection": 692, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33317715", "text": " or EGFR alterations. Larger multi-institutional studies are needed to further characterize the biology of this rare type of diffuse glioma in adults.", "offsetInBeginSection": 1552, "offsetInEndSection": 1702, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34405606", "text": "Objective: To analyze the clinicopathological and molecular features and prognostic implications of adult isocitrate dehydrogenase wild type (IDH-wt) diffuse gliomas.", "offsetInBeginSection": 8, "offsetInEndSection": 158, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34405606", "text": "Conclusions: TERT promoter, EGFR, PTEN, TP53, PDGFRA, CDK4 and MDM2 gene mutations are common molecular genetic changes in adult IDH-wt gliomas, and are associated with poor prognosis.", "offsetInBeginSection": 1592, "offsetInEndSection": 1742, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35988090", "text": "e sex. The median OS for females were 19.2\u00a0months (12.3-35.0) and 16.2\u00a0months (10.5-30.6) for males. No sex difference in survival was seen in other t", "offsetInBeginSection": 1324, "offsetInEndSection": 1474, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30937703", "text": "zed DNA methylation aberration is on the O6-methylguanine-DNA methyltransferase promoter. This aberration is associated with an improved response to t", "offsetInBeginSection": 527, "offsetInEndSection": 677, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33317715", "text": "Compared to non-midline high-grade glioma, adult DMG patients were younger (38 vs 61\u00a0years, p\u00a0<\u00a00.001) and lacked EGFR-alterations (0/9 vs 123/257, p\u00a0=\u00a00.004).", "offsetInBeginSection": 1099, "offsetInEndSection": 1249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28201752", "text": "n = 3, hypothalamus n = 1, and pineal region n = 1) and were IDH and BRAF-V600E wild type. The identification of an H3 K27M mutation significantly imp", "offsetInBeginSection": 623, "offsetInEndSection": 773, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35455749", "text": "This multi-omics analysis of the neurotransmission expression landscape of TCGA gliomas-which highlights the existence of neurotransmission-based glioma categories with different expression, epigenetic and inflammatory profiles-supports the existence of operational neurotransmitter signaling pathways in adult gliomas.", "offsetInBeginSection": 1307, "offsetInEndSection": 1457, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28201752", "text": "thological analysis hesitated between a diffuse glioma, ganglioglioma, or pilocytic astrocytoma. Compared with IDH/H3 wild-type gliomas, H3 K27M-mutan", "offsetInBeginSection": 928, "offsetInEndSection": 1078, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28201752", "text": "ut histone H3 and without isocitrate dehydrogenase (IDH) mutation (IDH/H3 wild type).\n\n\nRESULTS\nThe median age at diagnosis in H3 K27M-mutant gliomas ", "offsetInBeginSection": 344, "offsetInEndSection": 494, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35988090", "text": "liomas.\n\n\nCONCLUSION\nThere was a female survival advantage in glioblastoma, IDH-wildtype, independently of clinical data or MGMT promoter methylation ", "offsetInBeginSection": 1502, "offsetInEndSection": 1652, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1666470", "text": "ultifocal gliomas fall into four main categories: diffuse, multiple, multicentric and multiple-organ. Multicentric gliomas are uncommon lesions of the", "offsetInBeginSection": 1, "offsetInEndSection": 151, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415ca99690f196b51000019", "type": "yesno", "body": "Have chimeric antigen receptor (CAR)-T cell therapies been approved for the treatment of B cell malignancies?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31501612", "http://www.ncbi.nlm.nih.gov/pubmed/33275669", "http://www.ncbi.nlm.nih.gov/pubmed/34407361", "http://www.ncbi.nlm.nih.gov/pubmed/30915277", "http://www.ncbi.nlm.nih.gov/pubmed/32102267", "http://www.ncbi.nlm.nih.gov/pubmed/33689570", "http://www.ncbi.nlm.nih.gov/pubmed/36077787", "http://www.ncbi.nlm.nih.gov/pubmed/31754328", "http://www.ncbi.nlm.nih.gov/pubmed/34485921", "http://www.ncbi.nlm.nih.gov/pubmed/29499327", "http://www.ncbi.nlm.nih.gov/pubmed/33792221", "http://www.ncbi.nlm.nih.gov/pubmed/35653589", "http://www.ncbi.nlm.nih.gov/pubmed/34040345", "http://www.ncbi.nlm.nih.gov/pubmed/33630232", "http://www.ncbi.nlm.nih.gov/pubmed/32402724", "http://www.ncbi.nlm.nih.gov/pubmed/31783836", "http://www.ncbi.nlm.nih.gov/pubmed/36395496", "http://www.ncbi.nlm.nih.gov/pubmed/36389658", "http://www.ncbi.nlm.nih.gov/pubmed/35773047", "http://www.ncbi.nlm.nih.gov/pubmed/30880819", "http://www.ncbi.nlm.nih.gov/pubmed/30784102", "http://www.ncbi.nlm.nih.gov/pubmed/36313336", "http://www.ncbi.nlm.nih.gov/pubmed/33463538", "http://www.ncbi.nlm.nih.gov/pubmed/31658644", "http://www.ncbi.nlm.nih.gov/pubmed/32169439"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33792221", "text": " are currently under investigation. However, none of these current autologous therapies have been approved, and despite high overall response rates ac", "offsetInBeginSection": 525, "offsetInEndSection": 675, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32402724", "text": "Chimeric antigen receptor (CAR) T cell therapy is currently approved for treatment of refractory B-cell malignancies. Response rates in these diseases", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35773047", "text": "Different genome-editing platforms have been used to address human leukocyte antigen (HLA) barriers to generate universal CAR-T cell therapy and early applications have been reported in children and adults against B cell malignancies.", "offsetInBeginSection": 323, "offsetInEndSection": 473, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33689570", "text": "t allows the hybrid cell to target antigens of interest. CAR T-cell therapy has been approved to treat various hematologic malignancies, including rel", "offsetInBeginSection": 229, "offsetInEndSection": 379, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33463538", "text": "Chimeric antigen receptor (CAR) T cell therapy has shown considerable promise for hematologic malignancies, leading to the US Food and Drug Administration approval of two CAR T cell-based therapies for the treatment of B cell acute lymphoblastic leukemia and large B cell lymphoma.", "offsetInBeginSection": 85, "offsetInEndSection": 235, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34040345", "text": "nd plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies fo", "offsetInBeginSection": 107, "offsetInEndSection": 257, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29499327", "text": "cell malignancies, Kymriah and Yescarta, have recently been approved by the Food and Drug Administration. The administration of CAR T cells is a compl", "offsetInBeginSection": 86, "offsetInEndSection": 236, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30784102", "text": "CD19-targeted chimeric antigen receptor (CAR)-modified T (CAR-T) cell immunotherapy has demonstrated impressive results in B-cell malignancies, and CAR-T cell therapies targeting other antigens are in development for other cancers.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32169439", "text": "show promising efficacy and have been approved by the Food and Drug Administration for treating hematological malignancies. However, considering sever", "offsetInBeginSection": 319, "offsetInEndSection": 469, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31501612", "text": "Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed expectations, driving an ever-expanding number of clinical trials and the first US Food and Drug Administration approvals of cell therapies for the treatment of cancer.", "offsetInBeginSection": 9, "offsetInEndSection": 159, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33275669", "text": " including mature B-cell lymphomas. Although two CD19 CAR T-cell products have been commercially approved to treat relapsed/refractory B-cell lymphoma", "offsetInBeginSection": 114, "offsetInEndSection": 264, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31754328", "text": "Recently two CAR-T cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) approved by US FDA (US Food and Drug Administration) are now used for treatment of B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) respectively in the US.", "offsetInBeginSection": 198, "offsetInEndSection": 348, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30880819", "text": "or more lines of systemic therapy in adult patients, respectively. Additional indications have since been approved, and new agents are in development.", "offsetInBeginSection": 1173, "offsetInEndSection": 1323, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31783836", "text": "The approval of chimeric antigen receptor (CAR) T cell therapies by the US Food and Drug Administration (FDA) and the European Commission have generated substantial momentum for these first-in-class therapies to be used in patients with B cell malignancies.", "offsetInBeginSection": 145, "offsetInEndSection": 295, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34485921", "text": "Chimeric antigen receptor (CAR) T-cell therapies have evolved from a research tool to a paradigm-shifting therapy with impressive responses in B cell malignancies.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34407361", "text": "Since the historic approval of tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia in 2017, chimeric antigen receptor (CAR) T-cell therapies have altered the treatment paradigm for hematologic malignancies.", "offsetInBeginSection": 81, "offsetInEndSection": 231, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36077787", "text": "Two anti-BCMA (B cell maturation antigen) CAR (Chimeric Antigen Receptor) T-cell therapies have been recently approved for relapsed and refractory multiple myeloma with excellent efficacy even in the heavily pre-treated patient population.", "offsetInBeginSection": 301, "offsetInEndSection": 451, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36389658", "text": "To date, Food and Drug Administration (FDA) has approved six CAR-T therapies for specific non-Hodgkin lymphomas, B-cell acute lymphoblastic leukemia, and multiple myeloma.", "offsetInBeginSection": 162, "offsetInEndSection": 312, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36395496", "text": "Chimeric antigen receptor T cell (CAR-T) therapy is an immunotherapy, which represents a therapeutic breakthrough in the treatment of B-cell malignancies and multiple myeloma.", "offsetInBeginSection": 19, "offsetInEndSection": 169, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36313336", "text": "The CAR-T product was initially approved in 2017; however, only limited studies have investigated the adverse reactions owing to CAR-T therapy compared to that of clinically approved drugs.", "offsetInBeginSection": 946, "offsetInEndSection": 1096, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30915277", "text": "Chimeric antigen receptor (CAR) modified T cell therapy has revolutionized the treatment of relapsed and refractory hematological malignancies. Throug", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31658644", "text": "Chimeric antigen receptor (CAR) T-cell therapy has shown promising clinical impact against hematologic malignancies. CD19 is a marker on the surface o", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35653589", "text": "INTRODUCTION\nChimeric antigen receptor (CAR)-modified T-cell therapy has revolutionized the treatment of relapsed/refractory B-cell malignancies including acute lymphoblastic leukemia and non-Hodgkin lymphoma.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33630232", "text": "of relapsed B-cell lymphoid neoplasms. There are currently three FDA-approved products: axicabtagene ciluecel and tisagenlecleucel for the treatment o", "offsetInBeginSection": 446, "offsetInEndSection": 596, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30880819", "text": "and survival rates in individuals with B-cell malignancies. The current approved agents target CD19, an antigen commonly overexpressed in B-cell hemat", "offsetInBeginSection": 304, "offsetInEndSection": 454, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33630232", "text": "t potential in the treatment of relapsed B-cell lymphomas despite current limitations. Several novel CAR cell designs are currently being studied in c", "offsetInBeginSection": 1024, "offsetInEndSection": 1174, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32102267", "text": "Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL).", "offsetInBeginSection": 35, "offsetInEndSection": 185, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e4b690f196b51000022", "type": "yesno", "body": "Is golodirsen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19179609", "http://www.ncbi.nlm.nih.gov/pubmed/26136844", "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "http://www.ncbi.nlm.nih.gov/pubmed/26799743", "http://www.ncbi.nlm.nih.gov/pubmed/33025945", "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "http://www.ncbi.nlm.nih.gov/pubmed/33407808", "http://www.ncbi.nlm.nih.gov/pubmed/34788571", "http://www.ncbi.nlm.nih.gov/pubmed/17846262", "http://www.ncbi.nlm.nih.gov/pubmed/32139505", "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "http://www.ncbi.nlm.nih.gov/pubmed/34064562", "http://www.ncbi.nlm.nih.gov/pubmed/19517771", "http://www.ncbi.nlm.nih.gov/pubmed/32483212", "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "http://www.ncbi.nlm.nih.gov/pubmed/35213020", "http://www.ncbi.nlm.nih.gov/pubmed/36401026", "http://www.ncbi.nlm.nih.gov/pubmed/36401027", "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "http://www.ncbi.nlm.nih.gov/pubmed/33012180"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19517771", "text": "ing gene transfer strategies have been conducted, but no effective treatment has been established. Two plausible ways have been proposed. One is the i", "offsetInBeginSection": 294, "offsetInEndSection": 444, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505", "text": "sured by Western blot and immunohistochemistry.\n\n\nCONCLUSION\nGolodirsen was well-tolerated; muscle biopsies from golodirsen-treated patients showed in", "offsetInBeginSection": 1501, "offsetInEndSection": 1651, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "r dystrophy is a lethal neuromuscular disease that currently has no effective therapy. Transgenic overexpression of the alpha7 integrin in mdx/utrn(-/", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "es, most commonly as limb-girdle muscular dystrophy 2I. There is no effective therapy available. Glucocorticoid steroids have become the standard trea", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "text": "dystrophin, a 427-kDa cytoskeletal protein, but the effective therapeutic drug is presently unavailable. We previously reported that a trypsin-like pr", "offsetInBeginSection": 73, "offsetInEndSection": 223, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "se of mortality among Duchenne muscular dystrophy patients and lacks effective therapies. Phosphodiesterase type 5 is implicated in dystrophic patholo", "offsetInBeginSection": 42, "offsetInEndSection": 192, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "text": "ith Duchenne muscular dystrophy experienced severe acute heart failure triggered by pneumonia. Levosimendan was effective in improving heart function.", "offsetInBeginSection": 264, "offsetInEndSection": 414, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34788571", "text": "The aim of this Phase 1/2, 2-part, multicenter trial was to report clinical safety and efficacy of long-term golodirsen treatment among ambulatory patients with exon 53 skip-amenable Duchenne muscular dystrophy (DMD).", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505", "text": "CLASSIFICATION OF EVIDENCE\nThis study provides Class I evidence that golodirsen is safe and Class IV evidence that it induces exon skipping and novel dystrophin as confirmed by 3 different assays.", "offsetInBeginSection": 1798, "offsetInEndSection": 1948, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505", "text": "rsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping.\n\n\nMETHODS\nPart 1 was a randomized, double-blind, placebo-co", "offsetInBeginSection": 99, "offsetInEndSection": 249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": "ive degeneration of skeletal and cardiac muscles. Currently, there is no effective therapy for this disorder. However, the technology of cell reprogra", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "text": "ommon muscle disease found in male children. Currently, there is no effective therapy available for Duchenne muscular dystrophy patients. Therefore, i", "offsetInBeginSection": 41, "offsetInEndSection": 191, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401026", "text": "To date, four PMOs, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the FDA for the treatment of DMD.", "offsetInBeginSection": 316, "offsetInEndSection": 466, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "r levels of activated Akt in their muscles. Thus, VPA has important biological effects that may be applicable for the treatment of muscular dystrophy.", "offsetInBeginSection": 1056, "offsetInEndSection": 1206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33012180", "text": "icoids and the limited evidence of bone-protective therapies, clinical trials are needed. We conducted surveys to obtain the opinion of young people w", "offsetInBeginSection": 114, "offsetInEndSection": 264, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33407808", "text": "We demonstrate that the de novo dystrophin induced by exon skipping with PMO golodirsen is capable of conferring a histological benefit in treated patients with an increase in dystrophin associated proteins at the dystrophin positive regions of the sarcolemma in post-treatment biopsies.", "offsetInBeginSection": 709, "offsetInEndSection": 859, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26136844", "text": "essive pediatric muscle disorder. For decades, research has been conducted to find an effective therapy. This review presents current therapeutic meth", "offsetInBeginSection": 99, "offsetInEndSection": 249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "text": "We concluded that embryo analysis using associated techniques of PCR and array CGH seems to be safe for embryo selection in cases of X-linked disorders, such as Duchenne muscular dystrophy.", "offsetInBeginSection": 1251, "offsetInEndSection": 1401, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401027", "text": "Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression.", "offsetInBeginSection": 329, "offsetInEndSection": 479, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34788571", "text": "This study provides evidence for golodirsen biologic activity and long-term safety in a declining DMD population and suggests functional benefit versus external controls.", "offsetInBeginSection": 1347, "offsetInEndSection": 1497, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17846262", "text": "reatment options. We examined the possibility of moving forward with gene therapy, an approach that demonstrates promise for treating Duchenne muscula", "offsetInBeginSection": 77, "offsetInEndSection": 227, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33025945", "text": " down the disease progression. Golodirsen is a provisionally approved PMO-based drug for approx. 8% of all DMD patients amenable to exon 53 skipping. ", "offsetInBeginSection": 752, "offsetInEndSection": 902, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35213020", "text": "Several exon skipping antisense oligonucleotides (eteplirsen, golodirsen, viltolarsen, and casimersen) have been approved for the treatment of Duchenne muscular dystrophy, but many more are in development targeting an array of different DMD exons.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26799743", "text": "The study tested if increased intramuscular nitric oxide concentration can improve mitochondrial energy metabolism in Duchenne muscular dystrophy using a novel therapeutic approach through the combination of L-arginine with metformin.", "offsetInBeginSection": 190, "offsetInEndSection": 340, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212", "text": "earlier this year. Although promising, the efficacy of eteplirsen and AON sequence employed remain controversial. In addition, exon skipping faces cha", "offsetInBeginSection": 551, "offsetInEndSection": 701, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "These results, for the\u00a0first time, demonstrate the efficacy and feasibility of this alliance treatment of the two drugs for fukutin-related protein-muscular dystrophy.", "offsetInBeginSection": 1484, "offsetInEndSection": 1634, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34064562", "text": "s enrolled in a rehabilitation program and awaits the approval of the genetic treatment in Korea. This is the first report of an infantile presymptoma", "offsetInBeginSection": 1068, "offsetInEndSection": 1218, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "text": "From this review, it is clear that until a definitive treatment for Duchenne muscular dystrophy is available, the use of deflazacort and prednisone with judicious dietary control and close clinical monitoring for side effects seems the best intervention for interim preservation of function in such a common devastating disorder of young growing boys.", "offsetInBeginSection": 847, "offsetInEndSection": 997, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34064562", "text": "Current treatments based on genetic therapy can improve clinical results, but treatment must begin as early as possible before significant muscle damage.", "offsetInBeginSection": 275, "offsetInEndSection": 425, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f043e4f36125a426000023", "type": "yesno", "body": "Is Baricitinib effective for Alopecia Areata?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34090959", "http://www.ncbi.nlm.nih.gov/pubmed/31930807", "http://www.ncbi.nlm.nih.gov/pubmed/31767273", "http://www.ncbi.nlm.nih.gov/pubmed/21572877", "http://www.ncbi.nlm.nih.gov/pubmed/35330989", "http://www.ncbi.nlm.nih.gov/pubmed/20000871", "http://www.ncbi.nlm.nih.gov/pubmed/12942185", "http://www.ncbi.nlm.nih.gov/pubmed/26137574", "http://www.ncbi.nlm.nih.gov/pubmed/35334197", "http://www.ncbi.nlm.nih.gov/pubmed/31323149", "http://www.ncbi.nlm.nih.gov/pubmed/21592197", "http://www.ncbi.nlm.nih.gov/pubmed/29575039", "http://www.ncbi.nlm.nih.gov/pubmed/7215615", "http://www.ncbi.nlm.nih.gov/pubmed/28879192", "http://www.ncbi.nlm.nih.gov/pubmed/12433000", "http://www.ncbi.nlm.nih.gov/pubmed/36239359", "http://www.ncbi.nlm.nih.gov/pubmed/36070222", "http://www.ncbi.nlm.nih.gov/pubmed/33870531", "http://www.ncbi.nlm.nih.gov/pubmed/30745983", "http://www.ncbi.nlm.nih.gov/pubmed/28717940", "http://www.ncbi.nlm.nih.gov/pubmed/18076615", "http://www.ncbi.nlm.nih.gov/pubmed/32015973"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21572877", "text": "CONCLUSION\nA series of three monthly courses of medium-dose prednisolone pulse therapy is effective and well tolerated in most patients with active, multifocal alopecia areata.", "offsetInBeginSection": 1039, "offsetInEndSection": 1189, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31930807", "text": "e safety and efficacy of these medications. If indeed these treatments will prove to be effective and safe, they might become the first FDA-approved t", "offsetInBeginSection": 933, "offsetInEndSection": 1083, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34090959", "text": "GROUND\nThere are no treatments approved by the Food and Drug Administration for alopecia areata.\n\n\nOBJECTIVE\nTo evaluate the efficacy and safety of ba", "offsetInBeginSection": 4, "offsetInEndSection": 154, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31767273", "text": "pies as a drug therapy for this condition. However, there is insufficient evidence of its efficacy to support this recommendation. Thus, we sought to ", "offsetInBeginSection": 96, "offsetInEndSection": 246, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26137574", "text": "ovement during baricitinib treatment.\n\n\nINTERPRETATION\nBaricitinib may be an effective treatment for AA and warrants further investigation in clinical", "offsetInBeginSection": 851, "offsetInEndSection": 1001, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36239359", "text": "% CI [2.38, 9.66], p .0001).\n\n\nCONCLUSION\nWhen compared to placebo, baricitinib is an effective and well-tolerated medication for the treatment of AA.", "offsetInBeginSection": 1237, "offsetInEndSection": 1387, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20000871", "text": "unpredictable hair-loss condition. As there is no cure for alopecia areata and no effective conventional therapy, a substantial number of alopecia are", "offsetInBeginSection": 22, "offsetInEndSection": 172, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28879192", "text": "CONCLUSION\nSimvastatin/ezetimibe is not effective for treatment of alopecia areata, at least in severe and/or cases refractory to other treatments, either as monotherapy or as adjuvant.", "offsetInBeginSection": 1136, "offsetInEndSection": 1286, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18076615", "text": "CONCLUSION\nThe 308-nm excimer laser is an effective therapeutic option for patchy alopecia areata of the scalp and for some cases with patchy alopecia areata of the beard area.", "offsetInBeginSection": 998, "offsetInEndSection": 1148, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35330989", "text": "al trials and case reports. Among them, the application in the field of alopecia areata is the most encouraging, and we reviewed the mechanism in deta", "offsetInBeginSection": 951, "offsetInEndSection": 1101, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36239359", "text": "cent clinical trials using baricitinib demonstrated that it may be effective in treating AA. This meta-analysis was done to evaluate the effectiveness", "offsetInBeginSection": 213, "offsetInEndSection": 363, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21592197", "text": " alopecia areata. Systemic steroids, for example, are effective in the treatment of severe alopecia areata but have many side-effects. To avoid these ", "offsetInBeginSection": 49, "offsetInEndSection": 199, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33870531", "text": "increased risk of malignancies, particularly in long-term use. The significant efficacy of baricitinib, versus the probable adverse effects, urge furt", "offsetInBeginSection": 824, "offsetInEndSection": 974, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12942185", "text": "a areata showing only mild side effects. However, it is time-consuming and in some cases ineffective, making it desirable to develop new, more specifi", "offsetInBeginSection": 915, "offsetInEndSection": 1065, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12433000", "text": "Our cases indicate that combination therapy of topical SADBE with other therapies can be a choice for alopecia areata which is refractory to topical SADBE therapy alone.", "offsetInBeginSection": 1041, "offsetInEndSection": 1191, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35334197", "text": "Baricitinib, an oral, selective, reversible inhibitor of Janus kinases 1 and 2, may interrupt cytokine signaling implicated in the pathogenesis of alopecia areata.", "offsetInBeginSection": 206, "offsetInEndSection": 356, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7215615", "text": " One third of the latter were children in whom the treatment may be less effective than in adults. Contact allergy was induced in all but 1 case in wh", "offsetInBeginSection": 549, "offsetInEndSection": 699, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35334197", "text": "h dose vs. placebo). Secondary outcomes for baricitinib at a dose of 4 mg but not at a dose of 2 mg generally favored baricitinib over placebo. Acne, ", "offsetInBeginSection": 1565, "offsetInEndSection": 1715, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31767273", "text": "% and partial response; 46.7%).\n\n\nCONCLUSIONS\nTopical immunotherapy with SADBE is an effective treatment for alopecia areata. Therefore, the current t", "offsetInBeginSection": 1023, "offsetInEndSection": 1173, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35334197", "text": "CONCLUSIONS\nIn two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.", "offsetInBeginSection": 1903, "offsetInEndSection": 2053, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32015973", "text": "LEARNING POINTS\nBaricitinib is a small, orally active molecule that inhibits JAK-1 and JAK-2, which is used in the treatment of rheumatoid arthritis.Baricitinib has been also used in the treatment of psoriasis, alopecia areata and atopic dermatitis.Palmoplantar pustulosis is a rare cutaneous side effect of baricitinib.", "offsetInBeginSection": 721, "offsetInEndSection": 871, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36070222", "text": "Extensive subtypes of alopecia areata (AA) (totalis, universalis, or multifocal) still have no approved and effective treatments in Europe, although Janus kinase inhibitors, such as baricitinib, are promising treatments that have been recently approved by the FDA.", "offsetInBeginSection": 131, "offsetInEndSection": 281, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31323149", "text": "These results indicate that, while 2DG is effective for some autoimmune diseases, it was not efficacious for the cell-mediated autoimmune mouse disease, alopecia areata.", "offsetInBeginSection": 718, "offsetInEndSection": 868, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34090959", "text": "6) and 4-mg (51.9%, P = .001) groups versus placebo (3.6%). Baricitinib was well tolerated with no new safety findings.\n\n\nLIMITATIONS\nSmall sample siz", "offsetInBeginSection": 1065, "offsetInEndSection": 1215, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30745983", "text": "CONCLUSION\nOral mini-pulse methylprednisolone therapy is an effective and safe therapeutic option for alopecia areata without side effects, and the time of the treatment is short.", "offsetInBeginSection": 659, "offsetInEndSection": 809, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28717940", "text": "Nevertheless, depending on patient age, affected surface area and disease duration, an empiric treatment algorithm can be designed with corticosteroids and topical immunotherapy remaining the mainstay of therapy.", "offsetInBeginSection": 982, "offsetInEndSection": 1180, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21572877", "text": "BACKGROUND\nAlthough the exact etiology of alopecia areata is still unknown, systemic prednisolone treatment seem to be effective in early stages but significant side effects may occur leading to discontinuation of treatment.", "offsetInBeginSection": 35, "offsetInEndSection": 185, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29575039", "text": "ache.\n\n\nCONCLUSION\nThis retrospective series suggests that hydroxychloroquine can be considered as a treatment option for alopecia areata in children.", "offsetInBeginSection": 952, "offsetInEndSection": 1102, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12433000", "text": "Our cases indicate that combination therapy of topical SADBE with other therapies can be a choice for alopecia areata which is refractory to topical SADBE therapy alone.", "offsetInBeginSection": 0, "offsetInEndSection": 154, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64137616201352f04a000041", "type": "yesno", "body": "Anemia is not associated with chronic kidney failure", "documents": [], "snippets": []}, {"id": "6415bc8d690f196b5100000f", "type": "factoid", "body": "What is the estimated reduction in time when using online genetic counseling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30121717", "http://www.ncbi.nlm.nih.gov/pubmed/26142383", "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "http://www.ncbi.nlm.nih.gov/pubmed/21240560"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30121717", "text": "y from a high school course (37.3%), college course (28.1%), or online (11.5%). Familiarity was associated with factors such as female gender (p\u2009=\u20090.0", "offsetInBeginSection": 658, "offsetInEndSection": 808, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26142383", "text": "d genetic counseling between the birth and the time of the study (mean 3.5 years). Of those not receiving genetic counseling, 71% said they were not o", "offsetInBeginSection": 407, "offsetInEndSection": 557, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "text": "We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively. We showed online genetic counseling to be effective, ", "offsetInBeginSection": 1548, "offsetInEndSection": 1698, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21240560", "text": "Genetic counselor time spent collecting family and medical history and providing face-to-face counseling for a new patient session decreased from an average of 85-69\u00a0min when using the computer-assisted data collection.", "offsetInBeginSection": 911, "offsetInEndSection": 1061, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64163660690f196b5100001d", "type": "yesno", "body": "Is deflazacort more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27525172", "http://www.ncbi.nlm.nih.gov/pubmed/17541998", "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "http://www.ncbi.nlm.nih.gov/pubmed/15990951", "http://www.ncbi.nlm.nih.gov/pubmed/35381069", "http://www.ncbi.nlm.nih.gov/pubmed/34275333", "http://www.ncbi.nlm.nih.gov/pubmed/8521761", "http://www.ncbi.nlm.nih.gov/pubmed/31830002", "http://www.ncbi.nlm.nih.gov/pubmed/10951436", "http://www.ncbi.nlm.nih.gov/pubmed/31599456", "http://www.ncbi.nlm.nih.gov/pubmed/27746500", "http://www.ncbi.nlm.nih.gov/pubmed/33104035", "http://www.ncbi.nlm.nih.gov/pubmed/1822804", "http://www.ncbi.nlm.nih.gov/pubmed/16244521", "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "http://www.ncbi.nlm.nih.gov/pubmed/34440496", "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "http://www.ncbi.nlm.nih.gov/pubmed/30028519", "http://www.ncbi.nlm.nih.gov/pubmed/22655512", "http://www.ncbi.nlm.nih.gov/pubmed/11038071", "http://www.ncbi.nlm.nih.gov/pubmed/20581335", "http://www.ncbi.nlm.nih.gov/pubmed/34693725", "http://www.ncbi.nlm.nih.gov/pubmed/35713895"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34440496", "text": "In contrast, individuals with DMD undergoing pharmacotherapies with Deflazacort achieved lower HRV, akin to individuals with DMD without any medications, as demonstrated in the metrics: RMSSD; LF (n.u.", "offsetInBeginSection": 978, "offsetInEndSection": 1128, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11038071", "text": "cort slows the progress of Duchenne muscular dystrophy (DMD) with fewer side effects than prednisone. In mdx mice, deflazacort treatment augments repa", "offsetInBeginSection": 7, "offsetInEndSection": 157, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15990951", "text": " received prednisone and 19 received deflazacort. There was no difference in the shortening fraction between the two treated subgroups. Treated subjec", "offsetInBeginSection": 709, "offsetInEndSection": 859, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30028519", "text": "stable regimens throughout study. This post hoc analysis compares efficacy and safety for deflazacort and prednisone/prednisolone in the placebo arm.\n", "offsetInBeginSection": 173, "offsetInEndSection": 323, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "text": "e muscular dystrophy (DMD). Deflazacort (DFC) is supposed to have fewer side effects than prednisone (PRED). An ongoing double blind multicenter study", "offsetInBeginSection": 116, "offsetInEndSection": 266, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27746500", "text": "hildren on prednisolone was three times more.\n\n\nCONCLUSIONS\nPrednisolone is more beneficial than deflazacort at doses of 0.75 mg/kg/day and 0.9 mg/kg/", "offsetInBeginSection": 1985, "offsetInEndSection": 2135, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "text": "ndpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects. As mechanisms of improvement and side effect differen", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10951436", "text": " The two steroids were equally effective in improving motor function and functional performances. At 9 months, the average weight increase with respect to baseline value was 5% (2 kg) in the deflazacort group but 18% in the prednisone group (P < 0. 005), and the change remained significant after 12 months (P < 0.05). Other minor but nonsignificant side effects were observed. Steroid treatment with deflazacort appears to cause fewer side effects", "offsetInBeginSection": 812, "offsetInEndSection": 1260, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8521761", "text": "In general, deflazacort appears to have less effect than prednisone on parameters which may be associated with the development of corticosteroid-induced osteoporosis.", "offsetInBeginSection": 1192, "offsetInEndSection": 1342, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33104035", "text": " Glucocorticoid steroids such as prednisone and deflazacort are recommended for treating Duchenne Muscular Dystrophy where their use prolongs ambulation and life expectancy", "offsetInBeginSection": 99, "offsetInEndSection": 271, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20581335", "text": "t corticosteroids be offered (prednisone 0.75 mg/kg/d and deflazacort 0.9 mg/kg/d) as treatment. Recent reports emphasize that longer term treatment w", "offsetInBeginSection": 324, "offsetInEndSection": 474, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35381069", "text": "leted the trial. Both daily prednisone and daily deflazacort were more effective than intermittent prednisone for the primary outcome (P\u2009<\u2009.001 for da", "offsetInBeginSection": 1497, "offsetInEndSection": 1647, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22655512", "text": "o. Deflazacort has benefitted both cohorts by prolonged ambulation, preserved cardiac and respiratory function, less scoliosis and improved survival. ", "offsetInBeginSection": 226, "offsetInEndSection": 376, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17541998", "text": "teroids used are prednisone/prednisolone and deflazacort. They are probably equally effective in stabilizing muscle strength but may have different si", "offsetInBeginSection": 411, "offsetInEndSection": 561, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1822804", "text": "eflazacort (DF), an oxazoline derivative of prednisolone which reduces its side-effects. Myometric muscle strength measurements, Scott Score and timed", "offsetInBeginSection": 100, "offsetInEndSection": 250, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16244521", "text": "cular dystrophy may prolong ambulation and upper limb function with similar potency. Both steroids also improve pulmonary function, in addition to del", "offsetInBeginSection": 1483, "offsetInEndSection": 1633, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30028519", "text": "CONCLUSIONS\nThis analysis, limited by its post hoc nature, suggests greater preservation of 6MWD and 4-stair climb with deflazacort vs. prednisone/prednisolone.", "offsetInBeginSection": 869, "offsetInEndSection": 1019, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31830002", "text": "e disease resulting in progressive muscle degeneration and wasting. Glucocorticoids, specifically prednisone/prednisolone and deflazacort, are commonl", "offsetInBeginSection": 64, "offsetInEndSection": 214, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31599456", "text": "olone-treated patients experienced, on average, lower declines of 28.3 meters on 6-minute walk distance (95% confidence interval [CI], 5.7, 50.9; 2.9\u2009", "offsetInBeginSection": 735, "offsetInEndSection": 885, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35713895", "text": "Overall, the researchers found that the participants who took deflazacort were able to walk until a later age before they needed to use a wheelchair, compared with those who took prednisone.", "offsetInBeginSection": 1276, "offsetInEndSection": 1426, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27525172", "text": " and externalizing behaviors; however, on average boys taking deflazacort demonstrated more withdrawn behaviors than those taking prednisone, while on", "offsetInBeginSection": 795, "offsetInEndSection": 945, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34275333", "text": "erability' (67 and 47%). Switching was 'very' or 'somewhat' effective at addressing the primary reasons in 90-95% of patients. Conclusion: Physician-r", "offsetInBeginSection": 641, "offsetInEndSection": 791, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35381069", "text": "n, and satisfaction with treatment; there was no significant difference between the 2 daily corticosteroid regimens. The findings support the use of a", "offsetInBeginSection": 3110, "offsetInEndSection": 3260, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31599456", "text": "r Ambulatory Assessment linearized score).\n\n\nDISCUSSION\nDeflazacort-treated patients experienced significantly lower functional decline over 48\u2009weeks.", "offsetInBeginSection": 1048, "offsetInEndSection": 1198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34693725", "text": "Conclusion: Deflazacort provides clinically meaningful delays in loss of physical milestones over 48\u00a0weeks compared with prednisone/prednisolone for patients with\u00a0nonsense mutation Duchenne muscular dystrophy.", "offsetInBeginSection": 911, "offsetInEndSection": 1061, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10951436", "text": "ed DMD patients that served as natural history control. The two steroids were equally effective in improving motor function and functional performance", "offsetInBeginSection": 757, "offsetInEndSection": 907, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34693725", "text": "Aim: Compare efficacies of deflazacort and prednisone/prednisolone in providing clinically meaningful delays in loss of physical milestones in patients with nonsense mutation Duchenne muscular dystrophy.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "text": "The results suggest that (i) DFC and PRED in equal anti-inflammatory dosage are similarly or equally efficient in slowing down the decline of muscle strength in DMD; (ii) benefits outweigh the side effects.", "offsetInBeginSection": 1268, "offsetInEndSection": 1418, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "text": "From this review, it is clear that until a definitive treatment for Duchenne muscular dystrophy is available, the use of deflazacort and prednisone with judicious dietary control and close clinical monitoring for side effects seems the best intervention for interim preservation of function in such a common devastating disorder of young growing boys.", "offsetInBeginSection": 886, "offsetInEndSection": 1104, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8521761", "text": "t with corticosteroids. In children, however, even though available efficacy data are minimal, deflazacort should be considered as an initial option i", "offsetInBeginSection": 2016, "offsetInEndSection": 2166, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6402bc2d201352f04a000005", "type": "list", "body": "What are the targets of Mosunetuzumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21440000", "http://www.ncbi.nlm.nih.gov/pubmed/35803286", "http://www.ncbi.nlm.nih.gov/pubmed/24369848", "http://www.ncbi.nlm.nih.gov/pubmed/17848073", "http://www.ncbi.nlm.nih.gov/pubmed/34916237", "http://www.ncbi.nlm.nih.gov/pubmed/34003950", "http://www.ncbi.nlm.nih.gov/pubmed/35947358", "http://www.ncbi.nlm.nih.gov/pubmed/35152430", "http://www.ncbi.nlm.nih.gov/pubmed/12135991", "http://www.ncbi.nlm.nih.gov/pubmed/12727377", "http://www.ncbi.nlm.nih.gov/pubmed/29697788", "http://www.ncbi.nlm.nih.gov/pubmed/1594433", "http://www.ncbi.nlm.nih.gov/pubmed/34914545", "http://www.ncbi.nlm.nih.gov/pubmed/18824292", "http://www.ncbi.nlm.nih.gov/pubmed/19357322", "http://www.ncbi.nlm.nih.gov/pubmed/32859946"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34914545", "text": "PURPOSE\nMosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T cells to engage and eliminate malignant B cells and is being developed for relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32859946", "text": "d blinatumomab), including the dynamics of B- and T-lymphocytes in circulation, lymphoid tissues, and tumor. The model was developed and validated usi", "offsetInBeginSection": 530, "offsetInEndSection": 680, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35947358", "text": "Mosunetuzumab was recently conditionally approved in the EU for the treatment of relapsed or refractory follicular lymphoma in adults who have received at least two prior systemic therapies.", "offsetInBeginSection": 76, "offsetInEndSection": 226, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12135991", "text": "ent Targets. The targets for health are based on improvements in infant, child and maternal mortality. Progress towards these goals will be used to as", "offsetInBeginSection": 132, "offsetInEndSection": 282, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35152430", "text": "roadly classified into those which strive to modify bile, inflammation, cell survival, or fibrosis. In bile, shrinking the size of the bile acid pool ", "offsetInBeginSection": 645, "offsetInEndSection": 795, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34914545", "text": "days 1, 8, and 15 (group B), for eight or 17 cycles on the basis of tumor response.\n\n\nRESULTS\nTwo hundred thirty patients were enrolled. Doses up to 2", "offsetInBeginSection": 662, "offsetInEndSection": 812, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32859946", "text": "Mosunetuzumab, a T-cell dependent bispecific antibody that binds CD3 and CD20 to drive T-cell mediated B-cell killing, is currently being tested in non-Hodgkin lymphoma.", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35803286", "text": "ging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells. In a phase 1 study, mosunetuzumab was well tolerated and ac", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21440000", "text": "e Th1 and Th2 inflammation precipitating symptoms. In both, innate and adaptive immunities are involved, providing a series of potential targets for t", "offsetInBeginSection": 450, "offsetInEndSection": 600, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17848073", "text": "With the possible exception of extensive human vaccination, each of these approaches target post-spillover events and none of these avenues of research will have the slightest impact on reducing the risk of additional emergence of viruses or other pathogens from wildlife.", "offsetInBeginSection": 1056, "offsetInEndSection": 1206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35803286", "text": "INTERPRETATION\nFixed-duration mosunetuzumab has a favourable safety profile and induces high rates of complete remissions, allowing potential administration as an outpatient regimen, in patients with relapsed or refractory follicular lymphoma and two or more previous therapies.", "offsetInBeginSection": 3078, "offsetInEndSection": 3228, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34916237", "text": "e historically seen with standard care in patients with relapsed/refractory follicular lymphoma. Drug maker Genentech announced it will file for FDA a", "offsetInBeginSection": 163, "offsetInEndSection": 313, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35152430", "text": "re broadly classified into those which strive to modify bile, inflammation, cell survival, or fibrosis. In bile, shrinking the size of the bile acid p", "offsetInBeginSection": 641, "offsetInEndSection": 791, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12727377", "text": "used to generate a wide range of transgenic lines in which specific metabolic steps have been targeted. Attempts to increase yield of some agronomical", "offsetInBeginSection": 37, "offsetInEndSection": 187, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12135991", "text": "RESULTS\nAchieving the International Development Targets for infant, child and maternal mortality (66.7 and 75% reductions) will contribute very little to improving life expectancy in Russia (0.96 years).", "offsetInBeginSection": 1095, "offsetInEndSection": 1245, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29697788", "text": "Mucosal healing is currently recognized as the principal treatment target to be used in a \"treat to target\" paradigm, whereas histologic healing and normalization of biomarkers are being evaluated as potential future targets.", "offsetInBeginSection": 333, "offsetInEndSection": 483, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35152430", "text": "The nuclear hormone receptors, farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) regulate many of these pathways: cholestasis, inflammation, and fibrosis, which is why they are being enthusiastically pursued as potential therapeutic targets in PBC.", "offsetInBeginSection": 1575, "offsetInEndSection": 1725, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35803286", "text": "outpatient regimen, in patients with relapsed or refractory follicular lymphoma and two or more previous therapies.\n\n\nFUNDING\nF Hoffmann-La Roche and ", "offsetInBeginSection": 3097, "offsetInEndSection": 3247, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19357322", "text": "The collective method combining at least three profiles identified 50, 25, 10, and 4% of the 30, 84, 41, and 864 phase III, II, I, and nonclinical trial targets as promising, including eight to nine targets of positive phase III results.", "offsetInBeginSection": 603, "offsetInEndSection": 753, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18824292", "text": "The aim of this review is to discuss individual HDAC family members as drug targets in cancer taking into consideration their function under physiological conditions and their oncogenic potential in malignant disease.", "offsetInBeginSection": 1300, "offsetInEndSection": 1450, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1594433", "text": "experiments, there were two redundant-targets conditions, one with identical targets and one with the different members of a class. In both of the GNG", "offsetInBeginSection": 492, "offsetInEndSection": 642, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34003950", "text": "al targets will be importantly informative for low-vision research and assistive technology development. This study addressed this question through an", "offsetInBeginSection": 174, "offsetInEndSection": 324, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24369848", "text": "Of these, this brief overview particularly focuses on the following five different albeit non mutually exclusive questions: (i) \"Is nuclear DNA the only intracellular target for radiation effects?", "offsetInBeginSection": 674, "offsetInEndSection": 824, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64144200201352f04a000043", "type": "yesno", "body": "Is anaphylaxis a results of mast cell activation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32709306", "http://www.ncbi.nlm.nih.gov/pubmed/35080312", "http://www.ncbi.nlm.nih.gov/pubmed/28798744", "http://www.ncbi.nlm.nih.gov/pubmed/24586553", "http://www.ncbi.nlm.nih.gov/pubmed/23642289", "http://www.ncbi.nlm.nih.gov/pubmed/34385999", "http://www.ncbi.nlm.nih.gov/pubmed/24948367", "http://www.ncbi.nlm.nih.gov/pubmed/26480615", "http://www.ncbi.nlm.nih.gov/pubmed/22744266", "http://www.ncbi.nlm.nih.gov/pubmed/18596587", "http://www.ncbi.nlm.nih.gov/pubmed/31011586", "http://www.ncbi.nlm.nih.gov/pubmed/8092557", "http://www.ncbi.nlm.nih.gov/pubmed/32276688", "http://www.ncbi.nlm.nih.gov/pubmed/33361207", "http://www.ncbi.nlm.nih.gov/pubmed/27906487", "http://www.ncbi.nlm.nih.gov/pubmed/25240785", "http://www.ncbi.nlm.nih.gov/pubmed/25841551", "http://www.ncbi.nlm.nih.gov/pubmed/2661436", "http://www.ncbi.nlm.nih.gov/pubmed/33275825", "http://www.ncbi.nlm.nih.gov/pubmed/22529299", "http://www.ncbi.nlm.nih.gov/pubmed/16804320", "http://www.ncbi.nlm.nih.gov/pubmed/20526344", "http://www.ncbi.nlm.nih.gov/pubmed/31156646"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27906487", "text": "d in the amplification of the mast cell response during anaphylaxis are unclear. Mouse models of anaphylaxis demonstrate the critical involvement of n", "offsetInBeginSection": 33, "offsetInEndSection": 183, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22744266", "text": "In addition, monoclonal mast cell activation syndrome has been described presenting with anaphylaxis, especially in patients with hymenoptera venom anaphylaxis.", "offsetInBeginSection": 77, "offsetInEndSection": 227, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24586553", "text": "r, Ang-1's function in mast cell activation and anaphylaxis diseases is unknown. The results of our study suggest that Ang-1 decreased lipopolysacchar", "offsetInBeginSection": 391, "offsetInEndSection": 541, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8092557", "text": "ermine whether mast cell activation, as demonstrated by elevated serum tryptase concentrations, can occur in protracted anaphylaxis.\n\n\nMETHODS\nCase re", "offsetInBeginSection": 448, "offsetInEndSection": 598, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33361207", "text": "Further elucidating the mechanisms through which NHERF1 modulates mast cell responses will lend insights into the development of new therapeutic strategies to target mast cells during anaphylaxis or other allergic diseases.", "offsetInBeginSection": 1493, "offsetInEndSection": 1643, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25240785", "text": "The severity of anaphylaxis was associated with mast cell degranulation, increased plasma heparin levels, the intensity of contact system activation, and bradykinin formation.", "offsetInBeginSection": 1253, "offsetInEndSection": 1403, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31011586", "text": "Finally, we discuss the possible reasons for the mast cell to utilize compound exocytosis during anaphylaxis, the conflicting evidence in different mast cell models, and the open questions in the field which remain to be answered.", "offsetInBeginSection": 1017, "offsetInEndSection": 1167, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23642289", "text": "MCAS is a diagnosis of exclusion, and primary and secondary mast cell activation disorders as well as idiopathic anaphylaxis have to be ruled out before making the diagnosis.", "offsetInBeginSection": 1330, "offsetInEndSection": 1480, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20526344", "text": "arepsilonRI) on mast cells. However, the regulatory mechanism of mast cell activation is not completely understood. Here we identify an immunoglobulin", "offsetInBeginSection": 169, "offsetInEndSection": 319, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35080312", "text": "w clinical entities, such as the \u03b1-gal anaphylaxis. Anaphylaxis results from the massive activation of the mast cells (MCs). Thus, it is also necessar", "offsetInBeginSection": 465, "offsetInEndSection": 615, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24948367", "text": "ed that mast cell activation and anaphylaxis are negatively regulated by AMP-activated protein kinase (AMPK). However, little is known about the relat", "offsetInBeginSection": 342, "offsetInEndSection": 492, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2661436", "text": "s not affected. Calcium-independent early activation events in mast cell anaphylaxis indicated on inhibitory influence of PK-treatment. Inhibition of ", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16804320", "text": "hese results indicate that neither MBL nor activation of the complement cascade is crucial for the induction of anaphylaxis. In contrast mast cell act", "offsetInBeginSection": 1227, "offsetInEndSection": 1377, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32709306", "text": "CONCLUSIONS\nOur study suggests that the mast cell activation test can be used to diagnose IgE/Fc\u03b5RI-dependent immediate drug hypersensitivity reactions.", "offsetInBeginSection": 1495, "offsetInEndSection": 1645, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31156646", "text": "Results: SA considerably inhibited immunoglobulin (Ig) E-mediated mast cell activation, including \u03b2-hexosaminidase release, mRNA and protein expression of various cytokines, and PGD2 and LTC4 release.", "offsetInBeginSection": 898, "offsetInEndSection": 1048, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34385999", "text": "g Mas-related G protein-coupled receptor X2 (MRGPRX2), but many questions remain unanswered. Here, we address three of them, namely whether primary hu", "offsetInBeginSection": 152, "offsetInEndSection": 302, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27906487", "text": "oth compared to healthy controls.\n\n\nRESULTS\nIn 72 patients, 37 (51%) had severe anaphylaxis, 33 (60%) were histamine positive, and 47 (70%) were mast ", "offsetInBeginSection": 848, "offsetInEndSection": 998, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26480615", "text": "merged diagnosis. It shares the clinical features of anaphylaxis and mastocytosis despite having distinct mast cell biology. In this,paper we describe", "offsetInBeginSection": 55, "offsetInEndSection": 205, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31156646", "text": "stration of SA effectively and dose-dependently suppressed mast cell-mediated passive cutaneous and systemic anaphylaxis. SA significantly attenuated ", "offsetInBeginSection": 1138, "offsetInEndSection": 1288, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32276688", "text": "Elevated mast cell mediators such as tryptase and histamine have been reported during episodes, and mast cells are considered the primary cells responsible for driving anaphylaxis in humans.", "offsetInBeginSection": 491, "offsetInEndSection": 641, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24948367", "text": "Moreover, AMPK\u03b12 knockdown or deficiency led to increased Fc\u03b5RI-mediated mast cell activation and anaphylaxis that were insensitive to U0126 or activator 5-aminoimidazole-4-carboxamide-1-\u03b2-4-ribofuranoside, suggesting that the suppression of Fc\u03b5RI signals by the inhibition of the ERK1/2 pathway relies largely on AMPK activation.", "offsetInBeginSection": 1404, "offsetInEndSection": 1554, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31011586", "text": "m mast cells in response to an allergen, mostly through activation of the cells via the IgE-dependent pathway. While mast cells are specialized secret", "offsetInBeginSection": 214, "offsetInEndSection": 364, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28798744", "text": "Some usual clinical manifestations in anaphylaxis, such as angioedema or hypotension, or other less common, such as metrorrhagia, may be explained by the direct effect of the activation of the coagulation and contact system driven by mast cell mediators.", "offsetInBeginSection": 1449, "offsetInEndSection": 1599, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27906487", "text": "man anaphylaxis, suggesting they are activated early in the reaction, regardless of mast cell activation. This important finding increases our underst", "offsetInBeginSection": 1740, "offsetInEndSection": 1890, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18596587", "text": "SUMMARY\nAnaphylaxis is a systemic reaction involving multiple organ systems, but it is believed that it may be influenced by cellular events in mast cells and basophils resulting in the release of mediators.", "offsetInBeginSection": 1107, "offsetInEndSection": 1257, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25841551", "text": "Anaphylaxis results from severe systemic mast cell activation. In addition to IgE-mediated and physical triggers, it may occur with a clonal mast cell", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33275825", "text": "y in controlling acute symptoms of anaphylaxis to NMBAs caused by MRGPRX2 activation. Interestingly, however, sugammadex did impair MRGPRX2-induced CC", "offsetInBeginSection": 1773, "offsetInEndSection": 1923, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22529299", "text": " mast cell activation. However, extended SCF exposure in vivo conversely protects against fatal Ag-mediated anaphylaxis. In investigating this dichoto", "offsetInBeginSection": 303, "offsetInEndSection": 453, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32709306", "text": "en allergy and sensitisation. Extended studies are required to verify whether this technique can be used in other causes of perioperative anaphylaxis.", "offsetInBeginSection": 1815, "offsetInEndSection": 1965, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28798744", "text": "diated activation of mast cells/basophils, further mechanisms are involved in the occurrence of anaphylaxis. New insights into the potential relevance", "offsetInBeginSection": 253, "offsetInEndSection": 403, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415c6b6690f196b51000015", "type": "list", "body": "On which two clinical trials was the approval of Keytruda based?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28179454", "http://www.ncbi.nlm.nih.gov/pubmed/31580145", "http://www.ncbi.nlm.nih.gov/pubmed/28235882", "http://www.ncbi.nlm.nih.gov/pubmed/11514037", "http://www.ncbi.nlm.nih.gov/pubmed/20858147", "http://www.ncbi.nlm.nih.gov/pubmed/32272501", "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "http://www.ncbi.nlm.nih.gov/pubmed/29764494", "http://www.ncbi.nlm.nih.gov/pubmed/28533473", "http://www.ncbi.nlm.nih.gov/pubmed/30290675", "http://www.ncbi.nlm.nih.gov/pubmed/35524471", "http://www.ncbi.nlm.nih.gov/pubmed/34560672", "http://www.ncbi.nlm.nih.gov/pubmed/35182072"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34560672", "text": "orable trials (33%) met substantial benefit thresholds using the ESMO-MCBS and ASCO-VF, respectively. In the postmarketing period, 37 of 69 (54%) and ", "offsetInBeginSection": 1064, "offsetInEndSection": 1214, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32272501", "text": " Merkel cell carcinoma (MCC). Approval was based on Cancer Immunotherapy Trials Network protocol 9, also known as KEYNOTE-017 (NCT02267603), a multice", "offsetInBeginSection": 232, "offsetInEndSection": 382, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31580145", "text": "The proportion of patients in our sample who participated in trials leading to an approval by the Food and Drug Administration or a National Comprehensive Cancer Network guideline recommendation was 12.7% with 5\u2009years of follow-up, and 22.3% among pairings for which there were 8\u2009years of follow-up.", "offsetInBeginSection": 1629, "offsetInEndSection": 1779, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30290675", "text": " inclusion criteria. FDA approvals of these products were based on 22 pivotal trials. CMS NCDs were based on 27 original clinical trials; 14 clinical ", "offsetInBeginSection": 836, "offsetInEndSection": 986, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20858147", "text": "more comparative information.\n\n\nMETHODS\nA search of the literature (Medline, Embase), trial registries (Clinical Trials.gov, Controlled Trials.com), a", "offsetInBeginSection": 161, "offsetInEndSection": 311, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "text": "ificant improvement in PFS (HR 0.50; 95% CI: 0.37-0.68; p\u2009<\u2009.001). In KEYNOTE-010, patients with disease progression on or after platinum-containing c", "offsetInBeginSection": 1396, "offsetInEndSection": 1546, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28235882", "text": "Approval was based on demonstration of objective tumor responses with prolonged response durations in 89 patients enrolled in a randomized, multicenter, open-label, dose-finding, and activity-estimating phase 1 trial.", "offsetInBeginSection": 443, "offsetInEndSection": 593, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28533473", "text": "taining chemotherapy. Approval was based on the objective response rate (ORR) and duration of response (DoR) in a cohort of patients in a nonrandomize", "offsetInBeginSection": 317, "offsetInEndSection": 467, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35524471", "text": "ly. These results supported the accelerated approval pathway based on the promising efficacy data of small populations in anticancer drug development.", "offsetInBeginSection": 1615, "offsetInEndSection": 1765, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "text": " receiving pembrolizumab.Approval was based on two randomized, open-label, active-controlled trials demonstrating statistically significant improvemen", "offsetInBeginSection": 851, "offsetInEndSection": 1001, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28235882", "text": "Important regulatory issues in this application were role of durability of response in the evaluation of ORR for accelerated approval, reliance on data from a first-in-human trial, and strategies for dose selection.", "offsetInBeginSection": 1320, "offsetInEndSection": 1470, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28179454", "text": "or metastatic melanoma based on results of two randomized, open-label, active-controlled clinical trials. In trial PN006, 834 patients with ipilimumab", "offsetInBeginSection": 154, "offsetInEndSection": 304, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31580145", "text": "METHODS\nTo establish a historic benchmark of risk and benefit, we searched Medline and Embase for clinical trials testing anti-cancer drugs in combination within 5\u2009years of approval by the Food and Drug Administration of 12 anti-cancer \"index\" drugs first licensed 2005-2007 inclusive.", "offsetInBeginSection": 225, "offsetInEndSection": 375, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29764494", "text": "onths with complete responses observed; and (d) parallel development in adult and pediatric populations. With increasing accessibility to genetic anal", "offsetInBeginSection": 1762, "offsetInEndSection": 1912, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11514037", "text": "The central premise is that substantial information from multicenter studies has already shown efficacy in the United States or the European Union when a drug manufacturer seeks marketing approval in an Asian country.", "offsetInBeginSection": 1388, "offsetInEndSection": 1538, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "text": "rations prior to receiving pembrolizumab.Approval was based on two randomized, open-label, active-controlled trials demonstrating statistically signif", "offsetInBeginSection": 835, "offsetInEndSection": 985, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35182072", "text": "Clinical trials leading to approvals were reviewed for trial design (RCT vs single arm study, primary endpoint) and PD-L1 defined subgroup design (no subgroup analysis, single threshold 2-group analysis, nested subgroups and adjacent subgroups).", "offsetInBeginSection": 948, "offsetInEndSection": 1098, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28179454", "text": "Key considerations for approval were determination of pembrolizumab dose and interpretation of tumor response-based endpoints using RECIST or immune-related RECIST.", "offsetInBeginSection": 1316, "offsetInEndSection": 1466, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28533473", "text": "roval, Merck is required to conduct a confirmatory trial; this trial, KEYNOTE-040, is ongoing.\n\n\nIMPLICATIONS FOR PRACTICE\nThis accelerated approval e", "offsetInBeginSection": 1600, "offsetInEndSection": 1750, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34560672", "text": "SULTS\nWe found that 58 drugs were approved for 96 indications based on 96 trials. At registration, approval was based on improved OS in 39 trials (41%", "offsetInBeginSection": 693, "offsetInEndSection": 843, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e34690f196b51000021", "type": "yesno", "body": "Is viltolarsen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19179609", "http://www.ncbi.nlm.nih.gov/pubmed/26136844", "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "http://www.ncbi.nlm.nih.gov/pubmed/32453377", "http://www.ncbi.nlm.nih.gov/pubmed/36401022", "http://www.ncbi.nlm.nih.gov/pubmed/35634851", "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "http://www.ncbi.nlm.nih.gov/pubmed/19078632", "http://www.ncbi.nlm.nih.gov/pubmed/33285037", "http://www.ncbi.nlm.nih.gov/pubmed/34938127", "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "http://www.ncbi.nlm.nih.gov/pubmed/19517771", "http://www.ncbi.nlm.nih.gov/pubmed/32483212", "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "http://www.ncbi.nlm.nih.gov/pubmed/36401026", "http://www.ncbi.nlm.nih.gov/pubmed/36401027", "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "http://www.ncbi.nlm.nih.gov/pubmed/32947786"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19517771", "text": "ing gene transfer strategies have been conducted, but no effective treatment has been established. Two plausible ways have been proposed. One is the i", "offsetInBeginSection": 294, "offsetInEndSection": 444, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "se of mortality among Duchenne muscular dystrophy patients and lacks effective therapies. Phosphodiesterase type 5 is implicated in dystrophic patholo", "offsetInBeginSection": 42, "offsetInEndSection": 192, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32453377", "text": "80 mg/kg per week: mean [range] 5.9% [1.1-14.4] of normal). Viltolarsen was well tolerated; no treatment-emergent adverse events required dose reducti", "offsetInBeginSection": 1685, "offsetInEndSection": 1835, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "r dystrophy is a lethal neuromuscular disease that currently has no effective therapy. Transgenic overexpression of the alpha7 integrin in mdx/utrn(-/", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "text": "dystrophin, a 427-kDa cytoskeletal protein, but the effective therapeutic drug is presently unavailable. We previously reported that a trypsin-like pr", "offsetInBeginSection": 73, "offsetInEndSection": 223, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "text": "ith Duchenne muscular dystrophy experienced severe acute heart failure triggered by pneumonia. Levosimendan was effective in improving heart function.", "offsetInBeginSection": 264, "offsetInEndSection": 414, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "es, most commonly as limb-girdle muscular dystrophy 2I. There is no effective therapy available. Glucocorticoid steroids have become the standard trea", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022", "text": "runcated but functional form of dystrophin. It can treat approximately 8-10% of the DMD patient population.\u00a0This paper aims to summarize the developme", "offsetInBeginSection": 786, "offsetInEndSection": 936, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32453377", "text": "Conclusions and Relevance\nSystemic treatment of participants with DMD with viltolarsen induced de novo dystrophin production, and clinical improvement of timed function tests was observed.", "offsetInBeginSection": 2378, "offsetInEndSection": 2528, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33285037", "text": "OBJECTIVE\nThe novel morpholino antisense oligonucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD).", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": "ive degeneration of skeletal and cardiac muscles. Currently, there is no effective therapy for this disorder. However, the technology of cell reprogra", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26136844", "text": "essive pediatric muscle disorder. For decades, research has been conducted to find an effective therapy. This review presents current therapeutic meth", "offsetInBeginSection": 99, "offsetInEndSection": 249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35634851", "text": "red to a matched historical control group.\n\n\nOBJECTIVE\nTo evaluate long-term efficacy and safety of the anti-sense oligonucleotide viltolarsen in the ", "offsetInBeginSection": 356, "offsetInEndSection": 506, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19078632", "text": " not increased.\n\n\nCONCLUSION\nLong-term steroid treatment in Duchenne muscular dystrophy (average. 65 mo) proved beneficial m terms of muscle strength,", "offsetInBeginSection": 1303, "offsetInEndSection": 1453, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32453377", "text": "Objective\nTo evaluate the safety, tolerability, and efficacy of viltolarsen, a novel antisense oligonucleotide, in participants with DMD amenable to exon 53 skipping.", "offsetInBeginSection": 164, "offsetInEndSection": 314, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35634851", "text": "OBJECTIVE\nTo evaluate long-term efficacy and safety of the anti-sense oligonucleotide viltolarsen in the treatment of patients with DMD amenable to exon 53 skipping therapy.", "offsetInBeginSection": 1649, "offsetInEndSection": 1799, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "r levels of activated Akt in their muscles. Thus, VPA has important biological effects that may be applicable for the treatment of muscular dystrophy.", "offsetInBeginSection": 1056, "offsetInEndSection": 1206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "text": "ost common muscle disease found in male children. Currently, there is no effective therapy available for Duchenne muscular dystrophy patients. Therefo", "offsetInBeginSection": 36, "offsetInEndSection": 186, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212", "text": " in Japan earlier this year. Although promising, the efficacy of eteplirsen and AON sequence employed remain controversial. In addition, exon skipping", "offsetInBeginSection": 541, "offsetInEndSection": 691, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32947786", "text": "ar diseases. However, the studies also made clear that these therapies are still far from a cure. Personalized genetic medicine for neuromuscular dise", "offsetInBeginSection": 615, "offsetInEndSection": 765, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33285037", "text": "d in dystrophin expression and exon 53 skipping levels, and was safe and well tolerated. The decline in motor function appeared less marked in patient", "offsetInBeginSection": 1323, "offsetInEndSection": 1473, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "text": "From this review, it is clear that until a definitive treatment for Duchenne muscular dystrophy is available, the use of deflazacort and prednisone with judicious dietary control and close clinical monitoring for side effects seems the best intervention for interim preservation of function in such a common devastating disorder of young growing boys.", "offsetInBeginSection": 847, "offsetInEndSection": 997, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401027", "text": "Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression.", "offsetInBeginSection": 371, "offsetInEndSection": 521, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "Consequently, phosphodiesterase type 5 inhibition is a candidate therapy for slowing the development of cardiomyopathy in Duchenne muscular dystrophy patients.", "offsetInBeginSection": 1663, "offsetInEndSection": 1813, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19078632", "text": "PURPOSE\nIn tins retrospective study, positive results and side effects of long-term steroid treatment for Duchenne muscular dystrophy were analyzed. R", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "text": "We concluded that embryo analysis using associated techniques of PCR and array CGH seems to be safe for embryo selection in cases of X-linked disorders, such as Duchenne muscular dystrophy.", "offsetInBeginSection": 1251, "offsetInEndSection": 1401, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34938127", "text": "020 and the United States in August 2020, respectively. Viltolarsen is a mutation-specific drug and will work for 8% of the persons with DMD who carry", "offsetInBeginSection": 935, "offsetInEndSection": 1085, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "These results, for the\u00a0first time, demonstrate the efficacy and feasibility of this alliance treatment of the two drugs for fukutin-related protein-muscular dystrophy.", "offsetInBeginSection": 1484, "offsetInEndSection": 1634, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "These results, for the\u00a0first time, demonstrate the efficacy and feasibility of this alliance treatment of the two drugs for fukutin-related protein-muscular dystrophy.", "offsetInBeginSection": 1458, "offsetInEndSection": 1608, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401026", "text": "The canine X-linked muscular dystrophy in Japan (CXMDj), a dog model of DMD, produces no dystrophin and exhibits a severe phenotype similar to human patients from early childhood.", "offsetInBeginSection": 620, "offsetInEndSection": 770, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640410d1201352f04a000012", "type": "summary", "body": "What is Wilkie's syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29204239", "http://www.ncbi.nlm.nih.gov/pubmed/35047254", "http://www.ncbi.nlm.nih.gov/pubmed/1019644", "http://www.ncbi.nlm.nih.gov/pubmed/17298761", "http://www.ncbi.nlm.nih.gov/pubmed/18419824", "http://www.ncbi.nlm.nih.gov/pubmed/34786223", "http://www.ncbi.nlm.nih.gov/pubmed/16968185", "http://www.ncbi.nlm.nih.gov/pubmed/28688313", "http://www.ncbi.nlm.nih.gov/pubmed/29673098", "http://www.ncbi.nlm.nih.gov/pubmed/34401041", "http://www.ncbi.nlm.nih.gov/pubmed/35496747", "http://www.ncbi.nlm.nih.gov/pubmed/33083170", "http://www.ncbi.nlm.nih.gov/pubmed/28100055", "http://www.ncbi.nlm.nih.gov/pubmed/31501628", "http://www.ncbi.nlm.nih.gov/pubmed/26969279", "http://www.ncbi.nlm.nih.gov/pubmed/18008078", "http://www.ncbi.nlm.nih.gov/pubmed/31516794", "http://www.ncbi.nlm.nih.gov/pubmed/19066831", "http://www.ncbi.nlm.nih.gov/pubmed/30254733", "http://www.ncbi.nlm.nih.gov/pubmed/35304355", "http://www.ncbi.nlm.nih.gov/pubmed/30187852", "http://www.ncbi.nlm.nih.gov/pubmed/21365426", "http://www.ncbi.nlm.nih.gov/pubmed/32821627", "http://www.ncbi.nlm.nih.gov/pubmed/36287212", "http://www.ncbi.nlm.nih.gov/pubmed/21276386", "http://www.ncbi.nlm.nih.gov/pubmed/9455097", "http://www.ncbi.nlm.nih.gov/pubmed/32116320", "http://www.ncbi.nlm.nih.gov/pubmed/35475250"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/1019644", "text": "Of the three cases of superior mesenteric artery (Wilkie's) syndrome presented, one was associated with anorexia nervosa; this association has not been reported before.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33083170", "text": "Superior mesenteric artery syndrome, or Wilkie's syndrome, is an unexpected cause of upper gastrointestinal tract obstruction. The exact incidence of ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16968185", "text": "Superior mesenteric artery syndrome (Wilkie's syndrome) causes acute or chronic compression of the third part of the duodenum. Initially conservative ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28100055", "text": "Superior mesenteric artery syndrome, also Wilkie's syndrome, is an uncommon cause of upper intestinal obstruction. It includes compression of the thir", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18419824", "text": "INTRODUCTION\nWilkie's syndrome, a rare cause of intestinal obstruction, is related to anatomical and mechanical factors associated with the reduction of retroperitoneal fat padding.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21365426", "text": "Wilkie's syndrome (superior mesenteric artery syndrome) is a rare cause of obstruction to the third part of duodenum due to compression between the superior mesenteric artery and the abdominal aorta.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29673098", "text": "Superior mesenteric artery syndrome, also known as Wilkie's syndrome, is a rare cause of proximal duodenum obstruction in children. Here, we describe ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17298761", "text": "Superior mesenteric artery (SMA) syndrome (also known as Wilkie's syndrome, chronic duodenal ileus, or cast syndrome) occurs when the third portion of the duodenum is compressed between the SMA and the aorta.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9455097", "text": "Wilkie's syndrome is a rare disease that should be considered in the differential diagnosis of upper abdominal discomfort and weight loss. Compression", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19066831", "text": "The superior mesenteric artery syndrome--also known as Wilkie's syndrome or as arteriomesenteric obstruction of the duodenum--is a rare condition of upper intestinal obstruction in which the third part of the duodenum is compressed by the overlying, narrow-angled superior mesenteric artery against the posterior structures.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21276386", "text": "Wilkie's syndrome is a rare variant of small intestinal obstruction resulting from compression of third part of the duodenum by the superior mesenteric artery.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30254733", "text": "Wilkie's syndrome is a rare cause of duodenal obstruction that can easily be missed at clinical practice. It is characterized by nausea, abdominal pai", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35047254", "text": "c and with progressive weight gain. Wilkie's syndrome is a rare form of intestinal obstruction, which is commonly disregarded. Its non-specific sympto", "offsetInBeginSection": 1520, "offsetInEndSection": 1670, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34401041", "text": "Wilkie's Syndrome is a very rare disease caused by reduction of aorto-mesenteric space with consequent duodenum compression. It can combine with left ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34786223", "text": "Wilkie's syndrome is a very rare vascular alteration caused by congenital or acquired reduction of\u00a0space between the superior mesenteric artery (SMA) and\u00a0aorta.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29204239", "text": "Superior mesenteric artery syndrome, also known as Wilkie's syndrome, is a rare vascular disease caused by the anomalous course of the superior mesenteric artery arising from the abdominal aorta with a smaller angle than the norm (<22\u00b0).", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18008078", "text": "INTRODUCTION\nSuperior mesenteric artery or Wilkie's syndrome is defined as compression of the third part of duodenum by superior mesenteric artery. It", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35304355", "text": "Superior mesenteric artery syndrome (SMAS), also known as Wilkie's syndrome, is a rare cause of upper gastrointestinal tract obstruction. We report a ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31516794", "text": "s superior mesenteric artery (SMA) syndrome, is an infrequent and rare cause of small bowel obstruction. It is caused by extrinsic compression of the ", "offsetInBeginSection": 40, "offsetInEndSection": 190, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32116320", "text": "BACKGROUND\nThe superior mesenteric artery (SMA) syndrome, also known as Wilkie's syndrome, is one of the rarest causes of small bowel obstruction.\n\n\nC", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35047254", "text": "Wilkie's syndrome is a rare pathology caused by extrinsic compression of the third part of the duodenum by the superior mesenteric artery (SMA) at its origin.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35475250", "text": "solved in all 37 patients (100%). Conclusion Wilkie's syndrome, although rare, is frequently late-diagnosed or underdiagnosed. In cases of failure of ", "offsetInBeginSection": 2721, "offsetInEndSection": 2871, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30187852", "text": "Wilkie's syndrome is a rare condition in which a decreased angle and distance between the superior mesenteric artery and aorta causes a compression of the third part of the duodenum, resulting ultimately in gastric dilation, gastric rupture and acute ischaemia of the bowel.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28688313", "text": "INTRODUCTION\nSuperior mesenteric artery (SMA) syndrome also known as Wilkie's syndrome is a rare condition caused by the entrapment of the third part of the duodenum between the aorta and the SMA.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26969279", "text": "UNLABELLED\nSuperior mesenteric artery (SMA) syndrome, also named as Wilkie's syndrome, is a rare, potentially life-threatening gastro- vascular disorder and an uncommon cause of proximal bowel obstruction characterized by a compression of the third and final portion of the duodenum by the abdominal aorta and the overlying superior mesenteric artery.", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35496747", "text": "Superior mesenteric artery (SMA) syndrome, also known as Cast syndrome, Wilkie's syndrome, or duodenal ileus, is a rare condition involving compression of the duodenum between the aorta and the SMA, primarily attributed to loss of the intervening mesenteric fat pad.", "offsetInBeginSection": 113, "offsetInEndSection": 265, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36287212", "text": "In Wilkie's syndrome, the third part of the duodenum is compressed between the superior mesenteric artery and the abdominal aorta, causing various gastrointestinal symptoms.", "offsetInBeginSection": 324, "offsetInEndSection": 474, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32821627", "text": "Introduction Superior mesenteric artery (SMA) or Wilkie's syndrome is a rare condition arising due to compression of the third part of the duodenum between the abdominal aorta and the superior mesenteric artery.", "offsetInBeginSection": 3, "offsetInEndSection": 153, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31501628", "text": "INTRODUCTION\nWilkie's syndrome is a rare entity that presents as a chronic intestinal obstruction secondary to mechanical compression of the third portion of the duodenum due to a decreased aorto-mesenteric angle.", "offsetInBeginSection": 34, "offsetInEndSection": 212, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29204239", "text": " 12\u00a0kg in 4\u00a0months. B-mode ultrasound imaging revealed evidence of a reduced angle between the aorta and the superior mesenteric artery, as found in W", "offsetInBeginSection": 847, "offsetInEndSection": 997, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641461bb201352f04a000046", "type": "summary", "body": "What is a PROTAC?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35816671", "http://www.ncbi.nlm.nih.gov/pubmed/36142231", "http://www.ncbi.nlm.nih.gov/pubmed/34285415", "http://www.ncbi.nlm.nih.gov/pubmed/32976709", "http://www.ncbi.nlm.nih.gov/pubmed/36448571", "http://www.ncbi.nlm.nih.gov/pubmed/33160761", "http://www.ncbi.nlm.nih.gov/pubmed/33860212", "http://www.ncbi.nlm.nih.gov/pubmed/34025443", "http://www.ncbi.nlm.nih.gov/pubmed/32164504", "http://www.ncbi.nlm.nih.gov/pubmed/33010159", "http://www.ncbi.nlm.nih.gov/pubmed/36300631", "http://www.ncbi.nlm.nih.gov/pubmed/28379698", "http://www.ncbi.nlm.nih.gov/pubmed/32338867", "http://www.ncbi.nlm.nih.gov/pubmed/26593377", "http://www.ncbi.nlm.nih.gov/pubmed/36139095", "http://www.ncbi.nlm.nih.gov/pubmed/18752944", "http://www.ncbi.nlm.nih.gov/pubmed/10805251", "http://www.ncbi.nlm.nih.gov/pubmed/32082969", "http://www.ncbi.nlm.nih.gov/pubmed/34081921", "http://www.ncbi.nlm.nih.gov/pubmed/36084553", "http://www.ncbi.nlm.nih.gov/pubmed/32404196", "http://www.ncbi.nlm.nih.gov/pubmed/35344835", "http://www.ncbi.nlm.nih.gov/pubmed/36047364", "http://www.ncbi.nlm.nih.gov/pubmed/34240523", "http://www.ncbi.nlm.nih.gov/pubmed/33406191", "http://www.ncbi.nlm.nih.gov/pubmed/33642364"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33160761", "text": "Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3 ligase for target degradation via the ubiquitin-proteasome pathway, is a novel drug discovery paradigm which has been widely used as biological tools and medicinal molecules with the potential of clinical application value.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36300631", "text": "Proteolysis targeting chimeras (PROTACs), which harness the ubiquitin-proteasome system to selectively induce targeted protein degradation, represent an emerging therapeutic technology with the potential to modulate traditional undruggable targets.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33860212", "text": "Proteolysis-targeting chimeras (PROTACs) degrade target proteins by engaging the ubiquitin-proteasome system. Assays detecting target-PROTAC-E3 ligase", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34240523", "text": "Development of proteolysis targeting chimeras (PROTACs) is emerging as a promising strategy for targeted protein degradation. However, the drug develo", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34081921", "text": "Proteolysis-targeting chimeras (PROTACs) represent a new direction in small-molecule therapeutics whereby a heterobifunctional linker to a protein of interest (POI) induces its ubiquitination-based proteolysis by recruiting an E3 ligase.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32082969", "text": "teins and aggregated proteins is a challenging goal. PROTAC proteolysis-targeting chimaera (PROTAC) technology may be the solution, considering its ab", "offsetInBeginSection": 49, "offsetInEndSection": 199, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34285415", "text": "Proteolysis-targeting chimeras (PROTACs) are an emerging drug modality that may offer new opportunities to circumvent some of the limitations associated with traditional small-molecule therapeutics.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28379698", "text": "Here we report the development of a proteolysis targeting chimera (PROTAC) based on the combination of the unique features of the sirtuin rearranging ligands (SirReals) as highly potent and isotype-selective Sirt2 inhibitors with thalidomide, a bona fide cereblon ligand.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33860212", "text": "s, indicating the effectiveness of our assay for predicting PROTAC cellular activity. The TR-FRET ternary complex formation assay for BRD2(BD1)/PROTAC", "offsetInBeginSection": 985, "offsetInEndSection": 1135, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32976709", "text": "Proteolysis-targeting chimeras (PROTACs), which induce degradation by recruitment of an E3 ligase to a target protein, are gaining much interest as a new pharmacological modality.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32164504", "text": "PROTAC (Proteolysis Targeting Chimera) degraders based on protein knockdown technology are now suggested as a novel option for the treatment of various diseases.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26593377", "text": "Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33010159", "text": "Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted proteins by the ubiquitin-proteasome system, have emerged as a novel therapeutic technology with potential advantages over traditional inhibition strategies.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32404196", "text": "Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule c", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36139095", "text": "PROTAC (proteolysis-targeting chimeras), which selectively degrades target proteins, has become the most popular technology for drug development in recent years.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35344835", "text": "The overexpression of PI3K kinase exists in many cancers. The proteolytic target chimera (PROTAC) technology is a new technology that uses the ubiquit", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35816671", "text": "Proteolysis targeting chimera (PROTAC)-mediated protein degradation has prompted a radical rethink and is at a crucial stage in driving a drug discovery transition.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32338867", "text": "Targeting protein degradation with Proteolysis-Targeting Chimeras (PROTACs) is an area of great current interest in drug discovery. Nevertheless, alth", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36448571", "text": "Proteolysis Targeting Chimeras (PROTACs) are attractive therapeutic modalities for degrading disease-causing proteins. While many PROTACs have been de", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34025443", "text": "Proteolysis targeting chimeric (PROTAC) technology is an effective endogenous protein degradation tool developed in recent years that can ubiquitinate the target proteins through the ubiquitin-proteasome system (UPS) to achieve an effect on tumor growth.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33406191", "text": "A parallel, one-pot assembly approach to proteolysis targeting chimeras (PROTACs) is demonstrated utilizing activated esters generated in situ, and traceless Staudinger ligation chemistry.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36142231", "text": "nd degraded by the proteasome in the cell. At present, PROTAC, as a new type of drug, has been developed to degrade a variety of cancer target protein", "offsetInBeginSection": 551, "offsetInEndSection": 701, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36047364", "text": "Protease-targeted chimeras (PROTACs) have been employed as a novel therapeutic approach, utilizing the ubiquitin-proteasome system for targeted protein degradation.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33642364", "text": "ases for which appropriate drugs and treatments are lacking. Proteolysis targeting chimera (PROTAC) technology is a novel strategy to solve this probl", "offsetInBeginSection": 135, "offsetInEndSection": 285, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18752944", "text": "We have developed a heterobifunctional all-small molecule PROTAC (PROteolysis TArgeting Chimera) capable of inducing proteasomal degradation of the androgen receptor.", "offsetInBeginSection": 5, "offsetInEndSection": 155, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36142231", "text": "Proteolysis-targeting chimera (PROTAC) is a heterobifunctional molecule. Typically, PROTAC consists of two terminals which are the ligand of the prote", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32976709", "text": "ir modeling. We developed a combined protocol for the modeling of a ternary complex induced by a given PROTAC. Our protocol alternates between samplin", "offsetInBeginSection": 572, "offsetInEndSection": 722, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10805251", "text": "Protac may be suitable as an activator of PC in bovine and equine plasmas; however, it appears ineffective in generating anticoagulant activity in canine plasma.", "offsetInBeginSection": 2493, "offsetInEndSection": 2643, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36084553", "text": "TACs have emerged as a new class of drugs that can target the \"undruggable\" proteome by hijacking the ubiquitin proteasome system. Despite PROTACs' su", "offsetInBeginSection": 3, "offsetInEndSection": 153, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10805251", "text": "The commercial snake venom extract, Protac, is a specific activator of the anticoagulant zymogen, protein C (PC) in human plasma. This specific action", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410f839201352f04a000032", "type": "yesno", "body": "Can the concept of digital twins be applied in Precision Nutrition?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33215237", "http://www.ncbi.nlm.nih.gov/pubmed/35617022", "http://www.ncbi.nlm.nih.gov/pubmed/35701842", "http://www.ncbi.nlm.nih.gov/pubmed/32098079", "http://www.ncbi.nlm.nih.gov/pubmed/33377993", "http://www.ncbi.nlm.nih.gov/pubmed/36236216", "http://www.ncbi.nlm.nih.gov/pubmed/35607617", "http://www.ncbi.nlm.nih.gov/pubmed/35099399"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36236216", "text": "e of cattle is about 5.197 after optimization. The digital twins model developed in this work can be used to forecast the cattle's future time budget.", "offsetInBeginSection": 800, "offsetInEndSection": 950, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32098079", "text": "s under various damage/action conditions. The proposed method can serve as a foundation for further research on digital twins for large-scale structur", "offsetInBeginSection": 1282, "offsetInEndSection": 1432, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35617022", "text": "\nDigital twins could provide an individualized early warning system that predicts the risk of future health conditions and recommends the most effective intervention to minimize that risk. These insights could significantly improve an individual's quality of life and healthy life expectancy and reduce population-level health burdens", "offsetInBeginSection": 2415, "offsetInEndSection": 2749, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35701842", "text": "While the online data collection was successful, strategies need to be implemented to improve adherence, follow-up, control group credibility (for digital CBT-i), and twin recruitment rates (for twin trials).", "offsetInBeginSection": 2225, "offsetInEndSection": 2375, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35099399", "text": "The process-oriented ethical map we propose here can assist the developers of digital twins for personalized health care services in analyzing ethical risks in a more systematic manner.", "offsetInBeginSection": 2039, "offsetInEndSection": 2215, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33215237", "text": "Furthermore, applications of Digital Twins for the academic education of future control and bioprocess engineers as well as for the training of future bioreactor operators will be described.", "offsetInBeginSection": 971, "offsetInEndSection": 1147, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35607617", "text": "The development of Digital Twins has enabled them to be widely applied to various fields represented by intelligent manufacturing. A Metaverse, which ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35617022", "text": "An interdisciplinary approach is essential, as data science, artificial intelligence, and engineering concepts (digital twins) can identify key risk factors throughout the life course, potentially enabling personalized simulation of life-course risk for the development of multimorbidity.", "offsetInBeginSection": 424, "offsetInEndSection": 584, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33377993", "text": "The concept of digital twins has become increasingly popular in recent years. To exploit their full potential, integration of systems and data across ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eef6edf36125a42600000d", "type": "summary", "body": "What is the mechanism of action of Teclistamab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34388396", "http://www.ncbi.nlm.nih.gov/pubmed/32956453", "http://www.ncbi.nlm.nih.gov/pubmed/8957109", "http://www.ncbi.nlm.nih.gov/pubmed/27324312", "http://www.ncbi.nlm.nih.gov/pubmed/36352205", "http://www.ncbi.nlm.nih.gov/pubmed/19719780", "http://www.ncbi.nlm.nih.gov/pubmed/34417227", "http://www.ncbi.nlm.nih.gov/pubmed/35749004", "http://www.ncbi.nlm.nih.gov/pubmed/23089283", "http://www.ncbi.nlm.nih.gov/pubmed/36321843", "http://www.ncbi.nlm.nih.gov/pubmed/35661166"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34388396", "text": "b is a bispecific antibody that binds BCMA and CD3 to redirect T cells to multiple myeloma cells. The aim of the MajesTEC-1 study was to evaluate the ", "offsetInBeginSection": 162, "offsetInEndSection": 312, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32956453", "text": "Under more physiological conditions using healthy human whole blood, teclistamab mediated dose-dependent lysis of H929 cells and activation of T cells.", "offsetInBeginSection": 1020, "offsetInEndSection": 1170, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35749004", "text": "BACKGROUND\nTeclistamab (JNJ-64007957), a B-cell maturation antigen \u00d7 CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.", "offsetInBeginSection": 50, "offsetInEndSection": 200, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166", "text": "CONCLUSIONS\nTeclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma.", "offsetInBeginSection": 1934, "offsetInEndSection": 2084, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166", "text": "BACKGROUND\nTeclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells.", "offsetInBeginSection": 28, "offsetInEndSection": 196, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32956453", "text": "fic antibody (teclistamab [JNJ-64007957]) to recruit and activate T cells to kill BCMA-expressing MM cells. Teclistamab induced cytotoxicity of BCMA+ ", "offsetInBeginSection": 306, "offsetInEndSection": 456, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35749004", "text": " recommended Phase II dose (RP2D). With active doses, exposure was maintained above the mean EC90. All patients who responded to the RP2D of teclistam", "offsetInBeginSection": 1295, "offsetInEndSection": 1445, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36352205", "text": "Teclistamab (TECVAYLI\u00ae), a bispecific antibody that targets CD3 and B cell maturation antigen (BCMA), is being developed by Janssen Research and Development for the treatment of relapsed or refractory multiple myeloma.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34388396", "text": "At the recommended phase 2 dose, teclistamab showed promising efficacy, with durable responses that deepened over time, and was well tolerated, supporting further clinical development.", "offsetInBeginSection": 2808, "offsetInEndSection": 2958, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166", "text": " of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better).\n\n\nRESULTS\nAmong 165 patients who rec", "offsetInBeginSection": 732, "offsetInEndSection": 882, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283", "text": "The role of the mirror mechanism in cognition remains an intriguing and hotly debated topic in cognitive neuroscience. Since its discovery in the monk", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34388396", "text": "40 patients were administered the recommended phase 2 dose, identified as once per week subcutaneous administration of teclistamab at 1500 \u03bcg/kg, after 60 \u03bcg/kg and 300 \u03bcg/kg step-up doses (median follow-up 6\u00b71 months, IQR 3\u00b76-8\u00b72).", "offsetInBeginSection": 1620, "offsetInEndSection": 1770, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312", "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.", "offsetInBeginSection": 256, "offsetInEndSection": 406, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34417227", "text": "In a phase I trial, the optimal dose of teclistamab produced an overall response rate of 65%.", "offsetInBeginSection": 0, "offsetInEndSection": 93, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36321843", "text": "T-cell engager teclistamab for patients with relapsed or refractory multiple myeloma. In the clinical trial that led to its approval, patients had an overall response", "offsetInBeginSection": 36, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8957109", "text": "enesis of RA. The major effects of anti-TNFalpha therapy are in downregulating cytokine activity, and in reducing leucocyte trafficking to the joints.", "offsetInBeginSection": 529, "offsetInEndSection": 679, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19719780", "text": "The mechanism of the long duration of action of salmeterol at beta(2)-adrenoceptors has long been a matter of debate, and is still unresolved. Szczuka", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640c8309201352f04a000024", "type": "list", "body": "The diagnosis of cholestasis is based on the elevations seen in what liver function tests?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/108658", "http://www.ncbi.nlm.nih.gov/pubmed/2372276", "http://www.ncbi.nlm.nih.gov/pubmed/30899697", "http://www.ncbi.nlm.nih.gov/pubmed/6246298", "http://www.ncbi.nlm.nih.gov/pubmed/7142434", "http://www.ncbi.nlm.nih.gov/pubmed/24483054", "http://www.ncbi.nlm.nih.gov/pubmed/35295369", "http://www.ncbi.nlm.nih.gov/pubmed/24901263", "http://www.ncbi.nlm.nih.gov/pubmed/3416761", "http://www.ncbi.nlm.nih.gov/pubmed/1858028", "http://www.ncbi.nlm.nih.gov/pubmed/3316586", "http://www.ncbi.nlm.nih.gov/pubmed/25923022", "http://www.ncbi.nlm.nih.gov/pubmed/12664346", "http://www.ncbi.nlm.nih.gov/pubmed/25180107", "http://www.ncbi.nlm.nih.gov/pubmed/16825710", "http://www.ncbi.nlm.nih.gov/pubmed/30688121", "http://www.ncbi.nlm.nih.gov/pubmed/32211042", "http://www.ncbi.nlm.nih.gov/pubmed/7872869", "http://www.ncbi.nlm.nih.gov/pubmed/28106928", "http://www.ncbi.nlm.nih.gov/pubmed/36426309"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30688121", "text": "Intrahepatic cholestasis of pregnancy is a diagnosis of exclusion and presents with unexplained pruritus, abnormal liver function tests, and increased serum bile acid levels, particularly in the third trimester of pregnancy.", "offsetInBeginSection": 35, "offsetInEndSection": 185, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36426309", "text": " protein, and total bile acids were among the biochemical predictors. Blood tests that confirm obstetric cholestasis should alter the course of treatm", "offsetInBeginSection": 1270, "offsetInEndSection": 1420, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2372276", "text": "Liver function tests were abnormal in all patients with markedly elevated serum bilirubin concentration, alkaline phosphatase and aspartate transaminase levels.", "offsetInBeginSection": 235, "offsetInEndSection": 385, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7872869", "text": "Many tests have been proposed to help in differentiating these two entities, among which liver biopsy is the most frequently employed, and ultrasonography one of the most recently included.", "offsetInBeginSection": 336, "offsetInEndSection": 486, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30899697", "text": "d. Liver function tests improved following administration of phenylbutyrate and rifampicin. Her younger brother developed jaundice at two months of ag", "offsetInBeginSection": 791, "offsetInEndSection": 941, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1858028", "text": "unted but did not obliterate normal sequential elevations in H-ras found in control livers. The expression of c-myc was inhibited threefold with chole", "offsetInBeginSection": 1210, "offsetInEndSection": 1360, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1858028", "text": "cholestasis without cirrhosis. Despite early elevations of total hepatic DNA and RNA values, cholestatic livers demonstrated a significant threefold s", "offsetInBeginSection": 600, "offsetInEndSection": 750, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/108658", "text": "ter discontinuation of TPN, which suggests a causal relationship. Hepatic microscopy was abnormal in 12 of 14 infants examined. The main features were", "offsetInBeginSection": 422, "offsetInEndSection": 572, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16825710", "text": "The following investigations were performed: biochemical tests evaluating the function of the liver and cholestasis (serum bilirubin concentration and fractions, bile acids in serum, AlAT, AspAT, GGTP, FALK activities, serum electrophoresis, prothrombin index).", "offsetInBeginSection": 749, "offsetInEndSection": 899, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25180107", "text": "We present a case of a 57-year-old male who exhibited features of cholestatic jaundice including elevated liver function tests (LFTs) after taking cephalexin and showed improvement on removal of the offending agent.", "offsetInBeginSection": 256, "offsetInEndSection": 406, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25923022", "text": "ice and lower abdominal pain. Liver tests revealed marked cholestasis and high alkaline phosphatase and bilirubin levels. Imaging showed a normal-appe", "offsetInBeginSection": 380, "offsetInEndSection": 530, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28106928", "text": "Common presenting features include fatigue, pruritus, and cholestatic liver enzyme abnormalities wherein elevations of serum alkaline phosphatase and gamma-glutamyltransferases levels exceed those of alanine and aspartate aminotransferases.", "offsetInBeginSection": 221, "offsetInEndSection": 371, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16825710", "text": "r systems were obtained. The following investigations were performed: biochemical tests evaluating the function of the liver and cholestasis (serum bi", "offsetInBeginSection": 611, "offsetInEndSection": 761, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30688121", "text": "red in both groups and correlation analysis were performed between the YKL-40 and other liver function tests. Serum YKL-40 concentrations were higher ", "offsetInBeginSection": 507, "offsetInEndSection": 657, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35295369", "text": "bles, including neonatal demographic data, major medical diagnosis, liver function, medications, and maternal variables.\n\n\nRESULTS\nA total of 58 infan", "offsetInBeginSection": 1114, "offsetInEndSection": 1264, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3316586", "text": "is test were compared to those of standard serum tests of liver function, ultrasonography, and liver biopsy. The diagnosis of biliary atresia was sugg", "offsetInBeginSection": 234, "offsetInEndSection": 384, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16825710", "text": ". GGTP and FALK activities were markedly elevated in all children. Aminotransferases activities elevations were observed, more distinctively for AST. ", "offsetInBeginSection": 1331, "offsetInEndSection": 1481, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24901263", "text": "ence of a rash and deranged liver function tests, including raised serum bile acids. Intrahepatic cholestasis of pregnancy is associated with an incre", "offsetInBeginSection": 192, "offsetInEndSection": 342, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3416761", "text": "course due to the terminal loss of liver function. Extensive serological and imaging tests had not provided a uniform diagnosis which could have been ", "offsetInBeginSection": 261, "offsetInEndSection": 411, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24483054", "text": "Report the case of patient 25 years old, with 32 weeks of gestation, which presents severe pruritus, jaundice, altered liver function tests and lipid profile, with presumptive diagnosis of intrahepatic cholestasis of pregnancy.", "offsetInBeginSection": 245, "offsetInEndSection": 395, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12664346", "text": "iver function tests improved significantly during treatment with ursodeoxycholic acid (750 mg per day). Based on this case, it may be concluded that t", "offsetInBeginSection": 478, "offsetInEndSection": 628, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6246298", "text": "ntent, and 3) tumor spread and location. Liver function tests and plasma CEA recorded within 8 weeks of death, autopsy records of tumor spread, liver ", "offsetInBeginSection": 275, "offsetInEndSection": 425, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7872869", "text": "lution or operative findings. Sensitivity was 100% for ultrasonography and 76% for liver biopsy in diagnosing extrahepatic cholestasis. Accuracy was 8", "offsetInBeginSection": 1277, "offsetInEndSection": 1427, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6246298", "text": "histologic sections of tissue from 8 of 10 patients, and elevated bilirubin was seen in 7 of 10 patients with hepatic metastases and CEA levels greater than 1,000 ng/ml In contrast, histologically observed cholestasis and elevated bilirubin were seen in only 1 of 8 patients with CEA less than 500 ng/ml. A significant correlation was found between the plasma CEA level and histologically observed cholestasis (P less than 0.01). Serum bilirubin also correlated significantly (P less than 0.01), but alkaline phosphatase did not. Liver weight", "offsetInBeginSection": 604, "offsetInEndSection": 1146, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1858028", "text": " total hepatic DNA and RNA values, cholestatic livers demonstrated a significant threefold suppression of expected hepatocyte mitotic indexes 48 and 72 hours after PH, compared with livers after PH alone. Weight restoration in cholestatic livers was 11% +/- 5.2% compared with 40% +/- 4.3% in control livers (+/- SEM; p less than 0.001) 5 days after PH. Analysis of regenerating liver messenger RNA with complementary DNA probes", "offsetInBeginSection": 658, "offsetInEndSection": 1086, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7872869", "text": "olestasis were evaluated through a protocol which included liver biopsy and ultrasonography. The latter was performed after a 4 hour fast and was cons", "offsetInBeginSection": 709, "offsetInEndSection": 859, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7142434", "text": "Serum liver function tests were estimated in 57 patients admitted to an Intensive Therapy Unit (ITU) with a diagnosis of septic shock. Following an initial biochemical disturbance, persisting hyperbilirubinaemia was associated with a poor prognosis. Post-mortem liver histology ", "offsetInBeginSection": 0, "offsetInEndSection": 278, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32211042", "text": "ment of the liver function than the control group as evidenced by the biochemical tests (P < 0.01). Furthermore, the Bifidobacterium group exhibited l", "offsetInBeginSection": 2243, "offsetInEndSection": 2393, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415c599690f196b51000013", "type": "factoid", "body": "Which company produces Keytruda?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26631501", "http://www.ncbi.nlm.nih.gov/pubmed/35736598", "http://www.ncbi.nlm.nih.gov/pubmed/27398650", "http://www.ncbi.nlm.nih.gov/pubmed/30547369", "http://www.ncbi.nlm.nih.gov/pubmed/36223857"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30547369", "text": "As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme) of pembrolizumab (Keytruda\u00ae) to submit evidence of its clinical and cost effectiveness for the treatment of locally advanced or metastatic urothelial cancer where cisplatin is unsuitable.", "offsetInBeginSection": 79, "offsetInEndSection": 229, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26631501", "text": "lopment of checkpoint inhibitors that target the PD-1/PD-L1 pathway. Pembrolizumab (MK-3475, lambrolizumab, Keytruda(\u00ae)) is a PD-1 inhibitor that has ", "offsetInBeginSection": 111, "offsetInEndSection": 261, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27398650", "text": "ckade of PD1 is an important immunotherapeutic strategy for cancers. Pembrolizumab (Keytruda) is a humanized monoclonal anti-PD1 antibody that has bee", "offsetInBeginSection": 429, "offsetInEndSection": 579, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35736598", "text": "Pembrolizumab (Keytruda) is now approved as a single agent to treat advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient in those whose disease has progressed following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36223857", "text": ", six immune checkpoint inhibitors had been approved, with Keytruda and Opdivo accounting for the majority of global sales. Here, the impact of the di", "offsetInBeginSection": 84, "offsetInEndSection": 234, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64040edf201352f04a000011", "type": "yesno", "body": "Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15800139", "http://www.ncbi.nlm.nih.gov/pubmed/23050829", "http://www.ncbi.nlm.nih.gov/pubmed/29170725", "http://www.ncbi.nlm.nih.gov/pubmed/11570983", "http://www.ncbi.nlm.nih.gov/pubmed/16306243", "http://www.ncbi.nlm.nih.gov/pubmed/22503969", "http://www.ncbi.nlm.nih.gov/pubmed/35841241", "http://www.ncbi.nlm.nih.gov/pubmed/34146512", "http://www.ncbi.nlm.nih.gov/pubmed/34332638", "http://www.ncbi.nlm.nih.gov/pubmed/24648338", "http://www.ncbi.nlm.nih.gov/pubmed/31227652", "http://www.ncbi.nlm.nih.gov/pubmed/34220427"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34146512", "text": "e non-futility threshold.\n\n\nINTERPRETATION\nPioglitazone did not delay the onset of mild cognitive impairment. The biomarker algorithm demonstrated a 3", "offsetInBeginSection": 3689, "offsetInEndSection": 3839, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35841241", "text": "Power analyses showed that using prognostic models to recruit enriched cohorts of predicted decliners can reduce clinical trial sample sizes by as much as 51% while maintaining the same detection power.", "offsetInBeginSection": 2140, "offsetInEndSection": 2290, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23050829", "text": "omprise secondary measures.\n\n\nDISCUSSION\nCurrently, there is no effective pharmacological treatment available to delay cognitive decline and dementia ", "offsetInBeginSection": 1709, "offsetInEndSection": 1859, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31227652", "text": "Unfortunately, there are no drugs currently available that can delay and/or prevent the progression of disease in elderly individuals and in AD patients.", "offsetInBeginSection": 229, "offsetInEndSection": 379, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22503969", "text": "ctively. Furthermore, pioglitazone significantly prevented the fall in GSH levels and elevation in brain MDA levels induced by scopolamine. These resu", "offsetInBeginSection": 1215, "offsetInEndSection": 1365, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34332638", "text": "ts with Alzheimer's disease. If this study demonstrates at least stabilisation of memory function and/or good tolerability, the next step will be to r", "offsetInBeginSection": 2310, "offsetInEndSection": 2460, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29170725", "text": "SUMMARY\nDespite the considerable risk of cognitive impairment in people with diabetes and prediabetes, there is not enough evidence to support a specific treatment to prevent or slow mild cognitive impairment, or progression to Alzheimer's disease or related disorders.", "offsetInBeginSection": 736, "offsetInEndSection": 886, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11570983", "text": "Large-scale clinical trials in high-risk populations are needed to determine whether lowering blood homocysteine levels reduces the risk of cognitive impairment and may delay the clinical onset of dementia and perhaps of Alzheimer's disease.", "offsetInBeginSection": 880, "offsetInEndSection": 1030, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24648338", "text": "A new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer's disease dementia should provide insights into whether anti-amyloid therapy can delay cognitive decline.", "offsetInBeginSection": 57, "offsetInEndSection": 207, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35841241", "text": "CONCLUSIONS\nPrognostic tools for predicting cognitive decline and enriching clinical trials with participants at the highest risk of decline can improve trial quality, derisk endpoint failures, and accelerate therapeutic development in Alzheimer's disease.", "offsetInBeginSection": 2394, "offsetInEndSection": 2544, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16306243", "text": "However, it is likely that those with considerable brain or cognitive reserve will be able to mask cognitive deficits until very close to the onset of the dementia, rendering such cognitive measures insensitive.", "offsetInBeginSection": 545, "offsetInEndSection": 747, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22503969", "text": "hione (GSH) levels in the brain. Scopolamine produced significant reduction in SDL and prolongation of escape latency indicating cognitive impairment ", "offsetInBeginSection": 817, "offsetInEndSection": 967, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34220427", "text": "The results of animal testing suggest that pioglitazone can be corrective as well as protective, and that its efficacy is enhanced in a time- and dose-dependent manner, but the dose-effect relations are not monotonic or sigmoid.", "offsetInBeginSection": 773, "offsetInEndSection": 923, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23050829", "text": " for maintaining cognitive function, but few studies are investigating these benefits in high-risk populations. The aim of AIBL Active is to determine", "offsetInBeginSection": 621, "offsetInEndSection": 771, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15800139", "text": "xifene.\n\n\nCONCLUSIONS\nRaloxifene at a dose of 120 mg/day, but not 60 mg/day, resulted in reduced risk of cognitive impairment in postmenopausal women.", "offsetInBeginSection": 1564, "offsetInEndSection": 1714, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414638c201352f04a000047", "type": "factoid", "body": "Cereblon (CRBN)  has been identified as the target for what type of drug?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24755080", "http://www.ncbi.nlm.nih.gov/pubmed/36252444", "http://www.ncbi.nlm.nih.gov/pubmed/25860244", "http://www.ncbi.nlm.nih.gov/pubmed/34704527", "http://www.ncbi.nlm.nih.gov/pubmed/26535672", "http://www.ncbi.nlm.nih.gov/pubmed/32403132", "http://www.ncbi.nlm.nih.gov/pubmed/22966948", "http://www.ncbi.nlm.nih.gov/pubmed/32333926", "http://www.ncbi.nlm.nih.gov/pubmed/33777938", "http://www.ncbi.nlm.nih.gov/pubmed/32865967", "http://www.ncbi.nlm.nih.gov/pubmed/28978850", "http://www.ncbi.nlm.nih.gov/pubmed/34033753", "http://www.ncbi.nlm.nih.gov/pubmed/35831190", "http://www.ncbi.nlm.nih.gov/pubmed/31202702", "http://www.ncbi.nlm.nih.gov/pubmed/24993823", "http://www.ncbi.nlm.nih.gov/pubmed/23565715", "http://www.ncbi.nlm.nih.gov/pubmed/34115836", "http://www.ncbi.nlm.nih.gov/pubmed/32677118", "http://www.ncbi.nlm.nih.gov/pubmed/29718735", "http://www.ncbi.nlm.nih.gov/pubmed/25016816", "http://www.ncbi.nlm.nih.gov/pubmed/26186254", "http://www.ncbi.nlm.nih.gov/pubmed/21207098", "http://www.ncbi.nlm.nih.gov/pubmed/24328678", "http://www.ncbi.nlm.nih.gov/pubmed/32522938", "http://www.ncbi.nlm.nih.gov/pubmed/22552008"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34033753", "text": "ted with intellectual disability, was identified as primary target of thalidomide. Accumulating evidence has shown that CRBN is a substrate receptor o", "offsetInBeginSection": 56, "offsetInEndSection": 206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28978850", "text": "cluding multiple myeloma. Cereblon (CRBN) is a common primary target for IMiDs. It works as a substrate receptor of CRL4. Accumulating evidence has sh", "offsetInBeginSection": 242, "offsetInEndSection": 392, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36252444", "text": "biquitin ligase complex component. Cereblon is a well-known target of thalidomide and its derivatives. Cereblon is involved in multiple myeloma cell a", "offsetInBeginSection": 92, "offsetInEndSection": 242, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29718735", "text": "nts with this devastating disease. Cereblon (CRBN), the direct target of IMiDs, has been proposed as a predictive biomarker of response to IMiDs. Usin", "offsetInBeginSection": 242, "offsetInEndSection": 392, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33777938", "text": "We had previously demonstrated that cereblon (CRBN) is the target of thalidomide embryopathy and acts as a substrate receptor for the E3 ubiquitin ligase complex, Cullin-Ring ligase 4 (CRL4CRBN) in zebrafish and chicks.", "offsetInBeginSection": 172, "offsetInEndSection": 322, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21207098", "text": "ide-binding protein, cereblon (CRBN), as a primary target for thalidomide teratogenicity. Our data suggest that thalidomide initiates its teratogenic ", "offsetInBeginSection": 661, "offsetInEndSection": 811, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22966948", "text": "dy recently identified cereblon (CRBN) as a primary target of thalidomide teratogenicity. Subsequently it was demonstrated that CRBN is also required ", "offsetInBeginSection": 333, "offsetInEndSection": 483, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35831190", "text": "a substrate receptor of an E3 ubiquitin ligase as a primary target of thalidomide in 2010. CRBN binds not only to thalidomide, but also to various tha", "offsetInBeginSection": 477, "offsetInEndSection": 627, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32677118", "text": "cullin 4-RING ubiquitin ligase complex, and a binding target of immunomodulatory agents (IMiDs). CRBN is responsible for the pleiotropic effects of IM", "offsetInBeginSection": 59, "offsetInEndSection": 209, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32333926", "text": "ullin-ring E3 ubiquitin ligase (CRL), is a major target protein of immunomodulatory drugs. An earlier study demonstrated that CRBN directly interacts ", "offsetInBeginSection": 43, "offsetInEndSection": 193, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32403132", "text": "versus-host disease. Therefore, CRBN functions to harness the activation of CD8+ T cells, and this phenotype can be exploited by treatment with drugs.", "offsetInBeginSection": 1427, "offsetInEndSection": 1577, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23565715", "text": "Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to lenalidomide.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24328678", "text": "Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(CRBN) .", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32522938", "text": "Although the molecular mechanisms of thalidomide and its derivatives remained poorly understood until recently, we identified cereblon (CRBN), a primary direct target of thalidomide, using ferrite glycidyl methacrylate (FG) beads.", "offsetInBeginSection": 369, "offsetInEndSection": 519, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22552008", "text": "eblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another ", "offsetInBeginSection": 163, "offsetInEndSection": 313, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25860244", "text": "n in the CRBN-DDB1-CUL4 complex. Interestingly, treatment with other anti-myeloma drugs downregulated cellular contents of CRBN, and in a much faster ", "offsetInBeginSection": 709, "offsetInEndSection": 859, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32403132", "text": "Immunomodulatory drugs, such as thalidomide and related compounds, potentiate T-cell effector functions. Cereblon (CRBN), a substrate receptor of the ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33777938", "text": "These studies raise the possibility that CRBN-based small-molecule compounds regulating the proliferation of neural stem cells may be developed for application in regenerative medicine.", "offsetInBeginSection": 1622, "offsetInEndSection": 1772, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32865967", "text": "tly being explored as a therapeutic target for the treatment of acute myeloid leukemia. Molecular docking studies with CRBN and GSPT1 followed by anal", "offsetInBeginSection": 744, "offsetInEndSection": 894, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25016816", "text": "BN), has been identified as a direct molecular target for anti-neoplastic activities of IMiDs. CRBN has also been shown to be involved in IMiDs-mediat", "offsetInBeginSection": 543, "offsetInEndSection": 693, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34704527", "text": "ogical processes. It has also been identified as the target for immunomodulatory drugs (IMiDs). CRBN ligands are also important components of proteoly", "offsetInBeginSection": 153, "offsetInEndSection": 303, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31202702", "text": " for the treatment of multiple myeloma. Although the direct target of thalidomide had been unclear until recently, we identified cereblon (CRBN) as a ", "offsetInBeginSection": 107, "offsetInEndSection": 257, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26186254", "text": "Clinical interest in the measurement of Cereblon (CRBN), the primary target of the IMiDs immunomodulatory drugs lenalidomide and pomalidomide, has been fueled by its essential requirement for antitumor or immunomodulatory activity of both drugs in multiple myeloma (MM).", "offsetInBeginSection": 22, "offsetInEndSection": 172, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34115836", "text": "Cereblon is the direct binding target of the immunomodulatory drugs (IMiDs) that are commonly used to treat multiple myeloma (MM), the second most frequent hematologic malignancy.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24755080", "text": " was originally identified as a target protein for a mild type of mental retardation in humans. However, recent studies showed that CRBN acts as a neg", "offsetInBeginSection": 15, "offsetInEndSection": 165, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34704527", "text": " The promising area of research is in the identification of non-thalidomide-like chemotypes capable of binding to CRBN. Rational, crystallography-driv", "offsetInBeginSection": 1279, "offsetInEndSection": 1429, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36252444", "text": "on potential.\n\n\nMETHODS\nComputational investigations of possible CRBN inhibitors were investigated by molecular docking with Autodock Vina and DockTho", "offsetInBeginSection": 717, "offsetInEndSection": 867, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36252444", "text": "BSA method.\n\n\nRESULTS\nWe conducted computational investigations on 68 indanedione and indanone derivatives binding with cereblon. Ten molecules showed", "offsetInBeginSection": 1152, "offsetInEndSection": 1302, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26535672", "text": "We investigated the mechanisms of action of immuno-modulatory drug (lenalidomide) on the protein expression of cereblon (CRBN) and their therapeutic targets in the multiple myeloma cell line RPMI8226.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24993823", "text": "Here, we present results showing that CRBN can effectively regulate new protein synthesis through the mammalian target of rapamycin (mTOR) signaling pathway, a downstream target of AMPK.", "offsetInBeginSection": 266, "offsetInEndSection": 416, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f9cdb033942b094c000012", "type": "yesno", "body": "Does silencing of SRRM4 promote microexon inclusion?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25769695", "http://www.ncbi.nlm.nih.gov/pubmed/34445304", "http://www.ncbi.nlm.nih.gov/pubmed/35858306", "http://www.ncbi.nlm.nih.gov/pubmed/30100395", "http://www.ncbi.nlm.nih.gov/pubmed/30995482", "http://www.ncbi.nlm.nih.gov/pubmed/33621242"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33621242", "text": " SRRM4 is further silenced in tumors, resulting in the suppression of normal microexon inclusion. Remarkably, SRRM4 is the most consistently silenced ", "offsetInBeginSection": 738, "offsetInEndSection": 888, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35858306", "text": "Its deletion in zebrafish results in widespread down-regulation of microexon inclusion from early developmental stages, followed by other transcriptomic alterations, severe photoreceptor defects, and blindness.", "offsetInBeginSection": 788, "offsetInEndSection": 938, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30100395", "text": "While SRRM4 overexpression enhances SOX2 expression in both time- and dose-dependent manners in DU145 cells, RNA depletion of SOX2 compromises SRRM4-mediated stimulation of pluripotency genes.", "offsetInBeginSection": 1553, "offsetInEndSection": 1703, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25769695", "text": "We further show that the Rest target gene and alternative splicing factor srrm4 is a key downstream regulator of maturation; Srrm4 knockdown partially restores the ability of FBMNs to migrate in rest mutants while preventing their precocious morphological maturation.", "offsetInBeginSection": 1396, "offsetInEndSection": 1546, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34445304", "text": "mpared to diabetes-resistant mice, correlating with a preferential skipping of SRRM4 target exons. The repression of Srrm4 expression is presumably me", "offsetInBeginSection": 1298, "offsetInEndSection": 1448, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30995482", "text": "rtical neurons, overlapping SRRM3-SRRM4 activity regulates the development of interneuronal inhibition. In\u00a0vitro, SRRM3 and SRRM4 regulate the same sp", "offsetInBeginSection": 331, "offsetInEndSection": 481, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f03a20f36125a42600001c", "type": "list", "body": "Which drugs are included in the AZD7442?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33532768", "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "http://www.ncbi.nlm.nih.gov/pubmed/35871089", "http://www.ncbi.nlm.nih.gov/pubmed/35904210", "http://www.ncbi.nlm.nih.gov/pubmed/35797235", "http://www.ncbi.nlm.nih.gov/pubmed/36443846", "http://www.ncbi.nlm.nih.gov/pubmed/35914259", "http://www.ncbi.nlm.nih.gov/pubmed/35780162", "http://www.ncbi.nlm.nih.gov/pubmed/36411267", "http://www.ncbi.nlm.nih.gov/pubmed/35443106", "http://www.ncbi.nlm.nih.gov/pubmed/34548634", "http://www.ncbi.nlm.nih.gov/pubmed/35076282"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36443846", "text": "We conducted a retrospective multicentric study to evaluate pre-exposure prophylaxis with AZD7442 (tixagevimab/cilgavimab) for preventing COVID-19 in adult allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients.", "offsetInBeginSection": 251, "offsetInEndSection": 401, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "text": "For this reason, a BLI assay was developed and qualified to evaluate the reliability of screening SARS-CoV-2 spike trimer variants against anti-SARS-CoV-2 monoclonal antibodies (MAbs) tixagevimab and cilgavimab, the components of AZD7442, prior to in vitro pseudovirus neutralization susceptibility verification testing.", "offsetInBeginSection": 2184, "offsetInEndSection": 2334, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35443106", "text": "BACKGROUND\nThe monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models.", "offsetInBeginSection": 8, "offsetInEndSection": 158, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35914259", "text": "evin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386:2188-200. 3", "offsetInBeginSection": 1, "offsetInEndSection": 151, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "text": "For this reason, a BLI assay was developed and qualified to evaluate the reliability of screening SARS-CoV-2 spike trimer variants against anti-SARS-CoV-2 monoclonal antibodies (MAbs) tixagevimab and cilgavimab, the components of AZD7442, prior to in vitro pseudovirus neutralization susceptibility verification testing.", "offsetInBeginSection": 2176, "offsetInEndSection": 2326, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36411267", "text": "BACKGROUND\nWe report primary results of a phase 3 trial of AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis to prevent symptomatic coronavirus disease 2019 (COVID-19).", "offsetInBeginSection": 4, "offsetInEndSection": 154, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35904210", "text": "BACKGROUND\nIntramuscular AZD7442 (Tixagevimab-Cilgavimab, (Evusheld)) has been found effective among immunocompromised individuals (ICI) in reducing Sars-Cov-2 infection and severe disease in ICIs.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35871089", "text": "d change reduction\u2009~\u20092.7). Within the Evusheld /AZD7442 cocktail, Cilgavimab/AZD1061 is more active against BA.2 and BA.5 than against BA.1 (fold chan", "offsetInBeginSection": 681, "offsetInEndSection": 831, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33532768", "text": "To define the genetic and structural basis for SARS-CoV-2 neutralization, we determined the structures of two human monoclonal antibodies COV2-2196 and COV2-21301, which form the basis of the investigational antibody cocktail AZD7442, in complex with the receptor binding domain (RBD) of SARS-CoV-2.", "offsetInBeginSection": 236, "offsetInEndSection": 386, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35076282", "text": "Here, we describe AZD7442, a combination of two mAbs, AZD8895 (tixagevimab) and AZD1061 (cilgavimab), that simultaneously bind to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2.", "offsetInBeginSection": 392, "offsetInEndSection": 542, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34548634", "text": "We determined the structures of two human monoclonal antibodies-AZD8895 and AZD1061-which form the basis of the investigational antibody cocktail AZD7442, in complex with the receptor-binding domain (RBD) of SARS-CoV-2 to define the genetic and structural basis of neutralization.", "offsetInBeginSection": 158, "offsetInEndSection": 308, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "text": "AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19).", "offsetInBeginSection": 12, "offsetInEndSection": 162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35443106", "text": "rase-chain-reaction assay) occurring after administration of AZD7442 or placebo and on or before day 183.\n\n\nRESULTS\nA total of 5197 participants under", "offsetInBeginSection": 1180, "offsetInEndSection": 1330, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35797235", "text": "AZD7442 (Evusheld) is a combination of two human anti-severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs), tixagevimab (AZD8895) and cilgavimab (AZD1061).", "offsetInBeginSection": 41, "offsetInEndSection": 191, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35780162", "text": "Our data in mice demonstrate the resilience of S309 and AZD7442 mAbs against emerging SARS-CoV-2 variant strains and provide insight into the relationship between loss of antibody neutralization potency and retained protection in vivo.", "offsetInBeginSection": 1172, "offsetInEndSection": 1322, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35443106", "text": "Participants were randomly assigned in a 2:1 ratio to receive a single dose (two consecutive intramuscular injections, one containing tixagevimab and the other containing cilgavimab) of either 300 mg of AZD7442 or saline placebo, and they were followed for up to 183 days in the primary analysis.", "offsetInBeginSection": 764, "offsetInEndSection": 914, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35076282", "text": "ed to extend their half-lives and reduce effector functions. The AZD7442 mAbs individually prevent the spike protein from binding to angiotensin-conve", "offsetInBeginSection": 719, "offsetInEndSection": 869, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640ddd9d201352f04a000028", "type": "list", "body": "What were the first 2 PD-1 inhibitors approved by the FDA in 2014?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30304963", "http://www.ncbi.nlm.nih.gov/pubmed/27058852", "http://www.ncbi.nlm.nih.gov/pubmed/28546286", "http://www.ncbi.nlm.nih.gov/pubmed/30231333", "http://www.ncbi.nlm.nih.gov/pubmed/26285788", "http://www.ncbi.nlm.nih.gov/pubmed/29357948", "http://www.ncbi.nlm.nih.gov/pubmed/34196068"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29357948", "text": "Early-phase studies investigating several humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in advanced solid tumors paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.", "offsetInBeginSection": 447, "offsetInEndSection": 597, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27058852", "text": "and Drug Administration (FDA) has approved 2 PD-1 inhibitors, nivolumab and pembrolizumab, and several others are under investigation. Although PD-1 i", "offsetInBeginSection": 543, "offsetInEndSection": 693, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26285788", "text": "tration (FDA) was canagliflozin in March 2013. Two agents - dapagliflozin and empagliflozin - were FDA-approved in January and July 2014, respectively", "offsetInBeginSection": 599, "offsetInEndSection": 749, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30304963", "text": "FDA) approved the first PD-1 targeting agent, namely pembrolizumab, shortly followed by nivolumab. Areas covered: Nivolumab is a fully human immunoglo", "offsetInBeginSection": 360, "offsetInEndSection": 510, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34196068", "text": "BACKGROUND\nTo review and summarize all U.S. Food and Drug Administration (FDA) approvals of programmed death (PD)-1 and PD-ligand 1 blocking antibodies (collectively referred to as PD-[L]1 inhibitors) over a 6-year period and corresponding companion/complementary diagnostic assays.", "offsetInBeginSection": 46, "offsetInEndSection": 196, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28546286", "text": "The FDA has approved one PD-1 checkpoint inhibitor, pembrolizumab, and two PD-L1 checkpoint inhibitors, avelumab and durvalumab, to treat metastatic urothelial carcinoma in patients whose disease continues to progress despite platinum-based chemotherapy.", "offsetInBeginSection": 40, "offsetInEndSection": 190, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27058852", "text": "lignancies, FDA approval has been granted only in melanoma and in non-small cell lung cancer (NSCLC). Identifying biomarkers that can predict response", "offsetInBeginSection": 759, "offsetInEndSection": 909, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30231333", "text": "For the treatment of advanced disease, approvals were obtained for the immune checkpoint inhibitors ipilimumab (2011), nivolumab (2014), pembrolizumab (2014), the combination ipilimumab plus nivolumab (2015), and the oncolytic virus vaccine laherparepvec (2015).", "offsetInBeginSection": 652, "offsetInEndSection": 802, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c4cf690f196b51000006", "type": "factoid", "body": "What is the difference between dermatillomania and skin picking disorder?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19810989", "http://www.ncbi.nlm.nih.gov/pubmed/30024442", "http://www.ncbi.nlm.nih.gov/pubmed/27286530", "http://www.ncbi.nlm.nih.gov/pubmed/23145387", "http://www.ncbi.nlm.nih.gov/pubmed/25974792", "http://www.ncbi.nlm.nih.gov/pubmed/31777356", "http://www.ncbi.nlm.nih.gov/pubmed/25307926", "http://www.ncbi.nlm.nih.gov/pubmed/31605885", "http://www.ncbi.nlm.nih.gov/pubmed/22834980", "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "http://www.ncbi.nlm.nih.gov/pubmed/30920403", "http://www.ncbi.nlm.nih.gov/pubmed/30865412", "http://www.ncbi.nlm.nih.gov/pubmed/11891999", "http://www.ncbi.nlm.nih.gov/pubmed/29298167", "http://www.ncbi.nlm.nih.gov/pubmed/32106136", "http://www.ncbi.nlm.nih.gov/pubmed/22377838", "http://www.ncbi.nlm.nih.gov/pubmed/32781374", "http://www.ncbi.nlm.nih.gov/pubmed/32541332", "http://www.ncbi.nlm.nih.gov/pubmed/29305750", "http://www.ncbi.nlm.nih.gov/pubmed/33808008", "http://www.ncbi.nlm.nih.gov/pubmed/28761349", "http://www.ncbi.nlm.nih.gov/pubmed/24091067", "http://www.ncbi.nlm.nih.gov/pubmed/21323095"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/32106136", "text": "Disorders, Fifth Edition and characterized by repetitive skin picking behaviors resulting in skin lesions. Atomoxetine (ATX) is a selective norepineph", "offsetInBeginSection": 209, "offsetInEndSection": 359, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31777356", "text": "Photographic measurement is a consistent way of assessing skin lesions, but it does not reflect the impact of skin picking disorder on the individual's life.", "offsetInBeginSection": 1690, "offsetInEndSection": 1840, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "text": "Skin picking disorder, also termed dermatillomania is a condition that leads to repetitive\u00a0picking of their skin ending up in skin and soft tissue damage.", "offsetInBeginSection": 41, "offsetInEndSection": 191, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28761349", "text": "omania), is described as recurrent picking of skin, leading to skin lesions and significant distress or functional impairment. ED is listed as one of ", "offsetInBeginSection": 467, "offsetInEndSection": 617, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23145387", "text": "thologic skin picking (skin picking disorder [SPD]) is a prevalent and disabling condition, which has received increasing study. It is timely to consi", "offsetInBeginSection": 13, "offsetInEndSection": 163, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29298167", "text": " picking sufficient to damage cutaneous tissue, but with no underlying dermatological disease. The condition appears as an independent diagnosis in th", "offsetInBeginSection": 63, "offsetInEndSection": 213, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32541332", "text": "tal Disorders, Fifth Edition, and characterized by unintentional, repetitive skin picking behaviors. Atomoxetine is a selective noradrenaline reuptake", "offsetInBeginSection": 233, "offsetInEndSection": 383, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30920403", "text": "n an impulsive, repetitive manner despite the fact that no dermatological condition is detected. Skin picking disorder may also be comorbid in childre", "offsetInBeginSection": 104, "offsetInEndSection": 254, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21323095", "text": "d by repetitive, ritualistic, impulsive skin picking without an underlying dermatologic condition. It can lead to skin damage and distress and can aff", "offsetInBeginSection": 62, "offsetInEndSection": 212, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31777356", "text": "equently comorbid with depression and anxiety, which is underdiagnosed mainly by dermatologists. Assessment of skin picking disorder is based on instr", "offsetInBeginSection": 59, "offsetInEndSection": 209, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27286530", "text": "is a significant effect in terms of gender: As expected women showed higher skin picking scores than men. Overall the results of the present study sug", "offsetInBeginSection": 848, "offsetInEndSection": 998, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22377838", "text": "This study confirms that skin picking is an impulsive reaction and does not belong to the obsessive-compulsive disorders: impulsivity is defined by ineffective or failing control resulting in uninhibited behaviour.", "offsetInBeginSection": 722, "offsetInEndSection": 872, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24091067", "text": "N\nThe comorbidity of factitious disorder and dermatillomania makes diagnosis very difficult. The limit between the two disorders is sometimes unclear.", "offsetInBeginSection": 1740, "offsetInEndSection": 1890, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11891999", "text": "Although trichotillomania and pathological skin-picking are both characterized by repetitive self-injurious stereotypic behaviors, the former is classified as an impulse control disorder, while the latter is not given a specific diagnostic category in the Diagnostic and Statistical Manual of Mental Disorders (4th edition) [APA, 1994].", "offsetInBeginSection": 59, "offsetInEndSection": 209, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32781374", "text": "Those with current skin picking disorder were significantly more likely to be female compared to those who never had skin picking (Likelihood Ratio, LR chi-square\u00a0=\u00a031.705, p\u00a0<\u00a00.001).", "offsetInBeginSection": 537, "offsetInEndSection": 687, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29305750", "text": " a common mental disorder characterized by recurrent and excessive picking of dermatological irregularities. Different disorder models have been devel", "offsetInBeginSection": 30, "offsetInEndSection": 180, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33808008", "text": "Dermatillomania or skin picking disorder (SPD) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence that has a concerning negative impact on an individual's health and quality of life.", "offsetInBeginSection": 67, "offsetInEndSection": 217, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30865412", "text": "The prevalence of skin picking disorder proves more pervasive than previously realized and it has only recently been recognized by the DSM-5 as an independent diagnosis.", "offsetInBeginSection": 692, "offsetInEndSection": 842, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30024442", "text": "the treatment of skin-picking disorder. However, these agents can cause opposite effects in some cases. There is a report on SSRI-induced skin-picking", "offsetInBeginSection": 257, "offsetInEndSection": 407, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25307926", "text": "be a conscious response to anxiety or depression but is frequently done as an unconscious habit. In this case report, a patient undergoing orthodontic", "offsetInBeginSection": 337, "offsetInEndSection": 487, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19810989", "text": "n picking) is characterized by excessive scratching or picking of normal skin or skin with minor surface irregularities. Until recently, there have be", "offsetInBeginSection": 140, "offsetInEndSection": 290, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25974792", "text": " disorder. In certain patients, the skin lesions are shallow and have adherent crusts that can be mistaken for acne. These lesions, once healed, may a", "offsetInBeginSection": 796, "offsetInEndSection": 946, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31605885", "text": "The present study is the first to investigate the quality of premonitory urges, as well as the temporal relationship between urges and skin picking behavior in individuals with skin picking disorder.", "offsetInBeginSection": 353, "offsetInEndSection": 503, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22834980", "text": "Despite the clinical relevance of this disorder, no clear guidelines are available yet; clinical management is, therefore, compromised and the day-to-day clinical practice is burdened by difficulties.", "offsetInBeginSection": 454, "offsetInEndSection": 604, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eefa3bf36125a426000012", "type": "factoid", "body": "What causes Japanese Spotted Fever?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27197438", "http://www.ncbi.nlm.nih.gov/pubmed/23209240", "http://www.ncbi.nlm.nih.gov/pubmed/15131221", "http://www.ncbi.nlm.nih.gov/pubmed/30298801", "http://www.ncbi.nlm.nih.gov/pubmed/23743544", "http://www.ncbi.nlm.nih.gov/pubmed/31186196", "http://www.ncbi.nlm.nih.gov/pubmed/9204291", "http://www.ncbi.nlm.nih.gov/pubmed/29968555", "http://www.ncbi.nlm.nih.gov/pubmed/35545515", "http://www.ncbi.nlm.nih.gov/pubmed/1431380", "http://www.ncbi.nlm.nih.gov/pubmed/33510192", "http://www.ncbi.nlm.nih.gov/pubmed/18411764", "http://www.ncbi.nlm.nih.gov/pubmed/31645532", "http://www.ncbi.nlm.nih.gov/pubmed/29363442"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33510192", "text": "Japanese spotted fever, a tick-borne disease caused by Rickettsia japonica, was firstly described in southwestern Japan. There was a suspicion of Rick", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31645532", "text": "r (JSF) is an uncommon but potentially fatal infection transmitted by tick bites. We herein report a fulminant case of JSF infection that occurred in ", "offsetInBeginSection": 21, "offsetInEndSection": 171, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31186196", "text": "The study was conducted to determine the minimum inhibitory concentrations (MICs) of several antibacterial agents against Rickettsia japonica, which causes Japanese spotted fever.", "offsetInBeginSection": 56, "offsetInEndSection": 206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27197438", "text": "rein on a case of severe Japanese spotted fever complicated by acute respiratory failure in Kobe City. A 70-year-old female presenting with general ma", "offsetInBeginSection": 12, "offsetInEndSection": 162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23743544", "text": "anese spotted fever, who is the youngest reported patient so far. Tick-borne diseases, including Japanese spotted fever, should be included in the dif", "offsetInBeginSection": 58, "offsetInEndSection": 208, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9204291", "text": "Spotted fever group (SFG) rickettsioses, which are transmitted by ticks, were long thought not to exist in Japan. Three clinical cases of Japanese spo", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29968555", "text": "se spotted fever (JSF) is a zoonosis transmitted by ticks carrying the pathogen Rickettsia japonica. The classic triad of JSF symptoms is high fever, ", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35545515", "text": "JSF is considered an occupational disease. It is frequently caused by tick bites while working in the mountain areas of citrus cultivations. Hence, ci", "offsetInBeginSection": 1944, "offsetInEndSection": 2094, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18411764", "text": " Japanese spotted fever is generaly a curative disease with early diagnosis and minocycline. In this case, the patient died 3 days after proper diagno", "offsetInBeginSection": 980, "offsetInEndSection": 1130, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1431380", "text": "in skin inspection, so that it was clinically speculated to be caused by ticks. According to out field research, the tick fauna was very rich througho", "offsetInBeginSection": 211, "offsetInEndSection": 361, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23209240", "text": " isolated in 1984 in Japan, is the type strain of R. japonica, the tick-borne agent of Japanese spotted fever. Here, we report the 1.33-Mb genome of t", "offsetInBeginSection": 30, "offsetInEndSection": 180, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30298801", "text": "Scrub typhus and Japanese spotted fever-both rickettsial diseases-are endemic and notifiable in Japan and may cause a fatal outcome without prompt treatment.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15131221", "text": "To investigate the prevalence of spotted fever group rickettsioses in Korea, a serosurvey of Japanese spotted fever rickettsiosis in patients with acute febrile illness was conducted with an indirect immunofluorescence assay.", "offsetInBeginSection": 82, "offsetInEndSection": 232, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35545515", "text": "Objectives\u3000We investigated the infectious causes and management of Japanese spotted fever (JSF) and severe fever thrombocytopenia syndrome (SFTS), whi", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29363442", "text": "Spotted fever group rickettsioses are transmitted by several types of arthropods (including ticks, chiggers, fleas, and lice) and are distributed worldwide.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640dde93201352f04a000029", "type": "summary", "body": "What is the difference between PD-1 and PD-L1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33149767", "http://www.ncbi.nlm.nih.gov/pubmed/29545941", "http://www.ncbi.nlm.nih.gov/pubmed/33391266", "http://www.ncbi.nlm.nih.gov/pubmed/31008114", "http://www.ncbi.nlm.nih.gov/pubmed/26552662", "http://www.ncbi.nlm.nih.gov/pubmed/33380881", "http://www.ncbi.nlm.nih.gov/pubmed/34077347", "http://www.ncbi.nlm.nih.gov/pubmed/33816215", "http://www.ncbi.nlm.nih.gov/pubmed/27531770", "http://www.ncbi.nlm.nih.gov/pubmed/33333370", "http://www.ncbi.nlm.nih.gov/pubmed/30851544", "http://www.ncbi.nlm.nih.gov/pubmed/26239088", "http://www.ncbi.nlm.nih.gov/pubmed/36192730", "http://www.ncbi.nlm.nih.gov/pubmed/34271938", "http://www.ncbi.nlm.nih.gov/pubmed/35747564", "http://www.ncbi.nlm.nih.gov/pubmed/31190978", "http://www.ncbi.nlm.nih.gov/pubmed/33956235", "http://www.ncbi.nlm.nih.gov/pubmed/29053224", "http://www.ncbi.nlm.nih.gov/pubmed/34553519", "http://www.ncbi.nlm.nih.gov/pubmed/31237152", "http://www.ncbi.nlm.nih.gov/pubmed/30728907", "http://www.ncbi.nlm.nih.gov/pubmed/21645441"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26552662", "text": "(21.6-37.6%) and 13.5% (10.6-16.3%), respectively. The difference was significant (Z = 4.39, p < 0.001). The PFSR6m for PD-L1 positive and negative NS", "offsetInBeginSection": 1007, "offsetInEndSection": 1157, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33380881", "text": "ficity was lower. Further, we found that there is no statistically significant difference in efficacy between PD-1 and PD-L1 drugs.\n\n\nConclusions\nUrot", "offsetInBeginSection": 1380, "offsetInEndSection": 1530, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29545941", "text": "eutic options for several tumor types. Nonetheless, the differences in efficacy between PD-1/PD-L1 inhibitors and conventional treatments (chemotherap", "offsetInBeginSection": 136, "offsetInEndSection": 286, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27531770", "text": "that of PD-L1(-) patients, the difference between 2 groups was statistically significant (P<0.05); the expression rate of PD-L1(+) in patients with AL", "offsetInBeginSection": 1209, "offsetInEndSection": 1359, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26552662", "text": "were 66.8% (44.8%-88.9%) and 54.0% (32.6-75.3%). The difference was not significant (Z = 0.77, p = 0.441). Anti-PD-1/PD-L1 antibody can serve as a pro", "offsetInBeginSection": 1311, "offsetInEndSection": 1461, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26239088", "text": "The programmed cell death 1 (PD-1)/PD-L1 pathway inhibits host antitumor responses; however, little is known about how this pathway functions in the tumor microenvironment.", "offsetInBeginSection": 153, "offsetInEndSection": 303, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31190978", "text": "Results: We demonstrated that PD-L1 expression was significantly increased in HGIN and EGC compared with LGIN, and both PD-1 and PD-L1 showed similar expression patterns, being mainly detected in infiltrating immune cells.", "offsetInBeginSection": 1067, "offsetInEndSection": 1217, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34077347", "text": ") metastases.\n\n\nOBJECTIVE\nThis study aimed to assess the difference in efficacy of PD-1 or PD-L1 inhibitors in patients with and without CNS metastase", "offsetInBeginSection": 185, "offsetInEndSection": 335, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34271938", "text": " in cancer cases compared with benign tissues, whereas no difference in PD-1 positive expression was found. Moreover, the PD-L1 expression in tumour c", "offsetInBeginSection": 721, "offsetInEndSection": 871, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31237152", "text": "ive patients, the subgroup difference remains only in terms of progression-free survival. Conclusion: This meta-analysis confirms the superiority of I", "offsetInBeginSection": 667, "offsetInEndSection": 817, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35747564", "text": "The patients with low PD-L1 at diagnosis (median 25 mo [95% CI; 0-56.7]) had a longer overall survival compared with high PD-L1 (median 13 mo [95% CI; 5.52-25.17], p\u2009=\u20090.079).", "offsetInBeginSection": 801, "offsetInEndSection": 951, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29053224", "text": "n. The secondary objective was the assessment of the difference in specimen adequacy acquired via needles of different gauges.\n\n\nMETHODS\nPatients with", "offsetInBeginSection": 325, "offsetInEndSection": 475, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34553519", "text": "RESULTS\nThe ELISA results revealed higher circulating PD-1 and PD-L1 levels in dogs with tumors (2.9 [2.2-3.7] ng/mL; median [IQR] and 2.4 [1.4-4.4] ng/mL, respectively) than in healthy dogs (2.4 [1.9-3.0] ng/mL; p = 0.012 and 1.4 [0.9-2.1] ng/mL; p < 0.001, respectively).", "offsetInBeginSection": 508, "offsetInEndSection": 664, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33391266", "text": "all-grade neurological toxicities caused by PD-1/PD-L1 inhibitors was much lower in terms of peripheral neuropathy [OR = 0.07, 95%CI:(0.04, 0.13)], pe", "offsetInBeginSection": 851, "offsetInEndSection": 1001, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34271938", "text": "ancer cases compared with benign tissues, whereas no difference in PD-1 positive expression was found. Moreover, the PD-L1 expression in tumour cells ", "offsetInBeginSection": 726, "offsetInEndSection": 876, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30728907", "text": "ion seems predictive of response to anti-PD-1/PD-L1 agents, its prognostic value is unclear. In this study we investigated the prognostic value of PD-", "offsetInBeginSection": 323, "offsetInEndSection": 473, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33956235", "text": "reat > 15 different types of cancer. However, the response rate is not at 100% and some patients relapse. Importantly, up to 37% of patients treated w", "offsetInBeginSection": 250, "offsetInEndSection": 400, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33333370", "text": " PD-L1 staining ratio with a score greater than 0 was found to have lower survival. There were two positive staining patterns, patchy/diffuse and patc", "offsetInBeginSection": 572, "offsetInEndSection": 722, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26552662", "text": "51.0%) and 17.0% (14.3-19.7%), respectively. While the difference was significant (Z = 3.31, p < 0.001). The pooled ORR for non-squamous and squamous ", "offsetInBeginSection": 653, "offsetInEndSection": 803, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30851544", "text": "entage appeared to be more sensitive than the MFI methods. We found no correlation between PD-1 and PD-L1 expression levels and clinical features incl", "offsetInBeginSection": 1252, "offsetInEndSection": 1402, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35747564", "text": "edian 13 mo [95% CI; 5.52-25.17], p\u2009=\u20090.079). PD-L1 expression was lower at relapse (2.04\u2009\u00b1\u20090.79) compared to initial diagnosis (4.52\u2009\u00b1\u20090.93, p\u2009=\u20090.04", "offsetInBeginSection": 916, "offsetInEndSection": 1066, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33816215", "text": "In the present study, we systematically reviewed phase 2/3 trials of PD-1/PD-L1 inhibitors of advanced solid tumors that reported treatment effect (hazard ratio [HR]) in patients based on age (\u2265 75 years vs. < 75 years) and set anti-PD-1/PD-L1 monotherapy or combinational therapy as experimental arm.", "offsetInBeginSection": 488, "offsetInEndSection": 638, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21645441", "text": "t phase as compared to that in immune active phase (P < 0.05). No statistical difference found between the two groups for PD-L1 expression in Kupffer ", "offsetInBeginSection": 777, "offsetInEndSection": 927, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29545941", "text": "The progression-free survival HRs favored PD-1/PD-L1 inhibitors over conventional treatment (0.88; 95% CI, 0.82 to 0.95, P = 0.002), whereas median month difference was just the opposite (-0.69 months, 95% CI, -1.14 to -0.24, P < 0.001).", "offsetInBeginSection": 1142, "offsetInEndSection": 1292, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26239088", "text": "nts with PD-L1(-) DLBCL (P = .0009). In contrast, there was no significant difference in OS between mPD-L1(+) and mPD-L1(-) DLBCL (P = .31). The expre", "offsetInBeginSection": 1315, "offsetInEndSection": 1465, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31008114", "text": "RESULTS\nThe PD-L1 expression on corresponding immune cells has no significant difference between these two groups. We showed the downregulated PD-1 ex", "offsetInBeginSection": 492, "offsetInEndSection": 642, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29053224", "text": "dule needle aspiration in 9.1% of patients. There was no statistical difference in PD-L1 test success rates between sample methods (P\u2009=\u2009.99) or needle", "offsetInBeginSection": 1358, "offsetInEndSection": 1508, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27531770", "text": " patients after 1 and 2 course of treatment,the difference was statistically significant (P<0.05); the death rate of PD-L1(+) patients was higher than", "offsetInBeginSection": 955, "offsetInEndSection": 1105, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36192730", "text": "The difference in mean change between the PD-1/PD-L1 inhibitors group and the chemotherapy group in QLQ-C30 and EQ-5D VAS was 3.64 (95% CI = 1.62, 5.66; P = 0.001) and 4.74 (95% CI = 2.65, 6.83; P = 0.001), which supported PD-1/PD-L1 inhibitors.", "offsetInBeginSection": 1244, "offsetInEndSection": 1394, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33149767", "text": "[HR\u2009=\u20093.27 (1.27-8.41)]. HIV status and PD-L1 expression (CPS\u2009\u2a7e\u20091 or TPS\u2009\u2a7e\u200925%) were not associated with poor patient outcomes.\n\n\nCONCLUSION\nPD-L1 amp", "offsetInBeginSection": 1661, "offsetInEndSection": 1811, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410f8b2201352f04a000033", "type": "summary", "body": "What would be the benefits of using a virtual digital twin in nutrition?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33174065", "http://www.ncbi.nlm.nih.gov/pubmed/32770212", "http://www.ncbi.nlm.nih.gov/pubmed/29487613"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33174065", "text": "he process model and prediction algorithm to predict the bioprocess variables. These values could be used for optimization and control of the process.", "offsetInBeginSection": 1236, "offsetInEndSection": 1386, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33174065", "text": "Incorporation of such variables in process operation can provide improved control performance with enhanced productivity.In this chapter the linear discrete Kalman filter, the extended Kalman filter and the unscented Kalman filters are described and a brief overview of applications of the Kalman filter and its non-linear extensions to bioreactors are presented.", "offsetInBeginSection": 657, "offsetInEndSection": 807, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32770212", "text": "tion in a personalized manner. Such a model may revolutionize the management of obesity and its comorbidities, and provide a pillar for healthy aging.", "offsetInBeginSection": 818, "offsetInEndSection": 968, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29487613", "text": "This approach has the potential to deliver significant societal benefits, and can function as a social equalizer, by allowing for effective equalizing enhancement interventions.", "offsetInBeginSection": 1618, "offsetInEndSection": 1768, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64040af9201352f04a00000d", "type": "yesno", "body": "Is levosimendan effective for amyotrophic lateral sclerosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21455838", "http://www.ncbi.nlm.nih.gov/pubmed/36043141", "http://www.ncbi.nlm.nih.gov/pubmed/34901853", "http://www.ncbi.nlm.nih.gov/pubmed/23380453", "http://www.ncbi.nlm.nih.gov/pubmed/31730560", "http://www.ncbi.nlm.nih.gov/pubmed/23616585", "http://www.ncbi.nlm.nih.gov/pubmed/31315908", "http://www.ncbi.nlm.nih.gov/pubmed/22047468", "http://www.ncbi.nlm.nih.gov/pubmed/34536404", "http://www.ncbi.nlm.nih.gov/pubmed/17685869", "http://www.ncbi.nlm.nih.gov/pubmed/32985493", "http://www.ncbi.nlm.nih.gov/pubmed/12671287", "http://www.ncbi.nlm.nih.gov/pubmed/22206942", "http://www.ncbi.nlm.nih.gov/pubmed/36116464", "http://www.ncbi.nlm.nih.gov/pubmed/30963986", "http://www.ncbi.nlm.nih.gov/pubmed/21933809", "http://www.ncbi.nlm.nih.gov/pubmed/32639325", "http://www.ncbi.nlm.nih.gov/pubmed/35441136", "http://www.ncbi.nlm.nih.gov/pubmed/33241210", "http://www.ncbi.nlm.nih.gov/pubmed/16280684", "http://www.ncbi.nlm.nih.gov/pubmed/35278658", "http://www.ncbi.nlm.nih.gov/pubmed/32714567", "http://www.ncbi.nlm.nih.gov/pubmed/30530996", "http://www.ncbi.nlm.nih.gov/pubmed/8957010", "http://www.ncbi.nlm.nih.gov/pubmed/34376973", "http://www.ncbi.nlm.nih.gov/pubmed/33033799"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22047468", "text": "dly progressive, fatal neurodegenerative disorder for which there is no effective treatment. The diagnosis is dependent on the clinical presentation a", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30530996", "text": "st common neurodegenerative disease affecting motor neurons, lacks an effective treatment. A small fraction of amyotrophic lateral sclerosis cases hav", "offsetInBeginSection": 37, "offsetInEndSection": 187, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34901853", "text": "rative disease. Despite decades of clinical trials, effective disease-modifying drugs remain scarce. To understand the challenges of trial design and ", "offsetInBeginSection": 74, "offsetInEndSection": 224, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31315908", "text": "OBJECTIVE\nTo evaluate the efficacy and safety of oral levosimendan in patients with amyotrophic lateral sclerosis (ALS). This phase II, randomised, do", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17685869", "text": "ation of motor neurons in the brain and spinal cord. There are still no other effective therapies 10 years after the approval of riluzole for the trea", "offsetInBeginSection": 60, "offsetInEndSection": 210, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30963986", "text": "ithin 3 to 5 years from when the symptoms first appear. Currently, there is no cure for amyotrophic lateral sclerosis. Accumulating evidence suggests ", "offsetInBeginSection": 255, "offsetInEndSection": 405, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32639325", "text": "range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral scler", "offsetInBeginSection": 1012, "offsetInEndSection": 1162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34376973", "text": "ac settings (eg, septic shock, pulmonary hypertension) and for non-cardiac applications (eg, amyotrophic lateral sclerosis). This narrative review out", "offsetInBeginSection": 619, "offsetInEndSection": 769, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32714567", "text": "ange of cardiac and non-cardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral scler", "offsetInBeginSection": 1009, "offsetInEndSection": 1159, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35278658", "text": "cations, such as injuries to the liver and kidney. To date, there is no effective treatment for amyotrophic lateral sclerosis. In this regard, investi", "offsetInBeginSection": 285, "offsetInEndSection": 435, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22206942", "text": "There is currently very limited effective pharmacological treatment for amyotrophic lateral sclerosis. Recent evidence suggests that caffeic acid phen", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33241210", "text": "nd clinical studies have shown that modulation of energy balance can be beneficial in amyotrophic lateral sclerosis. However, the capacity to target s", "offsetInBeginSection": 293, "offsetInEndSection": 443, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34536404", "text": "\nLevosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis. Although levosimendan was generally well tolerated", "offsetInBeginSection": 2740, "offsetInEndSection": 2926, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21455838", "text": "Better understanding of the aetiology of amyotrophic lateral sclerosis is necessary to develop effective treatment of this progressive neurodegenerative disease.", "offsetInBeginSection": 1081, "offsetInEndSection": 1231, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31315908", "text": "ther adverse events.\n\n\nCONCLUSIONS\nLevosimendan did not achieve the primary endpoint of improving sitting SVC in ALS. Headache and increased heart rat", "offsetInBeginSection": 1447, "offsetInEndSection": 1597, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23616585", "text": "riluzole 100 mg/day. At the time of second testing all patients were tolerating the medication well. Motor evoked potential and compound muscle action", "offsetInBeginSection": 1081, "offsetInEndSection": 1231, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32985493", "text": "Together, our results suggest that serum creatine kinase levels can be used as an independent factor for predicting the prognosis of amyotrophic lateral sclerosis patients.", "offsetInBeginSection": 1597, "offsetInEndSection": 1747, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23380453", "text": "Clinically this complex presents with a levodopa-responsive parkinsonism and Amyotrophic Lateral Sclerosis and has been termed Brait-Fahn-Schwartz disease.", "offsetInBeginSection": 277, "offsetInEndSection": 427, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33033799", "text": "Immunity has emerged as a key player in neurodegenerative diseases such as amyotrophic lateral sclerosis, with recent studies documenting aberrant immune changes in patients and animal models.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31730560", "text": "haracterized by low cardiac output. Effects of levosimendan on noncardiac muscle suggest a possible new application in the treatment of people with am", "offsetInBeginSection": 311, "offsetInEndSection": 461, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21933809", "text": "Most patients have no family history of amyotrophic lateral sclerosis, but current understanding of such diseases suggests there should be an increased risk to relatives.", "offsetInBeginSection": 160, "offsetInEndSection": 310, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12671287", "text": "sult of these efforts, riluzole, an antiglutamatergic drug, has been established in the therapy of amyotrophic lateral sclerosis. A transgenic mouse s", "offsetInBeginSection": 372, "offsetInEndSection": 522, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16280684", "text": "fatal motoneuron disorder. Despite intensive research riluzole remains the only available therapy, with only marginal effects on survival. Here we rev", "offsetInBeginSection": 62, "offsetInEndSection": 212, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35441136", "text": " individuals in the United Kingdom. The cause of amyotrophic lateral sclerosis is unknown in the majority of cases. Two-sample Mendelian randomization", "offsetInBeginSection": 99, "offsetInEndSection": 249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36116464", "text": "research, current management of amyotrophic lateral sclerosis remains suboptimal from diagnosis to prognosis. Recognition of the phenotypic heterogene", "offsetInBeginSection": 90, "offsetInEndSection": 240, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35441136", "text": "myotrophic lateral sclerosis, we present evidence that estradiol is neuroprotective. Isoleucine is metabolized via methylmalonyl-CoA mutase encoded by", "offsetInBeginSection": 1872, "offsetInEndSection": 2022, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34536404", "text": "ractile function of the human diaphragm. We aimed to evaluate the safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosi", "offsetInBeginSection": 230, "offsetInEndSection": 380, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36043141", "text": "o the cervical subarachnoid space in adult wild-type mice induces permanent motor disability which is associated with hallmark pathological features o", "offsetInBeginSection": 909, "offsetInEndSection": 1059, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8957010", "text": "ragments of amyotrophic lateral sclerosis IgG. The blocking was prevented by serine protease inhibitors. Moreover, it was reproduced by plasminogen an", "offsetInBeginSection": 729, "offsetInEndSection": 879, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23616585", "text": "le, a benzothiazole derivative, has been shown to be effective in prolonging survival in amyotrophic lateral sclerosis. The mechanisms by which riluzo", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c0f7690f196b51000001", "type": "list", "body": "What are the clinical symptoms of an ornithine transcarbamylase deficiency?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10456765", "http://www.ncbi.nlm.nih.gov/pubmed/27447480", "http://www.ncbi.nlm.nih.gov/pubmed/30671162", "http://www.ncbi.nlm.nih.gov/pubmed/8778603", "http://www.ncbi.nlm.nih.gov/pubmed/8040774", "http://www.ncbi.nlm.nih.gov/pubmed/3826955", "http://www.ncbi.nlm.nih.gov/pubmed/20004862", "http://www.ncbi.nlm.nih.gov/pubmed/21642786", "http://www.ncbi.nlm.nih.gov/pubmed/22138526", "http://www.ncbi.nlm.nih.gov/pubmed/24850570", "http://www.ncbi.nlm.nih.gov/pubmed/25011434", "http://www.ncbi.nlm.nih.gov/pubmed/9266388", "http://www.ncbi.nlm.nih.gov/pubmed/17209350", "http://www.ncbi.nlm.nih.gov/pubmed/10799432", "http://www.ncbi.nlm.nih.gov/pubmed/2208768", "http://www.ncbi.nlm.nih.gov/pubmed/7155674", "http://www.ncbi.nlm.nih.gov/pubmed/10910641", "http://www.ncbi.nlm.nih.gov/pubmed/11216899", "http://www.ncbi.nlm.nih.gov/pubmed/7499756", "http://www.ncbi.nlm.nih.gov/pubmed/21070677", "http://www.ncbi.nlm.nih.gov/pubmed/25687292", "http://www.ncbi.nlm.nih.gov/pubmed/12788037", "http://www.ncbi.nlm.nih.gov/pubmed/1456259", "http://www.ncbi.nlm.nih.gov/pubmed/9065786"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25011434", "text": "manifestations of ornithine transcarbamylase deficiency included vomiting and seizure, which were the most frequent signs at admission. Two of the fou", "offsetInBeginSection": 859, "offsetInEndSection": 1009, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8040774", "text": "Recurrent episodes of bizarre behavior were the only clinical symptoms that finally led to the diagnosis of ornithine transcarbamylase deficiency in an 8-year-old boy.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8778603", "text": "hate and ornithine. A deficiency of this enzyme leads to hyperammonemia and hyperglutaminemia. In boys the disease is often fatal when its onset occur", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17209350", "text": "d urea cycle disorder. Its clinical manifestations as lethargy, vomites, coma and cerebral edema are the effect of the higher concentration of the amm", "offsetInBeginSection": 65, "offsetInEndSection": 215, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10799432", "text": "The subtle onset and course of ornithine transcarbamylase deficiency emphasises the need for plasma ammonia and amino acid measurements in clinical situations suggesting a disorder of this nature.", "offsetInBeginSection": 181, "offsetInEndSection": 331, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10910641", "text": " dominant trait. Clinical manifestations are more severe in hemizygous males than in heterozygous females. To date about 160 different mutations and 1", "offsetInBeginSection": 128, "offsetInEndSection": 278, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22138526", "text": "ency gene. In pregnancy it has been associated with altered mental status, seizures, coma and death, especially in the postpartum period. We report th", "offsetInBeginSection": 157, "offsetInEndSection": 307, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10456765", "text": "A 3-day-old infant presented with anorexia, irritability, hypotonia, and seizures. Blood ammonia was 2115 micromol/L and amino and organic acid analys", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25687292", "text": "s are mostly due to hyperammonemia and include nausea, vomiting, lethargia and even convulsions and coma. Common neurological symptoms at presentation", "offsetInBeginSection": 264, "offsetInEndSection": 414, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7155674", "text": "ee for 9 months and then developed an acute episode with liver failure and metabolic imbalance. Subsequently there was severe cerebral atrophy. Liver ", "offsetInBeginSection": 80, "offsetInEndSection": 230, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30671162", "text": "ts in the neonatal period. Late-onset presentation of OTC can cause mild to severe symptoms. We describe laboratory and clinical findings of late-onse", "offsetInBeginSection": 97, "offsetInEndSection": 247, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27447480", "text": "ficiency in the urea cycle. This disorder results in increased ammonia and glutamine in the blood. Accumulation of these metabolites without treatment", "offsetInBeginSection": 73, "offsetInEndSection": 223, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30671162", "text": "and severity in late-onset presentation of OTC ranging from seizures to cerebral herniation. Our literature review is the first to detail published la", "offsetInBeginSection": 1133, "offsetInEndSection": 1283, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9065786", "text": "ficiency, an X-linked disorder, is the most common cause of inherited urea cycle disorders. Approx. 90 mutations that produce reduced levels of ornith", "offsetInBeginSection": 29, "offsetInEndSection": 179, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20004862", "text": "Elevated arginine could augment nitric oxide synthesis, leading to oxidative damage. The hypothesis for the present study was that specific brain vuln", "offsetInBeginSection": 670, "offsetInEndSection": 820, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21642786", "text": "ficiency is an inborn error of metabolism that commonly presents as hyperammonemia in neonates. We present a case of a 2-year-old girl who was referre", "offsetInBeginSection": 29, "offsetInEndSection": 179, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21070677", "text": " X-linked manner and classically presents in neonates with encephalopathy and hyperammonemia in males. Females and males with hypomorphic mutations pr", "offsetInBeginSection": 121, "offsetInEndSection": 271, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3826955", "text": "ornithine transcarbamylase, an enzyme in the urea cycle, results in hyperammonemia. The X-linked recessive inheritance results in neonatal death of af", "offsetInBeginSection": 14, "offsetInEndSection": 164, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7499756", "text": "Symptoms included recurrent vomiting with lethargy (five patients), dietary protein intolerance (five), irritability (four), severe acute encephalopathy (three), ataxia (three), and acute hemiparesis (two).", "offsetInBeginSection": 495, "offsetInEndSection": 683, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12788037", "text": "Liver transplant can be considered when symptoms are life-threatening, although there may be severe complications.Gene replacement therapy is the hope of the future.", "offsetInBeginSection": 1570, "offsetInEndSection": 1720, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2208768", "text": "Somatic mosaicism for a deletion in the ornithine transcarbamylase gene is described in a boy with sporadic late onset ornithine transcarbamylase deficiency.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9065786", "text": "ower activity at physiological concentrations of ornithine, as well as its reduced stability, may contribute to the clinical effects that it produces.", "offsetInBeginSection": 2122, "offsetInEndSection": 2272, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8778603", "text": "CONCLUSIONS\nGirls with symptomatic ornithine transcarbamylase deficiency who are treated with drugs that activate new pathways of waste-nitrogen excretion have fewer hyperammonemic episodes and a reduced risk of further cognitive decline.", "offsetInBeginSection": 1652, "offsetInEndSection": 1802, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11216899", "text": "linked disorder that causes hyperammonemia leading to brain damage, mental retardation and death. The clinical and biochemical phenotype is extremely ", "offsetInBeginSection": 173, "offsetInEndSection": 323, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24850570", "text": "Our findings suggest a role for oxidative stress and aberrant glutamine metabolism in the acute clinical features of ornithine transcarbamylase deficiency even in the absence of hyperammonemia.", "offsetInBeginSection": 656, "offsetInEndSection": 806, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9266388", "text": "However, identification of causative mutations has important implications for diagnosis (particularly prenatal diagnosis), prediction of likely course and outcome and the eventual possibility of gene therapy.", "offsetInBeginSection": 195, "offsetInEndSection": 345, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21070677", "text": "Ornithine transcarbamylase deficiency should be considered in the differential diagnosis of unexplained acute confusion, even without a suggestive family history.", "offsetInBeginSection": 2072, "offsetInEndSection": 2222, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1456259", "text": " a clinical diagnosis of Reye's syndrome have, in general, an inborn error of metabolism. Medium-chain acyl Coenzyme A dehydrogenase deficiency and ot", "offsetInBeginSection": 757, "offsetInEndSection": 907, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12788037", "text": "The symptoms and signs of ornithine transcarbamylase deficiency are discussed. When the condition occurs among males in the neonatal period it is like", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20004862", "text": "The clinical presentation of arginase deficiency is considerably different, characterized by progressive spasticity involving the lower extremities and usually dementia.", "offsetInBeginSection": 261, "offsetInEndSection": 411, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63fa197c201352f04a000003", "type": "summary", "body": "How does SRSF11 contribute to metastasis potential of colorectal cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36394206", "http://www.ncbi.nlm.nih.gov/pubmed/16148991"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36394206", "text": "protein family, the involvement of SRSF11 in colorectal cancer (CRC) is unknown.\n\n\nMETHODS\nThe TCGA dataset and clinical samples were used to assess S", "offsetInBeginSection": 195, "offsetInEndSection": 345, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36394206", "text": "pressed and associated with a poor prognosis. And SRSF11 played a pro-metastatic role in vitro and in vivo. By screening SRSF11-regulated AS events, w", "offsetInBeginSection": 1029, "offsetInEndSection": 1179, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36394206", "text": "NCLUSIONS\nSRSF11 exerts pro-metastatic effects in CRC by inhibiting the AS of HSPA12A pre-RNA. Our findings point to SRSF11-regulated HSPA12A splicing", "offsetInBeginSection": 1595, "offsetInEndSection": 1745, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16148991", "text": " contribute to metastasis and proliferation of tumor by stimulating the growth of tumor vessel. Both of VEGF and angiopoietin- 2 contribute to angioge", "offsetInBeginSection": 1334, "offsetInEndSection": 1484, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eef60ef36125a42600000c", "type": "factoid", "body": "Olokizumab is tested for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25648633", "http://www.ncbi.nlm.nih.gov/pubmed/23083819", "http://www.ncbi.nlm.nih.gov/pubmed/24670876", "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "http://www.ncbi.nlm.nih.gov/pubmed/36368906", "http://www.ncbi.nlm.nih.gov/pubmed/24641941", "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "http://www.ncbi.nlm.nih.gov/pubmed/35455757", "http://www.ncbi.nlm.nih.gov/pubmed/25999170", "http://www.ncbi.nlm.nih.gov/pubmed/26982101", "http://www.ncbi.nlm.nih.gov/pubmed/34101570", "http://www.ncbi.nlm.nih.gov/pubmed/28703549", "http://www.ncbi.nlm.nih.gov/pubmed/11002950", "http://www.ncbi.nlm.nih.gov/pubmed/9208960", "http://www.ncbi.nlm.nih.gov/pubmed/27129012", "http://www.ncbi.nlm.nih.gov/pubmed/33142700", "http://www.ncbi.nlm.nih.gov/pubmed/35957736"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34101570", "text": "OBJECTIVE\nThis study aimed to evaluate the long-term safety and efficacy of olokizumab (OKZ), an anti-interleukin (IL)-6 monoclonal antibody, in patients with rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor-alpha inhibitors.", "offsetInBeginSection": 94, "offsetInEndSection": 244, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24641941", "text": "OBJECTIVES\nThe aim of this 12-week Phase IIb study was to assess the efficacy and safety of olokizumab (OKZ), a humanised anti-IL6 monoclonal antibody, in patients with rheumatoid arthritis (RA) with moderate-to-severe disease activity who had previously failed tumour necrosis factor (TNF) inhibitor therapy.", "offsetInBeginSection": 104, "offsetInEndSection": 254, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "text": "leukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.\n\n\nMETHODS\nIn a 24-week, phase 3, multicenter, placebo- and acti", "offsetInBeginSection": 158, "offsetInEndSection": 308, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34101570", "text": "CONCLUSION\nIn the 2 long-term studies, OKZ treatment demonstrated a safety profile expected for IL-6 blocking agents without new safety signals and led to sustained improvements in RA symptoms, physical function, and quality of life.", "offsetInBeginSection": 1916, "offsetInEndSection": 2066, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24670876", "text": "ical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olok", "offsetInBeginSection": 30, "offsetInEndSection": 180, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "text": "those receiving it every 4 weeks.\n\n\nCONCLUSIONS\nIn patients with rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was supe", "offsetInBeginSection": 2359, "offsetInEndSection": 2509, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "text": "AIM\nTo evaluate the efficacy and safety of Artlegia (olokizumab) for the treatment of subjects with a disease caused by the SARS-COV-2 virus in a real-world clinical setting.", "offsetInBeginSection": 442, "offsetInEndSection": 592, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "text": "CONCLUSION\nThe use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and laboratory parameters.", "offsetInBeginSection": 1489, "offsetInEndSection": 1639, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "text": "CONCLUSION\nThe use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and laboratory parameters.", "offsetInBeginSection": 1481, "offsetInEndSection": 1631, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "text": "other domains) at week 12, with each olokizumab dose tested for superiority to placebo. We also tested the noninferiority of each olokizumab dose to a", "offsetInBeginSection": 772, "offsetInEndSection": 922, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35455757", "text": "Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease and its treatment is an urgent problem of rheumatology. Olokizumab (OKZ) is a new", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35957736", "text": "first discovered to become the potential drugs for the treatment of SCI-induced OP. Drug discovery using text mining and pathway analysis is a signifi", "offsetInBeginSection": 1265, "offsetInEndSection": 1415, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9208960", "text": "costs of laparoscopic (LS) and open splenectomy (OS) for a variety of hematologic diseases.\n\n\nSTUDY DESIGN\nThe records of 137 patients who underwent s", "offsetInBeginSection": 69, "offsetInEndSection": 219, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25648633", "text": "In this article, we review the mechanism of anti-IL-6 in the treatment of RA, provide the key efficacy and safety data from clinical trials of approved anti-IL-6, TCZ, as well as six candidate IL-6 blockers including sarilumab, ALX-0061, sirukumab, MEDI5117, clazakizumab, and olokizumab, and their future perspectives in the treatment of RA.", "offsetInBeginSection": 1076, "offsetInEndSection": 1226, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28703549", "text": "be extended to other systemic inflammatory diseases, such as the giant cell arteritis. New molecules targetting the IL-6 pathway are under validation ", "offsetInBeginSection": 240, "offsetInEndSection": 390, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33142700", "text": "Rheumatoid arthritis (RA) is the most common autoimmune disease worldwide. Epigenetic alternations of microRNAs (miRNAs) can contribute to its pathoge", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35455757", "text": "Thus, the comprehensive assessment of polymorphic variants of HLA and non-HLA genes considering population characteristics in combination with clinical parameters allows for the elaboration of an RA prognostic panel.", "offsetInBeginSection": 1164, "offsetInEndSection": 1314, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36368906", "text": "CONCLUSION\nThe results of this SLR, together with one SLR on safety of DMARD and one on glucocorticoids, informed the taskforce of the 2022 update of the EULAR recommendations for pharmacological management of RA.", "offsetInBeginSection": 1799, "offsetInEndSection": 1949, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25999170", "text": "Using data from the Prevention of Pelvic Infection (POPI) chlamydia screening trial, we compared the characteristics of female students who did or did not get tested for chlamydia outside the trial during 12 months' follow-up.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26982101", "text": "Therefore, these newly designed macromolecules were proposed as potential lead antibodies to serve as a therapeutics option for IL-6-mediated diseases.", "offsetInBeginSection": 1127, "offsetInEndSection": 1277, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11002950", "text": "OBJECTIVE\nTo assess the prevalence of genitourinary Chlamydia trachomatis infection among women in different clinical settings, with a view to making decisions about who should be tested routinely.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27129012", "text": "Interleukin-6 (IL-6) is implicated in the pathophysiology of several inflammatory conditions. Olokizumab, a humanized anti-IL-6 monoclonal antibody, s", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36368906", "text": "tions for Rheumatology (EULAR) recommendations for management of rheumatoid arthritis (RA).\n\n\nMETHODS\nThis systematic literature review (SLR) investig", "offsetInBeginSection": 175, "offsetInEndSection": 325, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25999170", "text": "endent chlamydia test, including 30 (48%) of 63 women with undiagnosed chlamydia at baseline. Predictors of testing included having undiagnosed chlamy", "offsetInBeginSection": 580, "offsetInEndSection": 730, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23083819", "text": "It is important to assess the stage of liver fibrosis in chronic hepatitis C to guide treatment decisions. Liver biopsy has limitations in staging fib", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6413730e201352f04a00003f", "type": "summary", "body": "Please summarize the function of Trophinin-associated protein (TROAP)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36419876", "http://www.ncbi.nlm.nih.gov/pubmed/11804944", "http://www.ncbi.nlm.nih.gov/pubmed/33692939", "http://www.ncbi.nlm.nih.gov/pubmed/17360433", "http://www.ncbi.nlm.nih.gov/pubmed/29956806", "http://www.ncbi.nlm.nih.gov/pubmed/17495530", "http://www.ncbi.nlm.nih.gov/pubmed/35708862", "http://www.ncbi.nlm.nih.gov/pubmed/7758945", "http://www.ncbi.nlm.nih.gov/pubmed/14633596", "http://www.ncbi.nlm.nih.gov/pubmed/35251990", "http://www.ncbi.nlm.nih.gov/pubmed/18554632", "http://www.ncbi.nlm.nih.gov/pubmed/30284652", "http://www.ncbi.nlm.nih.gov/pubmed/30431120", "http://www.ncbi.nlm.nih.gov/pubmed/34077623", "http://www.ncbi.nlm.nih.gov/pubmed/29117881", "http://www.ncbi.nlm.nih.gov/pubmed/30021381", "http://www.ncbi.nlm.nih.gov/pubmed/33500384", "http://www.ncbi.nlm.nih.gov/pubmed/22201876", "http://www.ncbi.nlm.nih.gov/pubmed/15205339", "http://www.ncbi.nlm.nih.gov/pubmed/31285897", "http://www.ncbi.nlm.nih.gov/pubmed/17487845", "http://www.ncbi.nlm.nih.gov/pubmed/31198787", "http://www.ncbi.nlm.nih.gov/pubmed/30854102"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18554632", "text": "TS\nThe presence of trophinin and the trophinin associated proteins bystin and tastin in human sperm was confirmed by immunohistochemistry. Human sperm", "offsetInBeginSection": 1175, "offsetInEndSection": 1325, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35708862", "text": "BACKGROUND\nTrophinin-associated protein (TROAP) mediates embryonic transfer, regulates microtubules, and is associated with the biological behavior of various cancers.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33692939", "text": "sociated protein (TROAP) has been shown to be overexpressed and promotes tumor progression in some tumors. We performed this study to assess the biolo", "offsetInBeginSection": 12, "offsetInEndSection": 162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33500384", "text": "Here, we demonstrated that ectopic expression of trophinin-associated protein (TROAP) dramatically drove HCC cell growth assessed by foci formation in monolayer culture, colony formation in soft agar and orthotopic liver transplantation in nude mice.", "offsetInBeginSection": 132, "offsetInEndSection": 282, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29117881", "text": ". Taken together, these results indicate that TROAP suppresses cellular growth and migration in HCC. This discovery will further our understanding of ", "offsetInBeginSection": 1099, "offsetInEndSection": 1249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31285897", "text": "Trophinin-associated protein (TROAP) is a cytoplasmic protein first identified to mediate the process of embryo transplantation, which has been recently found to be involved in microtubule regulation.", "offsetInBeginSection": 177, "offsetInEndSection": 327, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17487845", "text": "sed in 65.6% of trophinin-positive patients (n = 32). These results suggest that trophinin promotes invasion through a mechanism involving HMGB1/RAGE.", "offsetInBeginSection": 1246, "offsetInEndSection": 1396, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30854102", "text": " that plays a significant role in the processes of embryo transplantation and microtubule regulation. However, the relevant survival analysis and canc", "offsetInBeginSection": 70, "offsetInEndSection": 220, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30431120", "text": "Trophinin associated protein (TROAP) is essential for centrosome integrity and proper bipolar organisation of spindle assembly during mitosis and plays an essential role in proliferation.", "offsetInBeginSection": 180, "offsetInEndSection": 330, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18554632", "text": "essed in human sperm, to our knowledge the function of this protein is not known. In this study we tested the effect of GWRQ on human sperm to evaluat", "offsetInBeginSection": 179, "offsetInEndSection": 329, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35251990", "text": " cancer cells for in vitro studies. Trophinin associated protein (TROAP) siRNA and treatment with or without actinomycin D was used in the cells for q", "offsetInBeginSection": 503, "offsetInEndSection": 653, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30021381", "text": "erified that trophinin associated protein (TROAP) was a direct target of miR-519d-3p in CRC cells. Using Oncomine database analysis, TROAP was confirm", "offsetInBeginSection": 1183, "offsetInEndSection": 1333, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30284652", "text": "BACKGROUND\nTrophinin-associated protein (TROAP) is a cytoplasmic protein that functions as an adhesion molecule in processes such as embryo implantation, spindle formation, and cancer.", "offsetInBeginSection": 26, "offsetInEndSection": 176, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18554632", "text": "acytoplasmic sperm injection in cases of severely low sperm motility. Trophinin may have a role in regulating adenosine triphosphatase in human sperm.", "offsetInBeginSection": 1676, "offsetInEndSection": 1826, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30854102", "text": " results. Altogether, our results show that TROAP is a novel crucial regulator of HCC progression and is a potential therapeutic biomarker for HCC pat", "offsetInBeginSection": 1444, "offsetInEndSection": 1594, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15205339", "text": "Trophinin is a membrane protein that is potentially involved in human embryo implantation by mediating homophillic cell adhesion between trophoblastic cells and endometrial cells.", "offsetInBeginSection": 60, "offsetInEndSection": 210, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34077623", "text": "AIMS\nExperimental evidence demonstrated a crucial role of TROAP (Trophinin-associated protein) in regulating the cell proliferation of multiple tumors, while TROAP expression and function were largely unknown in glioma.", "offsetInBeginSection": 49, "offsetInEndSection": 199, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31198787", "text": "n abilities of BC cells. The present study suggests that TROAP plays an important role in promoting the proliferation, invasion, and metastasis of BC.", "offsetInBeginSection": 1094, "offsetInEndSection": 1244, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36419876", "text": "Mounting evidence demonstrates the vital role of TROAP in regulating the proliferation and migration of cells, but it is unclear how it contributes to cancer progression.", "offsetInBeginSection": 132, "offsetInEndSection": 282, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17360433", "text": "These results suggest that trophinin-mediated cell adhesion functions as a molecular switch for trophectoderm activation in human embryo implantation.", "offsetInBeginSection": 1454, "offsetInEndSection": 1604, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7758945", "text": "One, named trophinin, is an intrinsic membrane protein and mediates homophilic self-binding. Another, named tastin, is a cytoplasmic protein and is ne", "offsetInBeginSection": 337, "offsetInEndSection": 487, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14633596", "text": "Both trophoblasts and endometrial epithelial cells express trophinin, which mediates apical cell adhesion through homophilic trophinin-trophinin binding.", "offsetInBeginSection": 154, "offsetInEndSection": 304, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15205339", "text": "etastases (n = 5). These results suggest strongly that trophinin enhances invasiveness of the cells and promotes metastasis of testicular germ cell tu", "offsetInBeginSection": 1754, "offsetInEndSection": 1904, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29956806", "text": "Trophinin associated protein (TROAP) is a cytoplasmic protein required for spindle assembly and cell invasion; however, its biological function in cancer remains to be elucidated.", "offsetInBeginSection": 17, "offsetInEndSection": 167, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17487845", "text": " cells. Its activity and in vivo expression pattern implicate trophinin in the initial attachment of trophectoderm cells to maternal epithelia. Subseq", "offsetInBeginSection": 72, "offsetInEndSection": 222, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11804944", "text": "Trophinin has been identified as a membrane protein mediating apical cell adhesion between two human cell lines: trophoblastic HT-H cells, and endometrial epithelial SNG-M cells.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22201876", "text": "tics of trophinin protein and of the trophinin-associated proteins bystin and tastin. We then describe trophinin-mediated signal transduction in troph", "offsetInBeginSection": 294, "offsetInEndSection": 444, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31285897", "text": "e interval (CI): 1.072-2.968, P=0.026].\n\n\nCONCLUSIONS\nOur results suggested that TROAP is an independent prognostic biomarker of poor survival in LAC.", "offsetInBeginSection": 1459, "offsetInEndSection": 1609, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15205339", "text": " (95%) in stage III (P < 0.001). Thus, trophinin expression positively correlates with clinical stage. Remarkably, trophinin was found in all of the c", "offsetInBeginSection": 847, "offsetInEndSection": 997, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17495530", "text": "sine phosphorylation. Therefore trophinin functions as an adhesion molecule on the cell surface and as a molecular switch for trophoblast activation i", "offsetInBeginSection": 766, "offsetInEndSection": 916, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410ed73201352f04a00002f", "type": "summary", "body": "How does SRSF11 promote metastasis of colon cancer?", "documents": [], "snippets": []}, {"id": "63f03fc8f36125a426000021", "type": "factoid", "body": "What disease can be treated with Lenacapavir?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36411257", "http://www.ncbi.nlm.nih.gov/pubmed/36272024", "http://www.ncbi.nlm.nih.gov/pubmed/34871187", "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "http://www.ncbi.nlm.nih.gov/pubmed/35028668"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187", "text": "SUMMARY\nOngoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent.", "offsetInBeginSection": 858, "offsetInEndSection": 1008, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35028668", "text": " conducted in a Phase 1b study of lenacapavir (Study 4072) in people with HIV (PWH).\n\n\nMETHODS\nMutations were inserted in a proviral DNA clone by site", "offsetInBeginSection": 308, "offsetInEndSection": 458, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35028668", "text": "bo-controlled, dose-ranging, randomized study of lenacapavir in untreated PWH. Participants received a single dose of lenacapavir (up to 750 mg) or pl", "offsetInBeginSection": 794, "offsetInEndSection": 944, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "text": "CONCLUSIONS\nIn patients with multidrug-resistant HIV-1 infection, those who received lenacapavir had a greater reduction from baseline in viral load than those who received placebo.", "offsetInBeginSection": 2216, "offsetInEndSection": 2366, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36411257", "text": " its predicted effectiveness for treatment and prevention, regardless of HIV-1 clades. The established conserved regions hence serve as a hallmark for", "offsetInBeginSection": 1256, "offsetInEndSection": 1406, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36272024", "text": "regimen. This article summarizes the milestones in the development of lenacapavir leading to this first approval for the treatment of HIV-1 infection.", "offsetInBeginSection": 546, "offsetInEndSection": 696, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187", "text": "ing antiretroviral classes and potent antiviral activity in persons with HIV-1. In persons with HIV-1, there was no preexisting resistance to lenacapa", "offsetInBeginSection": 311, "offsetInEndSection": 461, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "text": "BACKGROUND\nPatients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection have limited treatment options. Lenacapavir is a fi", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "text": "In both cohorts, lenacapavir-related capsid substitutions that were associated with decreased susceptibility developed in 8 patients during the maintenance period (6 with M66I substitutions).", "offsetInBeginSection": 2006, "offsetInEndSection": 2156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36411257", "text": "OBJECTIVES\nWe evaluated the HIV-1 capsid genetic variability and lenacapavir drug resistance-associated mutations (DRMs) among drug-naive individuals across HIV-1 clades.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641365f6201352f04a00003a", "type": "yesno", "body": "Is Iron deficiency anemia a common complication of chronic kidney disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17804903", "http://www.ncbi.nlm.nih.gov/pubmed/16198278", "http://www.ncbi.nlm.nih.gov/pubmed/35813388", "http://www.ncbi.nlm.nih.gov/pubmed/32077335", "http://www.ncbi.nlm.nih.gov/pubmed/28682026", "http://www.ncbi.nlm.nih.gov/pubmed/34514189", "http://www.ncbi.nlm.nih.gov/pubmed/22303745", "http://www.ncbi.nlm.nih.gov/pubmed/29696955", "http://www.ncbi.nlm.nih.gov/pubmed/35644772", "http://www.ncbi.nlm.nih.gov/pubmed/35058395", "http://www.ncbi.nlm.nih.gov/pubmed/29336855", "http://www.ncbi.nlm.nih.gov/pubmed/17533016", "http://www.ncbi.nlm.nih.gov/pubmed/22365163", "http://www.ncbi.nlm.nih.gov/pubmed/34860142", "http://www.ncbi.nlm.nih.gov/pubmed/29481308", "http://www.ncbi.nlm.nih.gov/pubmed/19833421", "http://www.ncbi.nlm.nih.gov/pubmed/27236129", "http://www.ncbi.nlm.nih.gov/pubmed/26342303", "http://www.ncbi.nlm.nih.gov/pubmed/19325171", "http://www.ncbi.nlm.nih.gov/pubmed/32556307", "http://www.ncbi.nlm.nih.gov/pubmed/16470356", "http://www.ncbi.nlm.nih.gov/pubmed/25756713", "http://www.ncbi.nlm.nih.gov/pubmed/30970355", "http://www.ncbi.nlm.nih.gov/pubmed/33615076"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25756713", "text": "The diagnosis of iron deficiency in chronic kidney disease can be problematic because inflammation is common, leading to false high circulating ferritin and false low transferrin saturation.", "offsetInBeginSection": 825, "offsetInEndSection": 975, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17804903", "text": "Iron deficiency anemia is common in people with chronic kidney disease (CKD) and its importance in supporting erythropoiesis is unquestioned especially in those patients treated with erythropoietin.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35644772", "text": "CONCLUSION\nThe prevalence of anemia was higher in Algerian chronic kidney disease (non-dialysis and hemodialysis) unlike malnutrition which remains associated with functional iron deficiency anemia.", "offsetInBeginSection": 1765, "offsetInEndSection": 1915, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34514189", "text": "Iron deficiency is common in individuals with chronic kidney disease and plays a major role in the development of anemia. Oral and intravenous iron ag", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17533016", "text": "he nondialysis chronic kidney disease population. Limited data suggest that iron deficiency is common in patients with chronic kidney disease with ane", "offsetInBeginSection": 160, "offsetInEndSection": 310, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30970355", "text": "Iron deficiency anemia is a common complication of chronic kidney disease (CKD). CKD patients suffer from both absolute and functional iron deficiency", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33615076", "text": "mia among patients with CKD is a common complication. Iron deficiency is one of the major causes. Iron deficiency is also one of the key causes of poo", "offsetInBeginSection": 334, "offsetInEndSection": 484, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22303745", "text": " diabetic nephropathy is a leading cause of CKD. One of the most common complications of CKD is anemia, the frequency and severity of which increase a", "offsetInBeginSection": 58, "offsetInEndSection": 208, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16470356", "text": "Anemia is as a frequent complication in patients with chronic kidney disease, which gains in importance in the treatment of patients with renal disease.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29696955", "text": "Anemia is the most common disorder\nof the blood with iron deficiency\nbeing the predominant cause. On the\nother hand, diabetes prevalence is\nincreasing", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34860142", "text": "BACKGROUND\nAnemia is an adverse outcome and common complication in chronic kidney disease patients. This is usually associated with iron deficiency, i", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29481308", "text": "Severe anemia and iron deficiency are common complications in chronic kidney disease. The cause of renal anemia is multifactorial and includes decreas", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26342303", "text": "Anemia is a common complication in patients with chronic kidney disease (CKD), mainly due to inadequate renal production of erythropoietin. In hemodia", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16198278", "text": "rnative because it requires less frequent injections. Iron deficiency is a major cause of anemia that is resistant to erythropoietin or darbepoetin al", "offsetInBeginSection": 520, "offsetInEndSection": 670, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19325171", "text": "o anemia. The other cause of anemia is deficiency of iron. Iron deficiency anemia is common in people with CKD and its importance in supporting erythr", "offsetInBeginSection": 316, "offsetInEndSection": 466, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19833421", "text": "sease (CKD) is a widespread health problem in the world and anemia is a common complication. Anemia conveys significant risk for cardiovascular diseas", "offsetInBeginSection": 17, "offsetInEndSection": 167, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27236129", "text": "Anemia is a common and clinically important consequence of chronic kidney disease (CKD). It is most commonly a result of decreased erythropoietin prod", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35813388", "text": "estigate whether \u03b1-Klotho deficiency present in CKD also contributes to the development of renal anemia. To address this, we administered \u03b1-Klotho to ", "offsetInBeginSection": 531, "offsetInEndSection": 681, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35644772", "text": "Absolute iron deficiency anemia was higher in non dialysis (48.33%; n=29) while functional iron deficiency anemia was higher in hemodialysis (34.52%; n=29).", "offsetInBeginSection": 1434, "offsetInEndSection": 1584, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22365163", "text": "rm cardio-renal anemia syndrome has been suggested. Iron deficiency is part of the pathophysiology of anemia in both CHF and chronic kidney disease, w", "offsetInBeginSection": 369, "offsetInEndSection": 519, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28682026", "text": "Anemia is a frequent complication in chronic kidney disease (CKD), and it is often accompanied by various clinical symptoms. The primary cause of anem", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35058395", "text": "The diagnosis of iron deficiency anemia in patients with CKD is complicated due to the relatively low predictive ability of routine serum iron markers (e.g., ferritin and transferrin saturation) and more invasive measurements such as bone marrow iron stores.", "offsetInBeginSection": 748, "offsetInEndSection": 898, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29336855", "text": "Anemia is a frequent complication during the later stages of chronic kidney disease. When present, it may cause symptoms such as fatigue and shortness", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35058395", "text": " development and treat complications including anemia. Anemia is one of the common complication of chronic kidney disease (CKD), which is a significan", "offsetInBeginSection": 223, "offsetInEndSection": 373, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35813388", "text": "Our findings demonstrate that \u03b1-Klotho does not have a direct role in renal anemia and that FGF23 suppresses erythropoiesis in CKD via a Klotho-independent mechanism.", "offsetInBeginSection": 1540, "offsetInEndSection": 1690, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32077335", "text": "Introduction: Anemia is a common extraintestinal complication of Crohn's disease (CD) mainly caused by iron deficiency, that affects the quality of life in CD patients.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32556307", "text": "increasing in more advanced disease. Although the most common cause is relative erythropoietin deficiency, other factors such as reduced iron availabi", "offsetInBeginSection": 195, "offsetInEndSection": 345, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35644772", "text": "The link between these two factors has been described at length in the literature highlighting an association of malnutrition with iron deficiency considered itself as one of the causes of anemia in chronic kidney disease (non-dialysis and hemodialysis).", "offsetInBeginSection": 179, "offsetInEndSection": 401, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33615076", "text": "However, questions exist regarding the use of serum ferritin concentration in people with CKD because it is an acute-phase reactant that can be raised in the context of acute and chronic inflammation.", "offsetInBeginSection": 892, "offsetInEndSection": 1042, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410ef9b201352f04a000031", "type": "yesno", "body": "Can modulation of KCNQ1 splicing prevent arrhythmias?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19687231", "http://www.ncbi.nlm.nih.gov/pubmed/19027783", "http://www.ncbi.nlm.nih.gov/pubmed/19340287", "http://www.ncbi.nlm.nih.gov/pubmed/29843720", "http://www.ncbi.nlm.nih.gov/pubmed/22199116", "http://www.ncbi.nlm.nih.gov/pubmed/32354382", "http://www.ncbi.nlm.nih.gov/pubmed/23608591", "http://www.ncbi.nlm.nih.gov/pubmed/32259418", "http://www.ncbi.nlm.nih.gov/pubmed/17161791", "http://www.ncbi.nlm.nih.gov/pubmed/17892302", "http://www.ncbi.nlm.nih.gov/pubmed/25087487", "http://www.ncbi.nlm.nih.gov/pubmed/22042987", "http://www.ncbi.nlm.nih.gov/pubmed/23825229", "http://www.ncbi.nlm.nih.gov/pubmed/12566121"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23608591", "text": "nd reduces arrhythmogenicity through the modulation of KCNQ1 splicing. We suggested that the modulation of KCNQ1 splicing may help prevent arrhythmia.", "offsetInBeginSection": 1615, "offsetInEndSection": 1765, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23608591", "text": "ial duration (APD) in cardiac myocytes. The consequences of drug-induced KCNQ1 splice alteration remain unknown.\n\n\nOBJECTIVE\nTo study the modulation o", "offsetInBeginSection": 173, "offsetInEndSection": 323, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32354382", "text": "In models of LQTS type 2 (LQTS2) using human induced pluripotent stem cell-derived cardiomyocytes, KCNQ1 antibodies reverse the prolonged cardiac repolarization and abolish arrhythmic activities.", "offsetInBeginSection": 1316, "offsetInEndSection": 1510, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17892302", "text": "Although its modulation of KCNQ1 function has been extensively characterized, many questions remain regarding KCNE1's structure and location within the channel complex.", "offsetInBeginSection": 384, "offsetInEndSection": 534, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25087487", "text": "long QT rabbit model. KCNQ1 immunization prevented dofetilide-induced QTc prolongation and attenuated long QT-related arrhythmias.\n\n\nCONCLUSION\nInduct", "offsetInBeginSection": 1619, "offsetInEndSection": 1769, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32259418", "text": "redisposition to sudden cardiac death. This might be prevented by pharmacological modulation of KCNQ1/KCNE1. The prototypic KCNQ1/KCNE1 activator 4,4'", "offsetInBeginSection": 208, "offsetInEndSection": 358, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17161791", "text": " KCNE2 can bind to KCNQ1 in the presence of KCNE1. Coexpressing KCNE2 with KCNQ1 and KCNE1 leads to a decrease in the I(Ks) current amplitude without altering the gating kinetics", "offsetInBeginSection": 1373, "offsetInEndSection": 1551, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19687231", "text": "cally with this protein, implying that accessory subunit binding alone is not sufficient for channel modulation. These observations indicate that the ", "offsetInBeginSection": 1215, "offsetInEndSection": 1365, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17161791", "text": "of this study was to study whether KCNE2 can associate with KCNQ1 in the presence of KCNE1 and modulate its function.\n\n\nMETHODS\nVoltage clamp methods ", "offsetInBeginSection": 332, "offsetInEndSection": 482, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19027783", "text": "e, leaving 10% of the normal allele transcript intact, which restores the hearing function. Our molecular and functional data provide the first eviden", "offsetInBeginSection": 860, "offsetInEndSection": 1010, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29843720", "text": "CONCLUSIONS\nIn MI mice, sEHI t-AUCB can repress miR-133, consequently stimulating KCNQ1 and KCNH2 mRNA and protein expression, suggesting a possible mechanism for its potential therapeutic application in ischemic arrhythmias.", "offsetInBeginSection": 2155, "offsetInEndSection": 2305, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23825229", "text": " These modifications are attenuated by the common Asian polymorphism KCNQ1 P448R, a genetic determinant preventing coxsackievirus-induced effects in vitro", "offsetInBeginSection": 971, "offsetInEndSection": 1125, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25087487", "text": "als (QTc). However, the electrophysiologic actions of KCNQ1 autoimmunity have not been assessed experimentally in a direct fashion.\n\n\nOBJECTIVE\nThe pu", "offsetInBeginSection": 323, "offsetInEndSection": 473, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32354382", "text": "els. Moreover, KCNQ1 antibodies were able to restore alterations in cardiac repolarization and most importantly to\u00a0suppress arrhythmias in LQTS2. KCNQ", "offsetInBeginSection": 1628, "offsetInEndSection": 1778, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19340287", "text": " KCNE1 exerts its specific regulation of KCNQ1 activation via interactions between membrane-spanning segments of the two proteins. Less detailed attention has been focused on the role of the KCNE1 C-terminus in regulating channel behavior. We analyzed the effects of an LQT5 point mutation (D76N) and the truncation of the entire C-terminus (Delta70) on channel regulation, assembly and interaction. Both mutations significantly shifted voltage dependence of activation in the depolarizing direction and decreased I(Ks) current density. They also accelerated rates of channel deactivation but notably, did not affect activation kinetics", "offsetInBeginSection": 288, "offsetInEndSection": 924, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22042987", "text": "that Ci-KCNQ1 was not properly modulated by KCNE1 and totally unaffected by coexpression of KCNE3. By making chimeras of Ci-KCNQ1 and human KCNQ1, we ", "offsetInBeginSection": 1072, "offsetInEndSection": 1222, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12566121", "text": "The data suggest that electrical remodeling of the cardiac ventricle during hypertrophy involves regulation of the gene expression through modulation of transcriptional and translational regulatory pathways.", "offsetInBeginSection": 1405, "offsetInEndSection": 1589, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22199116", "text": "riants.\n\n\nCONCLUSION\nOur data indicate that 3'UTR SNPs potently modify disease severity in LQT1. The allele-specific effects of the SNPs on disease se", "offsetInBeginSection": 1263, "offsetInEndSection": 1413, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32354382", "text": "OBJECTIVES\nHowever, a causative relationship between KCNQ1 antibodies and the observed electrophysiological effects has never been demonstrated, and thus presents the aim of this study.", "offsetInBeginSection": 497, "offsetInEndSection": 647, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f57f7f33942b094c000006", "type": "summary", "body": "What is Catamenial pneumothorax?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22024812", "http://www.ncbi.nlm.nih.gov/pubmed/34825583", "http://www.ncbi.nlm.nih.gov/pubmed/8378002", "http://www.ncbi.nlm.nih.gov/pubmed/35530874", "http://www.ncbi.nlm.nih.gov/pubmed/17540999", "http://www.ncbi.nlm.nih.gov/pubmed/21591450", "http://www.ncbi.nlm.nih.gov/pubmed/12097775", "http://www.ncbi.nlm.nih.gov/pubmed/31649227", "http://www.ncbi.nlm.nih.gov/pubmed/28925275", "http://www.ncbi.nlm.nih.gov/pubmed/17162716", "http://www.ncbi.nlm.nih.gov/pubmed/19033519", "http://www.ncbi.nlm.nih.gov/pubmed/29769481", "http://www.ncbi.nlm.nih.gov/pubmed/12607643", "http://www.ncbi.nlm.nih.gov/pubmed/25981153", "http://www.ncbi.nlm.nih.gov/pubmed/8693313", "http://www.ncbi.nlm.nih.gov/pubmed/18704865", "http://www.ncbi.nlm.nih.gov/pubmed/11526763", "http://www.ncbi.nlm.nih.gov/pubmed/28647447", "http://www.ncbi.nlm.nih.gov/pubmed/28762057", "http://www.ncbi.nlm.nih.gov/pubmed/9599089", "http://www.ncbi.nlm.nih.gov/pubmed/27516783", "http://www.ncbi.nlm.nih.gov/pubmed/11715807", "http://www.ncbi.nlm.nih.gov/pubmed/15887438", "http://www.ncbi.nlm.nih.gov/pubmed/19670769", "http://www.ncbi.nlm.nih.gov/pubmed/32190546", "http://www.ncbi.nlm.nih.gov/pubmed/16113003", "http://www.ncbi.nlm.nih.gov/pubmed/11933736", "http://www.ncbi.nlm.nih.gov/pubmed/23180431"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28925275", "text": "AIM\nCatamenial pneumothorax is menstrual cycle dependent and represents the most common form of thoracic endometriosis syndrome. Recurrences are very ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11715807", "text": " catamenial pneumothorax. Catamenial pneumothorax is one of the forms of spontaneous pneumothorax. An integral part of the paper is a review of the li", "offsetInBeginSection": 78, "offsetInEndSection": 228, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8693313", "text": "intrathoracic endometriosis is often assumed. Catamenial pneumothorax is rare and differs from primary spontaneous pneumothorax in its prevalence in t", "offsetInBeginSection": 150, "offsetInEndSection": 300, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9599089", "text": "Recurring pneumothorax associated with menstruation was named catamenial pneumothorax. Proposed causes for catamenial pneumothorax include allows air ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8378002", "text": "BACKGROUND\nCatamenial pneumothorax, a rare complication of systemic endometriosis, has been difficult to treat successfully. Successful medical therap", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15887438", "text": "ial pneumothorax is defined as spontaneous pneumothorax occurring within 72 hours before or after onset of menstruation. Although catamenial pneumotho", "offsetInBeginSection": 7, "offsetInEndSection": 157, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16113003", "text": "Catamenial pneumothorax, a variant of spontaneous pneumothorax occurs exclusively in women of menstrual age. Catamenial pneumothorax is associated wit", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19670769", "text": "illness every month. Since catamenial pneumothorax is caused by thoracic endometriosis, decisions on treatment should be made with a gynecologist's op", "offsetInBeginSection": 1070, "offsetInEndSection": 1220, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11526763", "text": "t thoracic are possible. Catamenial pneumothorax is a clinical variant of spontaneous pneumothorax. The 39 years old women with catamenial pneumothora", "offsetInBeginSection": 180, "offsetInEndSection": 330, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19033519", "text": " the Greek meaning \"monthly\". Catamenial pneumothorax is a rare complication of endometriosis. A patient with a history of endometriosis presented to ", "offsetInBeginSection": 229, "offsetInEndSection": 379, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19670769", "text": "Catamenial pneumothorax is an rare disease which arise in women during menses, etiologically related to endometriosis of diaphragm and lung. The five ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27516783", "text": "Catamenial pneumothorax should be defined as recurrent accumulation of air in the pleural cavity in reproductive-age women without concomitant respiratory diseases.", "offsetInBeginSection": 29, "offsetInEndSection": 179, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12097775", "text": "Catamenial pneumothorax is a rarely encountered entity characterized by recurrent pneumothorax concurrent with menstruation. Numerous mechanisms have ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34825583", "text": "Catamenial pneumothorax presents as recurrent spontaneous pneumothorax with a temporal relationship to the onset of menses, affecting mostly the right lung.", "offsetInBeginSection": 172, "offsetInEndSection": 322, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17540999", "text": "Catamenial pneumothorax is a recurrent pneumothorax temporally associated with menstruation. Pathogenesis remains debated however pleural endometriosi", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31649227", "text": "Catamenial pneumothorax is a rare condition. We report a case of a 36-year-old female who presented with dyspnoea every time before she had her regula", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28647447", "text": "BACKGROUND\nCatamenial pneumothorax is a rare but serious condition for women of reproductive age. We describe a trial of dienogest as hormonal therapy", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25981153", "text": "CONCLUSION\nCatamenial pneumothorax is the most common presentation of thoracic endometriosis syndrome and should always be suspected in women in childbearing age.", "offsetInBeginSection": 1469, "offsetInEndSection": 1619, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28762057", "text": "BACKGROUND\nCatamenial pneumothorax is an uncommon form of spontaneous pneumothorax in women. The exact epidemiology and pathogenesis remain elusive. V", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12607643", "text": "amenial pneumothorax is a rare entity characterized by recurrent accumulation of air in the thoracic space during menstruation. Catamenial pneumothora", "offsetInBeginSection": 14, "offsetInEndSection": 164, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17162716", "text": "Catamenial pneumothorax is an uncommon disease whose management is not consensual. We report the case of a patient who experienced several episodes of", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22024812", "text": " pneumothorax is defined as spontaneous pneumothorax that occurs within 72 hours before or after the onset of menstruation. It occurs in the right lun", "offsetInBeginSection": 98, "offsetInEndSection": 248, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29769481", "text": "CKGROUND Catamenial pneumothorax (CP) is a spontaneous pneumothorax commonly associated with menstrual periods. Endometrial tissues most commonly invo", "offsetInBeginSection": 2, "offsetInEndSection": 152, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32190546", "text": "Catamenial pneumothorax (CP) is considered to be the most common form of thoracic endometriosis syndrome, which also includes catamenial hemothorax, catamenial hemopneumothorax, catamenial hemoptysis, and endometriosis lung nodules.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23180431", "text": "Catamenial pneumothorax is a rare disorder with an unknown etiology. It is characterized by recurrent spontaneous pneumothorax during or preceding men", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21591450", "text": "We reported a case of catamenial pneumothorax caused by diaphragmatic endometriosis that was histologically confirmed. A 49-year-old female who had re", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25981153", "text": "CTION\nCatamenial pneumothorax (CP) is a spontaneous recurrent pneumothorax occurring in women in reproductive age. The etiology of CP has been associa", "offsetInBeginSection": 7, "offsetInEndSection": 157, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35530874", "text": "Catamenial pneumothorax is a unique condition associated with thoracic endometriosis. It often presents in females of reproductive age as a recurrent ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11933736", "text": "horax have been reported in the literature. They represent 2.8 to 5.6% of spontaneous pneumothroax in women. Diagnosis is evoked on the occurrence of ", "offsetInBeginSection": 736, "offsetInEndSection": 886, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18704865", "text": " pneumothorax is a rare entity of spontaneous, recurrent pneumothorax occurring in synchrony with the menstrual cycle. The etiology is not completely ", "offsetInBeginSection": 10, "offsetInEndSection": 160, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64144419201352f04a000045", "type": "summary", "body": "Please summarize haptenization.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2953821", "http://www.ncbi.nlm.nih.gov/pubmed/23928507", "http://www.ncbi.nlm.nih.gov/pubmed/15237856", "http://www.ncbi.nlm.nih.gov/pubmed/7681423", "http://www.ncbi.nlm.nih.gov/pubmed/1999650"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15237856", "text": "he innate immune system, or haptenization eliciting an immunoallergic response of the adaptive immune system. Besides licensed drugs, herbal and natur", "offsetInBeginSection": 813, "offsetInEndSection": 963, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23928507", "text": "Her particular hepatic metabolism further increased the drugs' concentration, favoring the haptenization of liver proteins, eventually leading to the development of an autoimmune hepatitis.", "offsetInBeginSection": 526, "offsetInEndSection": 676, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1999650", "text": "dentical results. Using the NIP-FAb' conjugate identical target cell haptenization was readily achieved from experiment to experiment. Using conjugate", "offsetInBeginSection": 465, "offsetInEndSection": 615, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2953821", "text": "A rapid and simple method was developed for the haptenization of monoclonal antibodies (MAbs), to be used in immunoenzyme single and double staining techniques.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7681423", "text": "y that MHC-associated, haptenated peptides create functional antigenic epitopes for TNP-specific CTL. Furthermore, using purified Kb-molecules and a p", "offsetInBeginSection": 511, "offsetInEndSection": 661, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c124690f196b51000002", "type": "yesno", "body": "Is trichotillomania encountered with equali frequency in males and females?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10216392", "http://www.ncbi.nlm.nih.gov/pubmed/29753253", "http://www.ncbi.nlm.nih.gov/pubmed/33124597", "http://www.ncbi.nlm.nih.gov/pubmed/3681332", "http://www.ncbi.nlm.nih.gov/pubmed/28143628", "http://www.ncbi.nlm.nih.gov/pubmed/29769783", "http://www.ncbi.nlm.nih.gov/pubmed/18970906", "http://www.ncbi.nlm.nih.gov/pubmed/1938977", "http://www.ncbi.nlm.nih.gov/pubmed/27172263", "http://www.ncbi.nlm.nih.gov/pubmed/30440191", "http://www.ncbi.nlm.nih.gov/pubmed/16396185", "http://www.ncbi.nlm.nih.gov/pubmed/11286115", "http://www.ncbi.nlm.nih.gov/pubmed/19470079", "http://www.ncbi.nlm.nih.gov/pubmed/22558146", "http://www.ncbi.nlm.nih.gov/pubmed/22056781", "http://www.ncbi.nlm.nih.gov/pubmed/9332906", "http://www.ncbi.nlm.nih.gov/pubmed/32334275", "http://www.ncbi.nlm.nih.gov/pubmed/9193740", "http://www.ncbi.nlm.nih.gov/pubmed/30901067", "http://www.ncbi.nlm.nih.gov/pubmed/10730761", "http://www.ncbi.nlm.nih.gov/pubmed/6671394", "http://www.ncbi.nlm.nih.gov/pubmed/19479123", "http://www.ncbi.nlm.nih.gov/pubmed/2050379", "http://www.ncbi.nlm.nih.gov/pubmed/23116460", "http://www.ncbi.nlm.nih.gov/pubmed/30099694"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23116460", "text": "1%). Among these students, 19 (9.0%) were engaged in dermatillomania, 28 (13.3%) in trichotillomania and 13 (6.2%) in onychophagia.\n\n\nCONCLUSIONS\nHigh", "offsetInBeginSection": 1149, "offsetInEndSection": 1299, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10216392", "text": "a, substance abuse, borderline personality, obsessive-compulsive disorder. Its onset is usually in childhood and females are more affected than males.", "offsetInBeginSection": 277, "offsetInEndSection": 427, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18970906", "text": "tatistical Manual of Mental Disorders, Fourth Edition, trichotillomania (85.3% females; mean age, 35.0 +/- 12.5). Comorbidity data were obtained with ", "offsetInBeginSection": 297, "offsetInEndSection": 447, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30901067", "text": "ified as an obsessive-compulsive spectrum disorder and is seen predominantly in females. This is a non-systematic review article focusing on the psych", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29753253", "text": "Trichotillomania is several times more common in women and has peak onset around puberty. The role of sex hormones, however, has received little resea", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3681332", "text": "Intraventricular (IVC) conduction abnormalities were encountered with similar frequency in both sexes: in 12/33 (36%) of affected males and 10/32 (31%) of affected females.", "offsetInBeginSection": 545, "offsetInEndSection": 695, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19479123", "text": "gh trichotillomania is a relatively common disorder no large epidemiological studies are available. The aims of this study were to determine the frequ", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18970906", "text": " .010).\n\n\nCONCLUSIONS\nThese preliminary results suggest that trichophagia is not uncommon in individuals with trichophagia. Subjects with and without ", "offsetInBeginSection": 1397, "offsetInEndSection": 1547, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11286115", "text": "ubsequent sense of relief. The mean age of onset is 8 years for males and 12 for females. Hair is pulled from a variety of sites, most frequently from", "offsetInBeginSection": 392, "offsetInEndSection": 542, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9332906", "text": ", and it may be effective in a subset of patients. Given the relatively low response rate, however, a controlled trial is needed before this agent can", "offsetInBeginSection": 887, "offsetInEndSection": 1037, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10730761", "text": "Oak moss remained the most common overall allergen throughout the study, positive in 38.3% of females and 35.6% of males who were tested to the constituents of the fragrance mix.", "offsetInBeginSection": 1037, "offsetInEndSection": 1187, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30440191", "text": "Trichotillomania is a relatively uncommon condition that classically occurs in young females. It can result in trichobezoar formation, which is usuall", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19479123", "text": "lieving drugs and sedatives). Trichotillomania is a relatively common disorder; however, not all dermatologists are sufficiently prepared to treat it.", "offsetInBeginSection": 1042, "offsetInEndSection": 1192, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6671394", "text": "se in general. Prosopagnosia was found to occur significantly more frequently in males than in females. Possible implications of this finding vis-\u00e0-vi", "offsetInBeginSection": 157, "offsetInEndSection": 307, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23116460", "text": "versity, Dow Medical College and Sind Medical College, Karachi, in equal proportion. Data were collected using a pre tested tool, \"Habit Questionnaire", "offsetInBeginSection": 577, "offsetInEndSection": 727, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9193740", "text": "ur algorithms by signal intensity-frequency histograms. Consistent with one a priori hypothesis, left putamen volume was found to be significantly sma", "offsetInBeginSection": 373, "offsetInEndSection": 523, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2050379", "text": "nti-3.7, was identified. The G6PD deficiency gene frequency was 0.08 and 0.032 in males and females, respectively. Several cases with 2 abnormal genes", "offsetInBeginSection": 765, "offsetInEndSection": 915, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1938977", "text": " 1.5% of males and 3.4% of females.\n\n\nCONCLUSION\nTrichotillomania may not be as rare as previously suspected and may affect males as often as females.", "offsetInBeginSection": 867, "offsetInEndSection": 1017, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30099694", "text": "ccur at any age but is observed more often in adolescents, with a strong predominance in females. Diagnosis of trichotillomania may be difficult, and ", "offsetInBeginSection": 146, "offsetInEndSection": 296, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27172263", "text": "A total of 33 patients had a diagnosis of trichotillomania (28 females, 5 males; peak age between 3 and 4 years). Scalp involvement was most common an", "offsetInBeginSection": 502, "offsetInEndSection": 652, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32334275", "text": "an age of onset for trichotillomania was 17.7 years. The mean age of onset differed significantly for males (mean 19.0 years) versus females (mean 14.", "offsetInBeginSection": 554, "offsetInEndSection": 704, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22056781", "text": "(1.34%), and 27 with fistulas (0.35%).  The frequency of the coronary artery anomalies was significantly higher in the females than the males (p = 0.0", "offsetInBeginSection": 873, "offsetInEndSection": 1023, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33124597", "text": "ted for the treatment of trichotillomania, though these are not effective for all patients. Therefore, new treatment options are needed. Five female p", "offsetInBeginSection": 327, "offsetInEndSection": 477, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19470079", "text": "hat all psychocutaneous disorders but delusion of parasitosis are commoner in females. Mood and anxiety disorders were common in patients with dermati", "offsetInBeginSection": 1220, "offsetInEndSection": 1370, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22056781", "text": " with fistulas (0.35%).  The frequency of the coronary artery anomalies was significantly higher in the females than the males (p = 0.001).  Of the co", "offsetInBeginSection": 888, "offsetInEndSection": 1038, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28143628", "text": "relatively understudied psychiatric disorder. Even less is known about this disorder in the elderly. We describe an unusual case of an elderly woman p", "offsetInBeginSection": 22, "offsetInEndSection": 172, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10730761", "text": " reactions to the fragrance mix was 8.5% in females (range 6.1-10.9) and 6.7% in males (range 5.1-12.9). Females were 1.3 times more likely to be alle", "offsetInBeginSection": 413, "offsetInEndSection": 563, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22558146", "text": "In contrast, males without recent access to mates were greater risk-takers; they approached females more rapidly and to closer proximity, regardless of risk.", "offsetInBeginSection": 1020, "offsetInEndSection": 1170, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16396185", "text": "In females the frequency of polyandry was not different between treatments, and polyandrous females produced larger clutches, suggesting that polyandry might be adaptive.", "offsetInBeginSection": 757, "offsetInEndSection": 907, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29769783", "text": "Trichotillomania is currently classified under obsessive and compulsive behavioral spectrum disorders and is often encountered in the younger population with research evidence of response to selective serotonin reuptake inhibitors (SSRIs), antipsychotics, and newer drugs such as N-acetyl cysteine.", "offsetInBeginSection": 573, "offsetInEndSection": 723, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64041701201352f04a000017", "type": "list", "body": "What is the triad of the Eagle-Barrett Syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34209816", "http://www.ncbi.nlm.nih.gov/pubmed/30560020", "http://www.ncbi.nlm.nih.gov/pubmed/31864313", "http://www.ncbi.nlm.nih.gov/pubmed/24833922", "http://www.ncbi.nlm.nih.gov/pubmed/35429431", "http://www.ncbi.nlm.nih.gov/pubmed/6231520", "http://www.ncbi.nlm.nih.gov/pubmed/12579407", "http://www.ncbi.nlm.nih.gov/pubmed/142096"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35429431", "text": "Eagle-Barrett Syndrome (EBS) is a rare congenital condition characterized by the triad of absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism.", "offsetInBeginSection": 65, "offsetInEndSection": 215, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12579407", "text": "BS) is characterized by the triad of abdominal muscle deficiency, urinary tract abnormalities, and cryptorchidism. Approximately 25% of patients with ", "offsetInBeginSection": 25, "offsetInEndSection": 175, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30560020", "text": "owing triad of symptoms: deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral cryptorchidism. The exact etiology is ", "offsetInBeginSection": 160, "offsetInEndSection": 310, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/142096", "text": "dder in a 20 1/2 week fetus which subsequently was proven to have the prune belly or Eagle-Barrett syndrome. Serial sonograms were used to follow the ", "offsetInBeginSection": 76, "offsetInEndSection": 226, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6231520", "text": "Abdominal muscle deficiency, urinary tract abnormalities, and cryptorchidism are the three major features of the prune-belly syndrome, also referred to as triad syndrome or Eagle-Barrett syndrome.", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24833922", "text": "The Female Athlete Triad (Triad) represents a syndrome of three interrelated conditions that originate from chronically inadequate energy intake to compensate for energy expenditure; this environment results in insufficient stored energy to maintain physiological processes, a condition known as low energy availability.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34209816", "text": "mptoms. Watt W. Eagle identified two types: stylo-hyoid classic syndrome and stylo-carotid artery syndrome. The aim of this systematic review of the l", "offsetInBeginSection": 185, "offsetInEndSection": 335, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31864313", "text": " variants of the Eagle syndrome. The classic one, mainly characterized by pain and dysphagia, and the carotid variant characterized by pain and someti", "offsetInBeginSection": 84, "offsetInEndSection": 234, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34209816", "text": "d correlations between the onset of symptoms in Eagle syndrome and traumatic events and highlighted two possibilities: traumatic event could fracture ", "offsetInBeginSection": 693, "offsetInEndSection": 843, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640c85e9201352f04a000026", "type": "factoid", "body": "What cells proliferate in Mantle Cell Lymphoma", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20663948", "http://www.ncbi.nlm.nih.gov/pubmed/22058203", "http://www.ncbi.nlm.nih.gov/pubmed/10463985", "http://www.ncbi.nlm.nih.gov/pubmed/20688354", "http://www.ncbi.nlm.nih.gov/pubmed/34804720", "http://www.ncbi.nlm.nih.gov/pubmed/9753060", "http://www.ncbi.nlm.nih.gov/pubmed/22371181", "http://www.ncbi.nlm.nih.gov/pubmed/22555177", "http://www.ncbi.nlm.nih.gov/pubmed/11903572", "http://www.ncbi.nlm.nih.gov/pubmed/6362835", "http://www.ncbi.nlm.nih.gov/pubmed/30065968", "http://www.ncbi.nlm.nih.gov/pubmed/22849733", "http://www.ncbi.nlm.nih.gov/pubmed/22790016"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/6362835", "text": "Mantle-zone lymphoma (MZL) is a histologically distinctive variant of follicular lymphocytic lymphoma which is characterized by a proliferation of atypical small lymphoid cells as wide mantles around benign-appearing germinal centers.", "offsetInBeginSection": 86, "offsetInEndSection": 236, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9753060", "text": "The majority of cases show uniform morphological and phenotypic features characterized by a monotonous proliferation of small-to-medium-sized irregular B cells that express CD5 and bright surface immunoglobulin IgM and IgD.", "offsetInBeginSection": 181, "offsetInEndSection": 331, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11903572", "text": "METHODS AND RESULTS\nIn the initial manifestation in the palatine tonsils, the neoplastic cells were found to grow exclusively within the marginal zones of secondary follicles which showed a preserved mantle zone.", "offsetInBeginSection": 105, "offsetInEndSection": 255, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22790016", "text": "Recently, the occurrence of cyclin D1-positive B cells with mantle cell lymphoma phenotype in the inner mantle zones of morphologically inconspicuous lymph nodes has been described and termed mantle cell lymphoma 'in situ'.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34804720", "text": "ive, rare form of non-Hodgkin lymphoma that arises from cells originating in the \"mantle zone.\" Here, we describe a case of mantle cell lymphoma assoc", "offsetInBeginSection": 44, "offsetInEndSection": 194, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6362835", "text": "lymphomas are derived from follicular center cells. Apparently, the lymphoid cells of MZL home to the mantle zones of secondary follicles, where they ", "offsetInBeginSection": 963, "offsetInEndSection": 1113, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22555177", "text": "ving CCND1 and a high number of additional genetic alterations. Chromosomal gains of 7p are frequent in mantle cell lymphoma, with insulin-like growth", "offsetInBeginSection": 126, "offsetInEndSection": 276, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10463985", "text": "BACKGROUND\nMantle cell lymphoma is a mature, virgin B-cell neoplasm characterized immunologically by a panB+, CD5+, CD23-, cyclin D1+ phenotype and genetically by t(11;14)(q13;q32) with overexpression of the cyclin D1 (bcl-1) gene.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22849733", "text": "node biopsy showed expanded mantle zones composed of uniformly small B lymphocytes. A cyclin D1 immunohistochemical stain was negative and the patient", "offsetInBeginSection": 155, "offsetInEndSection": 305, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22058203", "text": "BACKGROUND\nCyclin D1-positive B cells are occasionally found in the mantle zones of reactive lymphoid follicles, a condition that has been called \"in situ mantle cell lymphoma\".", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20663948", "text": " cell survival signals by apoptosis and cell viability assays.\n\n\nRESULTS\nSTAT3 was constitutively phosphorylated in the Jeko-1 mantle cell lymphoma ce", "offsetInBeginSection": 583, "offsetInEndSection": 733, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11903572", "text": "The specimen from the relapse occurring 8 months later exhibited diffuse monomorphous cells co-expressing B-cell antigens and CD5, CD43 and cyclin D1, leading to the diagnosis of mantle cell lymphoma.", "offsetInBeginSection": 583, "offsetInEndSection": 733, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20688354", "text": "Proliferation rate (Ki-67) was higher in blastoid/pleomorphic variants than in typical mantle cell lymphoma tumors and was inversely associated with p27 levels in typical mantle cell lymphoma.", "offsetInBeginSection": 1118, "offsetInEndSection": 1268, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22371181", "text": "RESULTS\nCo-culture of mantle cell lymphoma cells and human stromal cells results in the survival and proliferation of primary mantle cell lymphoma cells for at least 7 months compared to mantle cell lymphoma cells cultured alone.", "offsetInBeginSection": 790, "offsetInEndSection": 940, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20688354", "text": " B-cell lymphoma characterized by the t(11;14)(q13;q32). Mantle cell lymphomas exhibit a spectrum of morphologic findings, of which a subset of tumors is clinically aggressive with a high proliferation rate", "offsetInBeginSection": 42, "offsetInEndSection": 248, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30065968", "text": "ntle cell lymphoma at the mRNA level, silencing genes associated with cancer cell proliferation. We identified a lipid nanoparticle formulated with th", "offsetInBeginSection": 435, "offsetInEndSection": 585, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30065968", "text": "R-1 mantle cell lymphoma cell lines. Three therapeutic gene targets were examined for their effect on lymphoma growth. These included Cyclin D1, which is a cell cycle regulator, as well as Bcl-2 and Mcl-1, which prevent apoptosis. Gene knockdown with siRNA doses as low at 10 nM increased lymphoma cell apoptosis without carrier-mediated toxicity. Silencing of Cyclin D1 induced apoptosis despite a twofold \"compensation\" upregulation of Cyclin D2. Upon simultaneous silencing of all three genes, nearly 75% of JeKo-1 cells were apoptosing 3 days post-transfection. Furthermore, cells proliferated at only 15% of their pretreatment rate", "offsetInBeginSection": 642, "offsetInEndSection": 1278, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415bb3c690f196b5100000e", "type": "factoid", "body": "What is the estimated cost reduction when using telegenetics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26785833", "http://www.ncbi.nlm.nih.gov/pubmed/20411313", "http://www.ncbi.nlm.nih.gov/pubmed/34355459", "http://www.ncbi.nlm.nih.gov/pubmed/28578759", "http://www.ncbi.nlm.nih.gov/pubmed/25833335", "http://www.ncbi.nlm.nih.gov/pubmed/30559758", "http://www.ncbi.nlm.nih.gov/pubmed/33027215"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20411313", "text": "legenetics. Telegenetics offered them convenience and reduced travel and associated costs. The majority of women described feeling a high degree of so", "offsetInBeginSection": 604, "offsetInEndSection": 754, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "text": "sfaction. One economic analysis published thus far reported lower costs than in-person care. We hypothesized that telegenetics can also be beneficial ", "offsetInBeginSection": 351, "offsetInEndSection": 501, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33027215", "text": "GS\nImplementation of telegenetics in health systems is still limited, below 10%, somewhat higher for cancer genetic counseling. Nevertheless, telegene", "offsetInBeginSection": 190, "offsetInEndSection": 340, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25833335", "text": "Our randomized trial of telegenetics vs. in-person counseling found that telegenetics cost less than in-person counseling, with high satisfaction among those who attended.", "offsetInBeginSection": 1244, "offsetInEndSection": 1394, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30559758", "text": "egenetics may increase patients' access to genetic counseling with affordable costs. However, before further developing DTC telegenetics, more researc", "offsetInBeginSection": 1059, "offsetInEndSection": 1209, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25833335", "text": "k post-CGC via telephone survey using validated scales. Total costs were $106 per telegenetics patient and $244 per in-person patient. Patient satisfa", "offsetInBeginSection": 751, "offsetInEndSection": 901, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28578759", "text": "d were $16million and $14million respectively; an annual reduction of $85million in total. Conclusions The present study shows that the teledentistry ", "offsetInBeginSection": 1315, "offsetInEndSection": 1465, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34355459", "text": "In keeping with previous research, most genetics providers appraised telegenetics as a valuable addition to patient care (68%, N\u00a0=\u00a013) and hoped to offer it as an option beyond the pandemic (63%, N\u00a0=\u00a012).", "offsetInBeginSection": 2093, "offsetInEndSection": 2243, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f03ae6f36125a42600001d", "type": "factoid", "body": "What is the target of BI 1015550?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35569036", "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "http://www.ncbi.nlm.nih.gov/pubmed/36299369"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35569036", "text": "gent, prevented a decrease in lung function in patients with idiopathic pulmonary fibrosis. (Funded by Boehringer Ingelheim; 1305-0013 ClinicalTrials.", "offsetInBeginSection": 2035, "offsetInEndSection": 2185, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35569036", "text": "referential inhibitor of the PDE4B subtype, in patients with idiopathic pulmonary fibrosis. Patients were randomly assigned in a 2:1 ratio to receive ", "offsetInBeginSection": 312, "offsetInEndSection": 462, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "text": "In summary, the unique preferential inhibition of PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential, suggest BI 1015550 to be a promising oral clinical candidate for the treatment of IPF and other fibro-proliferative diseases.", "offsetInBeginSection": 2251, "offsetInEndSection": 2401, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "text": "To better understand the antifibrotic potential of BI 1015550 in vivo, its direct effect on human fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) was investigated in vitro.", "offsetInBeginSection": 1443, "offsetInEndSection": 1593, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36299369", "text": "ics of BI 1015550 in healthy male subjects and patients with idiopathic pulmonary fibrosis (IPF).\n\n\nMethods\nIn the phase I study, 42 subjects were par", "offsetInBeginSection": 195, "offsetInEndSection": 345, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "text": "is a novel PDE4 inhibitor showing a preferential enzymatic inhibition of PDE4B. In vitro, BI 1015550 inhibits lipopolysaccharide (LPS)-induced tumor n", "offsetInBeginSection": 362, "offsetInEndSection": 512, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36299369", "text": "s. For both studies, the primary endpoint was the number of subjects with drug-related adverse events (AEs).\n\n\nResults\nIn the Phase I study, drug-rela", "offsetInBeginSection": 636, "offsetInEndSection": 786, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35569036", "text": "that BI 1015550 was superior to placebo, 0.998). Among patients with background antifibrotic use, the median change in the FVC was 2.7 ml (95% credibl", "offsetInBeginSection": 1133, "offsetInEndSection": 1283, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64089be7201352f04a000022", "type": "summary", "body": "Please summarize the difference between REMS and RMPs", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10500302", "http://www.ncbi.nlm.nih.gov/pubmed/8529555", "http://www.ncbi.nlm.nih.gov/pubmed/31122578", "http://www.ncbi.nlm.nih.gov/pubmed/23244814", "http://www.ncbi.nlm.nih.gov/pubmed/19665493"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/31122578", "text": "l severity of illness; however, no studies have adequately addressed the intra or inter-rater reliability of the score.\n\n\nCONCLUSIONS\nThere is evidenc", "offsetInBeginSection": 1085, "offsetInEndSection": 1235, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10500302", "text": "RMPs exhibit strong conservation of function across divergent species, and display species-specific interactions with SSB and enzymes to neutralize the SSB barrier to enzyme-ssDNA assembly.", "offsetInBeginSection": 356, "offsetInEndSection": 506, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23244814", "text": " patient safety. Currently, neither agency provides specific guidance on how risk should be related to benefit either qualitatively or quantitatively.", "offsetInBeginSection": 1605, "offsetInEndSection": 1755, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19665493", "text": "The most typical differences between the two rebound groups were the increased cumulative time and longer average duration of REMS episodes without significant change in the number of these episodes of the small platform animals during the passive phase.", "offsetInBeginSection": 769, "offsetInEndSection": 919, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8529555", "text": "In another condition subjects were given the same 4 h testing condition prior to sleep, the only difference being that they were instructed not to move their gaze; therefore only \"attentional movements\" were possible.", "offsetInBeginSection": 456, "offsetInEndSection": 606, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f9cd2f33942b094c000011", "type": "yesno", "body": "Does microexon alternative splicing of small GTPase regulators have implication in central nervous system diseases?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11473790", "http://www.ncbi.nlm.nih.gov/pubmed/28186082", "http://www.ncbi.nlm.nih.gov/pubmed/25838543", "http://www.ncbi.nlm.nih.gov/pubmed/21561415", "http://www.ncbi.nlm.nih.gov/pubmed/23303910", "http://www.ncbi.nlm.nih.gov/pubmed/28163190", "http://www.ncbi.nlm.nih.gov/pubmed/30934641", "http://www.ncbi.nlm.nih.gov/pubmed/30404949", "http://www.ncbi.nlm.nih.gov/pubmed/35274098", "http://www.ncbi.nlm.nih.gov/pubmed/29484299", "http://www.ncbi.nlm.nih.gov/pubmed/26853282", "http://www.ncbi.nlm.nih.gov/pubmed/31559909", "http://www.ncbi.nlm.nih.gov/pubmed/35841978", "http://www.ncbi.nlm.nih.gov/pubmed/34346508", "http://www.ncbi.nlm.nih.gov/pubmed/17565696", "http://www.ncbi.nlm.nih.gov/pubmed/28765332", "http://www.ncbi.nlm.nih.gov/pubmed/28106138", "http://www.ncbi.nlm.nih.gov/pubmed/29671263", "http://www.ncbi.nlm.nih.gov/pubmed/34155820", "http://www.ncbi.nlm.nih.gov/pubmed/33378678", "http://www.ncbi.nlm.nih.gov/pubmed/25686034", "http://www.ncbi.nlm.nih.gov/pubmed/25879033", "http://www.ncbi.nlm.nih.gov/pubmed/24910101"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35841978", "text": "r, its implication in cardiovascular embryogenesis and diseases remains largely unknown. In this review, we summarize previous findings and reveal the", "offsetInBeginSection": 416, "offsetInEndSection": 566, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30404949", "text": "ing events. However, the functional significance of microexons and their contribution to signaling diversity is poorly understood. The Met receptor ty", "offsetInBeginSection": 105, "offsetInEndSection": 255, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11473790", "text": "s process is underscored by the finding that its misregulation is a common characteristic of human disease. This review highlights the current views o", "offsetInBeginSection": 637, "offsetInEndSection": 787, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34155820", "text": "We consider recent findings of microexon alternative splicing and their implication for regulating the function of small GTPases in the context of the microglia, and we extrapolate these findings to what is known in neurons.", "offsetInBeginSection": 1066, "offsetInEndSection": 1216, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29484299", "text": "In this review, we focus on recent progress toward understanding the contributions of alternative splicing to neurogenesis and brain development, which has shed light on how splicing defects may cause brain disorders and diseases.", "offsetInBeginSection": 1206, "offsetInEndSection": 1356, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23303910", "text": "The flipside of these highly integrated functions is that they make small GTPase regulators susceptible to biochemical abnormalities that are directly correlated with diseases, notably a striking number of missense mutations in congenital diseases, and susceptible to bacterial mimics of GEFs, GAPs, and GDIs that take command of small GTPases in infections.", "offsetInBeginSection": 1098, "offsetInEndSection": 1248, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34155820", "text": "We consider recent findings of microexon alternative splicing and their implication for regulating the function of small GTPases in the context of the microglia, and we extrapolate these findings to what is known in neurons.", "offsetInBeginSection": 1052, "offsetInEndSection": 1202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28765332", "text": "nervous systems. Alternative splicing involving an N1-Src-specific microexon leads to a 5 or 6 aa insertion into the SH3 domain of Src. A prevailing m", "offsetInBeginSection": 172, "offsetInEndSection": 322, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35274098", "text": "In patients with myotonic dystrophy type 1 (DM1), dysregulation of RNA-binding proteins like MBNL and CELF1 leads to alternative splicing of exons and is thought to induce a return to fetal splicing patterns in adult tissues, including the central nervous system (CNS).", "offsetInBeginSection": 111, "offsetInEndSection": 261, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11473790", "text": "lating protein activities in a temporal and spatial manner. The relevance of alternative splicing to diseases of the nervous system is also discussed.", "offsetInBeginSection": 1515, "offsetInEndSection": 1665, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28186082", "text": "This event is synergized with EGF-activated SR proteins to alter alternative splicing of a key small GTPase Rac1 to enhance cell migration, highlighting converging EGF signals on both negative and positive splicing regulators to jointly promote a key cancer pathway.", "offsetInBeginSection": 275, "offsetInEndSection": 425, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24910101", "text": "Our results indicate that combinatorial regulation of alternative splicing in distinct neurons provides a mechanism to specialize metazoan nervous systems.", "offsetInBeginSection": 882, "offsetInEndSection": 1032, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30404949", "text": "These data highlight microexon skipping as a mechanism to spatially restrict signaling and provide a mechanistic link between RTK-initiated phosphoinositide microdomains and Arf6 during signal transduction and cancer cell migration.", "offsetInBeginSection": 928, "offsetInEndSection": 1078, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25686034", "text": " responses in a variety of organisms, and disruption of this machinery is often implicated in human diseases. Previously, we discovered a long form of", "offsetInBeginSection": 201, "offsetInEndSection": 351, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31559909", "text": "Neuronal microexons represent the most highly conserved class of alternative splicing events and their timed expression shapes neuronal biology, including neuronal commitment and differentiation.", "offsetInBeginSection": 45, "offsetInEndSection": 195, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28106138", "text": "ryonic stem cells inhibited neurite outgrowth. Our results suggest that SRRM4 controls neurite outgrowth through regulation of alternative splicing of", "offsetInBeginSection": 1174, "offsetInEndSection": 1324, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30934641", "text": "We will then proceed to the final and main part of this review, where we will thoroughly comment on the implication of the regulators for Rho GTPases-GEFs (Guanine nucleotide Exchange Factors) and GAPs (GTPase-activating Proteins)-in neurological diseases and disorders.", "offsetInBeginSection": 1126, "offsetInEndSection": 1292, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21561415", "text": "Finally, we present several lines of evidence showing the involvement of Rho GTPase signaling in the development and progression of neurodegenerative diseases.", "offsetInBeginSection": 807, "offsetInEndSection": 957, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17565696", "text": "ssue regulated fashion. The majority of these AS events display differential regulation in central nervous system (CNS) tissues. Approximately half of", "offsetInBeginSection": 561, "offsetInEndSection": 711, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26853282", "text": "alian CNS. Notably, there is increasing evidence that implicates the dysregulation of neuronal splicing events in several neurological disorders. Ther", "offsetInBeginSection": 1029, "offsetInEndSection": 1179, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29671263", "text": "Misregulation of alternative pre-mRNA splicing contributes to various diseases. Understanding how alternative splicing is regulated paves the way to modulating or correcting molecular pathogenesis of the diseases", "offsetInBeginSection": 0, "offsetInEndSection": 212, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508", "text": "C metastasis. Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon spl", "offsetInBeginSection": 1164, "offsetInEndSection": 1314, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28163190", "text": " Recent studies have demonstrated that RhoGAPs also regulate numerous aspects of neuronal development and are related to various neurodegenerative diseases in GAP-dependent and GAP-independent manners", "offsetInBeginSection": 349, "offsetInEndSection": 549, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33378678", "text": "ssing phagocytosed cargo. Splicing analysis reveals a role for QKI in regulating microexon networks of the Rho GTPase pathway. We show an increase in ", "offsetInBeginSection": 269, "offsetInEndSection": 419, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33378678", "text": "Overall, our findings identify QKI as an alternative splicing regulator governing a network of Rho GTPase microexons with implications for CNS remyelination and MS patients.", "offsetInBeginSection": 959, "offsetInEndSection": 1109, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25879033", "text": "In this review, we summarize the current understanding of GEFs and GAPs for Rac1, with emphasis on the molecular function and disease implication of these regulators in the nervous system.", "offsetInBeginSection": 1019, "offsetInEndSection": 1169, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35274098", "text": "rns in the adult DM1 brain as a consequence of an imbalance in antagonistic MBNL and CELF1 activities. Our atlas serves as a solid foundation for furt", "offsetInBeginSection": 1056, "offsetInEndSection": 1206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25838543", "text": "The main component of the altered AS program comprises 3- to 27-nucleotide (nt) neural microexons, an emerging class of highly conserved AS events associated with the regulation of protein interaction networks in developing neurons and neurological disorders.", "offsetInBeginSection": 880, "offsetInEndSection": 1040, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eeeaaaf36125a426000004", "type": "factoid", "body": "Beremagene Geperpavec is tested for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35347281"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35347281", "text": "COL7A1 containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. B-VEC restored C7 expression in RDEB keratinocytes, fibroblasts, RDE", "offsetInBeginSection": 311, "offsetInEndSection": 461, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35347281", "text": "These studies show that B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with RDEB.", "offsetInBeginSection": 1378, "offsetInEndSection": 1528, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64138ce8201352f04a000042", "type": "factoid", "body": "Hairpatches is a single gene mutation associated with what disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23301070", "http://www.ncbi.nlm.nih.gov/pubmed/17141278", "http://www.ncbi.nlm.nih.gov/pubmed/19126050"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23301070", "text": "y alopecia. This mutation is a model for the rare human disorder \"glomerulonephritis with sparse hair and telangiectases\" (OMIM 137940). Fine mapping ", "offsetInBeginSection": 200, "offsetInEndSection": 350, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23301070", "text": "The Hairpatches mouse model allows an investigation into the effects of Tal1, a transcription factor characterized by complex regulation patterns, and its effects on renal disease.", "offsetInBeginSection": 1126, "offsetInEndSection": 1276, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19126050", "text": "BACKGROUND\nA three-generation Chinese family with Hailey-Hailey disease (HHD) was identified and characterized. The proband developed HHD with severe ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17141278", "text": "lamp technique. A novel mutation, W1191X, was identified in a family with BS. Expression of the WT or the mutant channel (Na(v)1.5/W1191X) co-transfec", "offsetInBeginSection": 626, "offsetInEndSection": 776, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f9cd0b33942b094c000010", "type": "factoid", "body": "What is the alternative microexon splicing by RBFOX2 and PTBP1 associated with?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34731606", "http://www.ncbi.nlm.nih.gov/pubmed/24307554", "http://www.ncbi.nlm.nih.gov/pubmed/34346508", "http://www.ncbi.nlm.nih.gov/pubmed/32762877", "http://www.ncbi.nlm.nih.gov/pubmed/33184471", "http://www.ncbi.nlm.nih.gov/pubmed/25110022"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34731606", "text": "h has a well-established role in alternative splicing, is linked to heart diseases. However, it is unclear whether RBFOX2 has other roles in RNA proce", "offsetInBeginSection": 12, "offsetInEndSection": 162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32762877", "text": " controls tissue-specific alternative splicing of exons in diverse processes of development. The progenitor cytotrophoblast of the human placenta diff", "offsetInBeginSection": 44, "offsetInEndSection": 194, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25110022", "text": " RNA-binding protein involved in tissue specific alternative splicing regulation and steroid receptors transcriptional activity. Its ability to regula", "offsetInBeginSection": 175, "offsetInEndSection": 325, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24307554", "text": "PTBP1, and RBFOX2, that contribute to establishing these cell type-specific splicing programs. All of the analyzed data sets are freely available in a", "offsetInBeginSection": 843, "offsetInEndSection": 993, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33184471", "text": "ation. These proteins are involved in neurogenesis and have been associated with various neurological conditions. Here, we analyzed Rbfox2 expression ", "offsetInBeginSection": 71, "offsetInEndSection": 221, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32762877", "text": "By studying alternative splicing we further our understanding of placental development, yielding possible insights into preeclampsia, where expression of antiangiogenic isoforms produced through alternative splicing play a critical role in disease development and severity.", "offsetInBeginSection": 1605, "offsetInEndSection": 1755, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508", "text": "licing in CRC cells. RBFOX2 and PTBP1 were found to directly bind to microexon-containing pre-mRNAs and to control their splicing in such cells. Diffe", "offsetInBeginSection": 766, "offsetInEndSection": 916, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f56f7533942b094c000002", "type": "factoid", "body": "Which gene is implicated in Canavan disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28626388", "http://www.ncbi.nlm.nih.gov/pubmed/20129749", "http://www.ncbi.nlm.nih.gov/pubmed/17177147", "http://www.ncbi.nlm.nih.gov/pubmed/25647544", "http://www.ncbi.nlm.nih.gov/pubmed/10704428", "http://www.ncbi.nlm.nih.gov/pubmed/22219087", "http://www.ncbi.nlm.nih.gov/pubmed/18978679", "http://www.ncbi.nlm.nih.gov/pubmed/25177395", "http://www.ncbi.nlm.nih.gov/pubmed/17999961", "http://www.ncbi.nlm.nih.gov/pubmed/26992473", "http://www.ncbi.nlm.nih.gov/pubmed/10701101", "http://www.ncbi.nlm.nih.gov/pubmed/24682784", "http://www.ncbi.nlm.nih.gov/pubmed/10464621", "http://www.ncbi.nlm.nih.gov/pubmed/12108830", "http://www.ncbi.nlm.nih.gov/pubmed/16113575", "http://www.ncbi.nlm.nih.gov/pubmed/11713764", "http://www.ncbi.nlm.nih.gov/pubmed/8088831", "http://www.ncbi.nlm.nih.gov/pubmed/32975148", "http://www.ncbi.nlm.nih.gov/pubmed/24272958", "http://www.ncbi.nlm.nih.gov/pubmed/16138249", "http://www.ncbi.nlm.nih.gov/pubmed/36267868", "http://www.ncbi.nlm.nih.gov/pubmed/12162821", "http://www.ncbi.nlm.nih.gov/pubmed/23253610", "http://www.ncbi.nlm.nih.gov/pubmed/11589315", "http://www.ncbi.nlm.nih.gov/pubmed/15907664", "http://www.ncbi.nlm.nih.gov/pubmed/16217711"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/11589315", "text": "It has an autosomal recessive mode of inheritance, and is caused by mutations in the gene for aspartoacetylase, localized to the short arm of chromosome 17.", "offsetInBeginSection": 206, "offsetInEndSection": 356, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18978679", "text": "PURPOSE\nCanavan disease, caused by a deficiency of aspartoacylase, is one of the most common cerebral degenerative diseases of infancy. The aims of th", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12108830", "text": " leukodystrophy more common among Ashkenazi Jews. The enzyme defect, apartoacylase, has been identified, and the gene cloned. Only two mutations accou", "offsetInBeginSection": 27, "offsetInEndSection": 177, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22219087", "text": "Linkage analysis was performed by typing three short tandem repeat markers D17S1583 (7.19\u00a0cM), D17S1828 (10.02\u00a0cM) and D17S919 (14.69\u00a0cM) for an already-reported gene/locus ASPA at chromosome 17p13.2 causing Canavan disease.", "offsetInBeginSection": 687, "offsetInEndSection": 837, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17177147", "text": "Canavan disease is a childhood leukodystrophy caused by mutations in the gene for human aspartoacylase ( ASPA), which leads to an abnormal accumulation of the substrate molecule N-acetyl-aspartate (NAA) in the brain.", "offsetInBeginSection": 17, "offsetInEndSection": 167, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8088831", "text": "f the brain, is a severe leukodystrophy caused by the deficiency of aspartoacylase (ASPA). Recently, a missense mutation was identified in human ASPA ", "offsetInBeginSection": 41, "offsetInEndSection": 191, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17999961", "text": " over the world. Canavan disease is caused by a genetic mutation in aspartoacylase gene. We have identified a novel mutation, a homozygous C432+1G>A m", "offsetInBeginSection": 196, "offsetInEndSection": 346, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28626388", "text": "Canavan disease is caused by mutations in the gene encoding aspartoacylase (ASPA), a deacetylase that catabolizes N-acetylaspartate (NAA). The precise", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24272958", "text": "orm leukodystrophy caused by an autosomal recessive mutation in the aspartoacylase gene. Deficiency of oligodendroglial aspartoacylase activity and a ", "offsetInBeginSection": 28, "offsetInEndSection": 178, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26992473", "text": "orpus callosum. The genetic testing revealed homozygous mutation of aspartoacylase gene [c.859 G>A (p.Ala287Thr)] in Exon 6.\n\n\nCONCLUSION\nPossibility ", "offsetInBeginSection": 521, "offsetInEndSection": 671, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15907664", "text": "Canavan disease (CD) is an autosomal recessive disorder caused by aspartoacylase (ASPA) gene mutations resulting enzyme deficiency. The homozygous kno", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24682784", "text": "Canavan disease is a leukodystrophy caused by mutations in the ASPA gene. This gene encodes the enzyme that converts N-acetylaspartate into acetate an", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25177395", "text": "Canavan disease (MIM 271900) is a rare autosomal recessive leukodystrophy due to mutations in the ASPA gene (MIM 608034) and characterized by a clinical onset at 3-5\u00a0months of life, macrocephaly and poor head control, weak cry and suck, development regression and hypotonia.", "offsetInBeginSection": 25, "offsetInEndSection": 175, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20129749", "text": "t two novel mutations: c.2T>C/M1T, an initiation codon mutation, and c.209A>G/N70S, which is located at the enzyme-substrate binding site. The combina", "offsetInBeginSection": 133, "offsetInEndSection": 283, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16113575", "text": "gment harboring the Y231X mutation and 0% for the fragment harboring the E285A mutation. One cycle of PGD was performed in each family. In the first, ", "offsetInBeginSection": 1065, "offsetInEndSection": 1215, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23253610", "text": "Canavan disease is a hereditary leukodystrophy caused by mutations in the aspartoacylase gene (ASPA), leading to loss of enzyme activity and increased concentrations of the substrate N-acetyl-aspartate (NAA) in the brain.", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32975148", "text": "ve disorder caused by mutations in ASPA, a gene encoding the enzyme aspartoacylase. Patients present with macrocephaly, developmental delay, hypotonia", "offsetInBeginSection": 70, "offsetInEndSection": 220, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10701101", "text": " Ashkenazi Jewish individuals with two predominant mutations in the aspartoacylase (ASPA) gene. The disease is less frequent in non-Jewish individuals", "offsetInBeginSection": 139, "offsetInEndSection": 289, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8088831", "text": "ty of cross-species hybridization of coding sequences suggests that aspartoacylase has been conserved during evolution. It should now be possible to i", "offsetInBeginSection": 1131, "offsetInEndSection": 1281, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12162821", "text": "This procedure involves neurosurgical administration of approximately 900 billion genomic particles (approximately 10 billion infectious particles) of recombinant adeno-associated virus (AAV) containing the aspartoacylase gene (ASPA) directly to affected regions of the brain in each of 21 patients with Canavan disease.", "offsetInBeginSection": 812, "offsetInEndSection": 962, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16217711", "text": "altered NAA metabolism has been traced to mutations in the gene encoding ASPA, located on chromosome 17 (17p13-ter). We present here a patient with a ", "offsetInBeginSection": 432, "offsetInEndSection": 582, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11713764", "text": "fatal in affected probands. CD is characterized by mutations in the aspartoacylase (ASPA) gene, resulting in loss of enzyme activity. In this review, ", "offsetInBeginSection": 247, "offsetInEndSection": 397, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36267868", "text": "Genetic analysis revealed novel mutations in the aspartoacylase or ASPA gene that possibly accounts for the severe form of Canavan disease, which probably explains the imaging findings.", "offsetInBeginSection": 633, "offsetInEndSection": 783, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16113575", "text": " and is caused by a deficiency of aspartoacylase which is encoded by the ASPA gene. In Ashkenazi Jews, one major mutation (E285A) and one minor mutati", "offsetInBeginSection": 184, "offsetInEndSection": 334, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16138249", "text": "in early childhood. It is an autosomal recessive disorder due to an aspartoacylase (ASPA) deficiency. The causative gene has been mapped to chromosome", "offsetInBeginSection": 96, "offsetInEndSection": 246, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10464621", "text": " the defective enzyme, aspartoacylase. This discovery allowed for accurate diagnosis of the disease. The gene for aspartoacylase has been cloned and t", "offsetInBeginSection": 226, "offsetInEndSection": 376, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25647544", "text": "ges. Urine excretion of N-acetylaspartic acid was grossly increased, suggesting Canavan disease. Mutation screening of the ASPA gene confirmed this di", "offsetInBeginSection": 241, "offsetInEndSection": 391, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10704428", "text": "sease, while prior to that, a brain biopsy was needed. The gene for aspartoacylase has been cloned and two mutations predominate among Ashkenazi Jewis", "offsetInBeginSection": 672, "offsetInEndSection": 822, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24272958", "text": "lved in the partial prevention of spongy degeneration. These observations highlight aquaporin 4 as a potential therapeutic target for Canavan disease.", "offsetInBeginSection": 1499, "offsetInEndSection": 1649, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12162821", "text": "autosomal recessive disease in which the gene coding for the enzyme aspartoacylase (ASPA) is defective. The lack of functional enzyme leads to an incr", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6411b4a8201352f04a000035", "type": "yesno", "body": "Is prosopagnosia also known as lack of auditory recognition?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8954241", "http://www.ncbi.nlm.nih.gov/pubmed/29213598", "http://www.ncbi.nlm.nih.gov/pubmed/10957793", "http://www.ncbi.nlm.nih.gov/pubmed/9606594", "http://www.ncbi.nlm.nih.gov/pubmed/14872395", "http://www.ncbi.nlm.nih.gov/pubmed/17337129", "http://www.ncbi.nlm.nih.gov/pubmed/30625291", "http://www.ncbi.nlm.nih.gov/pubmed/33392335", "http://www.ncbi.nlm.nih.gov/pubmed/16767465"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17337129", "text": "rceptual system seems adequate to allow for recognition, yet recognition cannot take place. Our hypothesis is that a possible cause of associative pro", "offsetInBeginSection": 301, "offsetInEndSection": 451, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10957793", "text": "odies and rhythms persisted over time. She was also impaired in some aspects of visual recognition including prosopagnosia. To study this patient comp", "offsetInBeginSection": 285, "offsetInEndSection": 435, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17337129", "text": " explained through the concepts of dynamic attractors. Although there is no known cure for prosopagnosia, we believe that the focus of any treatment s", "offsetInBeginSection": 1396, "offsetInEndSection": 1546, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33392335", "text": "CONCLUSION\nOur case demonstrates that the presentation of prosopagnosia can be atypical, and visual difficulties might be a clinical manifestation solely of prosopagnosia, which emphasizes the importance of routinely considering face recognition impairment among elderly patients with brain lesions.", "offsetInBeginSection": 1404, "offsetInEndSection": 1554, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16767465", "text": "Prosopagnosia is the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In contrast to the acquire", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9606594", "text": "These results provide further evidence that prosopagnosia does not necessarily reflect a general disorder in exemplar recognition, but can be a face-specific deficit.", "offsetInBeginSection": 457, "offsetInEndSection": 607, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8954241", "text": "ial damage to face recognition units (FRUs). Prosopagnosia without false recognition was seen following near complete destruction of FRUs, but this ty", "offsetInBeginSection": 706, "offsetInEndSection": 856, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14872395", "text": "Agnosia is a neurological recognition deficit that affects a single modality. Visual agnosias include pure object agnosia, prosopagnosia, akinetopsia,", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30625291", "text": "These results indicate that, in some subjects with developmental prosopagnosia, the face recognition deficit is not an isolated impairment but is associated with deficits in other domains, such as auditory perception.", "offsetInBeginSection": 1363, "offsetInEndSection": 1513, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29213598", "text": "ve cortex areas, but there is also a congenital form known as developmental prosopagnosia.\n\n\nOBJECTIVES\nTo describe a case of developmental prosopagno", "offsetInBeginSection": 122, "offsetInEndSection": 272, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415babe690f196b5100000d", "type": "summary", "body": "What is telegenetics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32132456", "http://www.ncbi.nlm.nih.gov/pubmed/11747665", "http://www.ncbi.nlm.nih.gov/pubmed/21799430", "http://www.ncbi.nlm.nih.gov/pubmed/34596296", "http://www.ncbi.nlm.nih.gov/pubmed/33817891", "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "http://www.ncbi.nlm.nih.gov/pubmed/27987158", "http://www.ncbi.nlm.nih.gov/pubmed/35464100", "http://www.ncbi.nlm.nih.gov/pubmed/33225573", "http://www.ncbi.nlm.nih.gov/pubmed/34265143", "http://www.ncbi.nlm.nih.gov/pubmed/25898928", "http://www.ncbi.nlm.nih.gov/pubmed/30825358", "http://www.ncbi.nlm.nih.gov/pubmed/20411313", "http://www.ncbi.nlm.nih.gov/pubmed/20406122", "http://www.ncbi.nlm.nih.gov/pubmed/35833346", "http://www.ncbi.nlm.nih.gov/pubmed/28737998", "http://www.ncbi.nlm.nih.gov/pubmed/34779303", "http://www.ncbi.nlm.nih.gov/pubmed/22498847", "http://www.ncbi.nlm.nih.gov/pubmed/23393646", "http://www.ncbi.nlm.nih.gov/pubmed/25833335", "http://www.ncbi.nlm.nih.gov/pubmed/30559758", "http://www.ncbi.nlm.nih.gov/pubmed/28471436", "http://www.ncbi.nlm.nih.gov/pubmed/29362948"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33225573", "text": "Clinic structure, telegenetics (video and/or telephone consultations) use and acceptability, and professional practices before and during the pandemic were compared.", "offsetInBeginSection": 314, "offsetInEndSection": 464, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11747665", "text": "ical genetics. Patients were randomly allocated to either a telegenetic (cases) or face-to-face (control) conventional clinic. The telegenetic consult", "offsetInBeginSection": 90, "offsetInEndSection": 240, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34265143", "text": "At the University of Pennsylvania (UPenn), a large academic hospital in an urban setting, nearly all genetic counseling (GC) visits for adult-onset disorders within the Department of Neurology were conducted via secure videoconferencing (telegenetics) or telephone between March and December 2020.", "offsetInBeginSection": 241, "offsetInEndSection": 391, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23393646", "text": "re services. Telemedicine may also be effectively utilized in clinical genetics services\u2014an application that has been termed \u201ctelegenetics.\u201d\n\n\nMETHODS", "offsetInBeginSection": 164, "offsetInEndSection": 314, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29362948", "text": "rovided remotely by telephone) and telegenetics (counseling provided remotely using videoconferencing). Little is known about the experience of geneti", "offsetInBeginSection": 185, "offsetInEndSection": 335, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22498847", "text": "re services. Telemedicine may also be effectively utilized in clinical genetics services-an application that has been termed \"telegenetics.\"\n\n\nMETHODS", "offsetInBeginSection": 164, "offsetInEndSection": 314, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25898928", "text": "Telegenetics could be an effective and efficient way of counseling, but its use in Europe is not widely reported, nor is there evidence of international collaboration.", "offsetInBeginSection": 261, "offsetInEndSection": 411, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32132456", "text": "Telegenetics is a satisfactory solution for both patient and provider and provides benefits for rural patients despite ethical, legal, and reimbursement considerations.", "offsetInBeginSection": 424, "offsetInEndSection": 574, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35464100", "text": "Telegenetics is the use of telemedicine to deliver clinical genetic services to patients. During the COVID-19 public health emergency (PHE), telegenet", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34779303", "text": "PURPOSE\nTelegenetics has become the predominant mode of cancer genetic counseling during the COVID-19 pandemic. We sought to identify potential patien", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20406122", "text": "OBJECTIVE\nVideoconferencing for clinical genetics services, or telegenetics, is becoming an increasingly utilized method of delivering genetic counseling to rural areas; however, there has been little qualitative exploration of the practitioner's experience, particularly for hereditary breast/ovarian cancer counseling.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "text": " and professionals. Most telegenetics reports describe applications in large geographical areas, showing positive patients' and professionals' satisfa", "offsetInBeginSection": 204, "offsetInEndSection": 354, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30559758", "text": "Telegenetics, the application of telemedicine in the context of genetic services, is a growing market. One of the recent developments in this field is", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27987158", "text": "Although telegenetics as a telehealth tool for online genetic counseling was primarily initiated to improve access to genetics care in remote areas, t", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20406122", "text": "fficulty in detecting nonverbal cues. Telegenetics was seen as a structured interaction that allowed less time for emotional exploration than a tradit", "offsetInBeginSection": 1058, "offsetInEndSection": 1208, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35833346", "text": "INTRODUCTION\nDirect-to-patient telegenetics, which uses video conferencing to connect health professionals directly to patients' devices, has been widely adopted during the pandemic.", "offsetInBeginSection": 18, "offsetInEndSection": 168, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35833346", "text": "DISCUSSION\nOur results suggest that direct-to-patient telegenetics is a satisfactory service delivery model that does not appear to compromise patient-genetic counsellor relationships or increase patient distress.", "offsetInBeginSection": 1994, "offsetInEndSection": 2144, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33817891", "text": "Telegenetics involves the use of technology (generally video conferencing) to remotely provide genetic services. A telegenetics platform is critical f", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30825358", "text": "r, little is known about the current landscape of clinical telehealth models in the field of genetics (i.e., telegenetics). This survey aimed to addre", "offsetInBeginSection": 119, "offsetInEndSection": 269, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34596296", "text": "pted to set up telegenetic services for patients and families with genetic disorders. Genetic medicine poses special challenges because the unit of co", "offsetInBeginSection": 125, "offsetInEndSection": 275, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25833335", "text": "Telegenetics-genetic counseling via live videoconferencing-can improve access to cancer genetic counseling (CGC) in underserved areas, but studies on cancer telegenetics have not applied randomized methodology or assessed cost.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20411313", "text": "Telegenetics offers an alternative model of delivering genetic counseling to rural and outreach areas; however there is a dearth of qualitative research into the patient's experience.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21799430", "text": "This study compared the effectiveness and acceptability of genetic counseling for hereditary breast and ovarian cancer through videoconferencing (hereafter referred to as \"telegenetics\").", "offsetInBeginSection": 167, "offsetInEndSection": 317, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33817891", "text": "health professionals and that telegenetics provided access to genetics services for underserved communities. The main benefits cited include cost-effe", "offsetInBeginSection": 766, "offsetInEndSection": 916, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21799430", "text": "CONCLUSION\nTelegenetics seems to be an acceptable and effective method of delivering genetic counseling services for hereditary breast and ovarian cancer to underserved areas.", "offsetInBeginSection": 1255, "offsetInEndSection": 1405, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23393646", "text": "CONCLUSIONS\nThis review suggests that telegenetics may be a useful tool for providing routine counseling and has the potential to evaluate pediatric patients with suspected genetic conditions.", "offsetInBeginSection": 1113, "offsetInEndSection": 1263, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34265143", "text": "Surveys included the modified telehealth usability questionnaire (MTUQ), genetic counseling satisfaction scale (GCSS), and novel questions about future telehealth use.", "offsetInBeginSection": 1180, "offsetInEndSection": 1330, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22498847", "text": "CONCLUSIONS\nThis review suggests that telegenetics may be a useful tool for providing routine counseling and has the potential to evaluate pediatric patients with suspected genetic conditions.", "offsetInBeginSection": 1113, "offsetInEndSection": 1263, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28471436", "text": "The telegenetics clinic offers a viable solution to providing competent and convenient access to a geneticist for patients in chronically underserved regions.", "offsetInBeginSection": 1335, "offsetInEndSection": 1485, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28737998", "text": "motional health, ease of access to services, and telegenetics satisfaction/acceptability.\n\n\nRESULTS\n158/174 (90%) participants returned pre- and immed", "offsetInBeginSection": 552, "offsetInEndSection": 702, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f04546f36125a426000024", "type": "summary", "body": "What is the mechanism of action of Mitapivat?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35988546", "http://www.ncbi.nlm.nih.gov/pubmed/33822774", "http://www.ncbi.nlm.nih.gov/pubmed/35366607", "http://www.ncbi.nlm.nih.gov/pubmed/36124781", "http://www.ncbi.nlm.nih.gov/pubmed/27324312", "http://www.ncbi.nlm.nih.gov/pubmed/35576529", "http://www.ncbi.nlm.nih.gov/pubmed/35964609", "http://www.ncbi.nlm.nih.gov/pubmed/34987744", "http://www.ncbi.nlm.nih.gov/pubmed/23089283", "http://www.ncbi.nlm.nih.gov/pubmed/6572387", "http://www.ncbi.nlm.nih.gov/pubmed/36260990", "http://www.ncbi.nlm.nih.gov/pubmed/31483964", "http://www.ncbi.nlm.nih.gov/pubmed/35417638"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35964609", "text": "We aimed to investigate the safety and efficacy of mitapivat (Agios Pharmaceuticals, Cambridge, MA, USA), a pyruvate kinase activator, in adults with non-transfusion-dependent (NTD) \u03b1-thalassaemia or NTD \u03b2-thalassaemia.", "offsetInBeginSection": 303, "offsetInEndSection": 453, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36260990", "text": "Kuo and colleagues1 evaluated the safety and efficacy of mitapivat, an oral pyruvate kinase activator, in\u00a0adults with non-transfusion-dependent \u03b1-thalassemia or \u03b2-thalassemia.", "offsetInBeginSection": 13, "offsetInEndSection": 163, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35576529", "text": "rved. This study provides proof of concept that mitapivat has disease-modifying potential in patients with SCD. This trial was registered at www.clini", "offsetInBeginSection": 1558, "offsetInEndSection": 1708, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546", "text": ") and 24-week fixed-dose period. The primary endpoint was a reduction in transfusion burden (\u226533% reduction in number of RBC units transfused during t", "offsetInBeginSection": 818, "offsetInEndSection": 968, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35366607", "text": "mitapivat yielded potential benefits in HbSS mice. Mitapivat further increased ATP without significantly changing 2,3-DPG or hemoglobin levels, and de", "offsetInBeginSection": 945, "offsetInEndSection": 1095, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35576529", "text": "thophysiology of sickle cell disease (SCD). In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine tripho", "offsetInBeginSection": 60, "offsetInEndSection": 210, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638", "text": "In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency.", "offsetInBeginSection": 158, "offsetInEndSection": 308, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35366607", "text": "y. These factors can be modulated by mitapivat, which activates erythrocyte pyruvate kinase (PKR) and improves sickling kinetics in SCD patients. We i", "offsetInBeginSection": 321, "offsetInEndSection": 471, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31483964", "text": "tic anemia. Mitapivat is an oral, small-molecule allosteric activator of pyruvate kinase in red cells.\n\n\nMETHODS\nIn this uncontrolled, phase 2 study, ", "offsetInBeginSection": 99, "offsetInEndSection": 249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36124781", "text": "XPERT OPINION\nMitapivat is a first-in-class allosteric activator of pyruvate kinase and the first FDA-approved disease directed therapy for PKD. It ha", "offsetInBeginSection": 755, "offsetInEndSection": 905, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34987744", "text": " first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme. Mitapivat has been shown to significantly upregulate both wild", "offsetInBeginSection": 30, "offsetInEndSection": 180, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34987744", "text": "potential efficacy in erythrocyte membranopathies as well. With convenient oral dosing and a safety profile comparable with placebo in adults with PKD", "offsetInBeginSection": 1382, "offsetInEndSection": 1532, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33822774", "text": "Mitapivat reduced duodenal Dmt1 expression potentially by activating the pyruvate kinase M2-HIF2\u03b1 axis, representing a mechanism additional to Hamp in controlling iron absorption and preventing \u03b2-thalassemia-related liver iron overload.", "offsetInBeginSection": 1028, "offsetInEndSection": 1178, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546", "text": " kinase deficiency receiving regular transfusions, and is the first disease-modifying agent approved in this disease.\n\n\nFUNDING\nAgios Pharmaceuticals.", "offsetInBeginSection": 2467, "offsetInEndSection": 2617, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31483964", "text": "CONCLUSIONS\nThe administration of mitapivat was associated with a rapid increase in the hemoglobin level in 50% of adults with pyruvate kinase deficiency, with a sustained response during a median follow-up of 29 months during the extension phase.", "offsetInBeginSection": 1756, "offsetInEndSection": 1906, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35964609", "text": "During a 24-week core period, mitapivat was administered orally at 50 mg twice daily for the first 6 weeks followed by an escalation to 100 mg twice daily for 18 weeks thereafter.", "offsetInBeginSection": 920, "offsetInEndSection": 1070, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33822774", "text": "hrocytes, impacting cell metabolism. We hypothesized that increased pyruvate kinase activity induced by mitapivat (AG-348) in the Hbbth3/+ mouse model", "offsetInBeginSection": 233, "offsetInEndSection": 383, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31483964", "text": "CONCLUSIONS\nThe administration of mitapivat was associated with a rapid increase in the hemoglobin level in 50% of adults with pyruvate kinase deficiency, with a sustained response during a median follow-up of 29 months during the extension phase.", "offsetInBeginSection": 1732, "offsetInEndSection": 1882, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638", "text": "twice daily) or placebo for 24 weeks. The primary end point was a hemoglobin response (an increase from baseline of \u22651.5 g per deciliter in the hemogl", "offsetInBeginSection": 628, "offsetInEndSection": 778, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546", "text": "BACKGROUND\nMitapivat, an oral activator of pyruvate kinase (PK) in red blood cells (RBCs), has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular transfusions.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638", "text": "CONCLUSIONS\nIn patients with pyruvate kinase deficiency, mitapivat significantly increased the hemoglobin level, decreased hemolysis, and improved patient-reported outcomes.", "offsetInBeginSection": 1966, "offsetInEndSection": 2116, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33822774", "text": "controlling iron absorption and preventing \u03b2-thalassemia-related liver iron overload. In ex vivo studies on erythroid precursors from patients with \u03b2-thalassemia, mitapivat enhanced erythropoiesis, promoted erythroid maturation, and decreased apoptosis", "offsetInBeginSection": 1174, "offsetInEndSection": 1426, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283", "text": "The role of the mirror mechanism in cognition remains an intriguing and hotly debated topic in cognitive neuroscience. Since its discovery in the monk", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312", "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.", "offsetInBeginSection": 256, "offsetInEndSection": 406, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36124781", "text": "Mitapivat has been shown to offer early and durable improvement in hemoglobin with reduction in transfusion burden, and preliminary data suggest it can induce a negative iron balance in many patients without the use of dedicated iron chelators.", "offsetInBeginSection": 530, "offsetInEndSection": 680, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6572387", "text": "enylate cyclase activities that are stimulated by human chorionic gonadotropin (hCG) and thyrotropin, respectively. Both cell types also respond to ch", "offsetInBeginSection": 96, "offsetInEndSection": 246, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641357bc201352f04a000039", "type": "yesno", "body": "Do cells undergoing necroptosis show disruption of their cell membranes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27158445", "http://www.ncbi.nlm.nih.gov/pubmed/35365636", "http://www.ncbi.nlm.nih.gov/pubmed/34539677", "http://www.ncbi.nlm.nih.gov/pubmed/30294675", "http://www.ncbi.nlm.nih.gov/pubmed/27834956", "http://www.ncbi.nlm.nih.gov/pubmed/35293986", "http://www.ncbi.nlm.nih.gov/pubmed/28388403", "http://www.ncbi.nlm.nih.gov/pubmed/33848465", "http://www.ncbi.nlm.nih.gov/pubmed/29643440", "http://www.ncbi.nlm.nih.gov/pubmed/32156734", "http://www.ncbi.nlm.nih.gov/pubmed/31138766", "http://www.ncbi.nlm.nih.gov/pubmed/6615313", "http://www.ncbi.nlm.nih.gov/pubmed/30355688", "http://www.ncbi.nlm.nih.gov/pubmed/28388412", "http://www.ncbi.nlm.nih.gov/pubmed/30136239", "http://www.ncbi.nlm.nih.gov/pubmed/24991764", "http://www.ncbi.nlm.nih.gov/pubmed/34698396", "http://www.ncbi.nlm.nih.gov/pubmed/32561730", "http://www.ncbi.nlm.nih.gov/pubmed/30709919", "http://www.ncbi.nlm.nih.gov/pubmed/30341907", "http://www.ncbi.nlm.nih.gov/pubmed/30449002", "http://www.ncbi.nlm.nih.gov/pubmed/31640957"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35293986", "text": "death. Necroptosis is a form of regulated cell death, where cells show necrotic morphology. Necroptosis is triggered by death receptors, toll-like rec", "offsetInBeginSection": 663, "offsetInEndSection": 813, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32156734", "text": "to promote MLKL polymerization. Interestingly, knockdown of Hsp70 in cells leads to MLKL destabilization, suggesting that MLKL might also be a client ", "offsetInBeginSection": 1146, "offsetInEndSection": 1296, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34698396", "text": "quitylation during necroptosis, yet neither the mechanism nor the significance of this event has been demonstrated. Here, we show that necroptosis-spe", "offsetInBeginSection": 324, "offsetInEndSection": 474, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34539677", "text": "oss for species adaptation and suggests that necroptosis is not required for normal mammalian development. Moreover, this study highlights a co-evolut", "offsetInBeginSection": 1534, "offsetInEndSection": 1684, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31138766", "text": " exocytosis. Thus, cells undergoing necroptosis need to overcome these independent suppressive mechanisms before plasma membrane disruption can occur.", "offsetInBeginSection": 664, "offsetInEndSection": 814, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30341907", "text": "ease in cell volume, cell membrane permeabilization, and rupture that lead to cellular demise. Necroptosis is initiated by tumor necrosis factor and o", "offsetInBeginSection": 563, "offsetInEndSection": 713, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28388403", "text": "m MLKL-mediated disruption of the cell membrane. In this issue of Cell, Gong et\u00a0al. challenge the notion that MLKL activation is a point of no return ", "offsetInBeginSection": 83, "offsetInEndSection": 233, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27158445", "text": "Finally, based on current evidence, we discuss the potential mechanisms by which the essential, and possibly terminal, necroptotic effector, MLKL, triggers the disruption of cellular membranes to cause cell lysis.", "offsetInBeginSection": 905, "offsetInEndSection": 1055, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32156734", "text": "neage kinase domain-like protein (MLKL), which mediate proinflammatory cell membrane disruption. We screened compound libraries provided by the Nation", "offsetInBeginSection": 200, "offsetInEndSection": 350, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30355688", "text": "zation and membrane translocation, leading to membrane disruption and a loss of cellular ion homeostasis. It has recently been reported that influenza", "offsetInBeginSection": 443, "offsetInEndSection": 593, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35365636", "text": "Necroptosis is a form of caspase-independent programmed cell death that arises from disruption of cell membranes by the mixed lineage kinase domain-like (MLKL) pseudokinase after its activation by the upstream kinases, receptor interacting protein kinase (RIPK)-1 and RIPK3, within a complex known as the necrosome.", "offsetInBeginSection": 53, "offsetInEndSection": 203, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30294675", "text": "loid-like structure that causes cell membrane disruption resulting in cell death. Although the core necroptosis pathway has been elucidated, the detai", "offsetInBeginSection": 622, "offsetInEndSection": 772, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30449002", "text": "dependent manner. Imaging flow cytometry confirmed that 59% of the cells underwent necroptosis after 3-h incubation with the peptide. It is noteworthy", "offsetInBeginSection": 1396, "offsetInEndSection": 1546, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30355688", "text": "inflammatory in nature owing to the release of danger-associated molecular patterns from the ruptured cell membrane. However, necroptosis also constit", "offsetInBeginSection": 1349, "offsetInEndSection": 1499, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27834956", "text": "In the present study, we discovered that mitochondrial perturbations play a critical role in Smac mimetic/Dexamethasone (Dexa)-induced necroptosis independently of death receptor ligands.", "offsetInBeginSection": 192, "offsetInEndSection": 342, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30136239", "text": "IPK3 (receptor interacting protein kinase 3) is a hallmark of cells dying by necroptosis. RIPK3 phosphorylates both itself and the pseudokinase MLKL (", "offsetInBeginSection": 26, "offsetInEndSection": 176, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6615313", "text": "membranes, fusion between granule and plasma membranes, and disruption of plasma membranes. Communication was established between the exterior of the ", "offsetInBeginSection": 564, "offsetInEndSection": 714, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30449002", "text": "n a concentration-dependent manner. Imaging flow cytometry confirmed that 59% of the cells underwent necroptosis after 3-h incubation with the peptide", "offsetInBeginSection": 1378, "offsetInEndSection": 1528, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30709919", "text": "anslocates to and disrupts the plasma membrane, thereby causing necroptotic cell lysis. Herein, we show that activation of necroptosis in mouse dermal", "offsetInBeginSection": 235, "offsetInEndSection": 385, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31640957", "text": "Annexin V/PI double staining showed that inhibition of cell apoptosis caused an increase in cell necrosis manifested by such changes as mitochondrial swelling and plasma membrane disruption, as shown by electron microscopy; Hoechst staining showed that the percentage of apoptotic cells was significantly reduced.", "offsetInBeginSection": 1082, "offsetInEndSection": 1232, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28388412", "text": "Here, we show that, during necroptosis, MLKL-dependent calcium (Ca2+) influx and phosphatidylserine (PS) exposure on the outer leaflet of the plasma membrane preceded loss of PM integrity.", "offsetInBeginSection": 202, "offsetInEndSection": 384, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24991764", "text": "reof have not been documented before. We demonstrate here that mitochondria are released from cells undergoing tumor necrosis factor-\u03b1 (TNF-\u03b1)-induced", "offsetInBeginSection": 208, "offsetInEndSection": 358, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30449002", "text": "Morphological studies using scanning electron microscopy demonstrated disruption of the plasma membrane from cells treated with LyeTx I-b, including the formation of holes or pores.", "offsetInBeginSection": 715, "offsetInEndSection": 895, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29643440", "text": "pase activity during PFT-induced necroptosis increased the release of alarmins to the extracellular milieu. Caspase-mediated alarmin release was found", "offsetInBeginSection": 899, "offsetInEndSection": 1049, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34539677", "text": "Here, we show, counterintuitively, that in different mammalian lineages, central components of necroptosis, such as RIPK3 and MLKL, are deleted or display inactivating mutations.", "offsetInBeginSection": 650, "offsetInEndSection": 800, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33848465", "text": "We also show that disruption of endosomal trafficking increases cell viability during necroptosis, possibly by preventing recruitment, or removal, of phosphoMLKL from the plasma membrane.", "offsetInBeginSection": 895, "offsetInEndSection": 1045, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32156734", "text": "nhibitor, block the formation of MLKL polymers, but not MLKL tetramers in necroptosis-induced cells. In vitro, recombinant Hsp70 interacts with the N-", "offsetInBeginSection": 596, "offsetInEndSection": 746, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32561730", "text": "rane disruption, although the precise choreography of events is incompletely understood. Here, we use single-cell imaging approaches to map the chrono", "offsetInBeginSection": 227, "offsetInEndSection": 377, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29643440", "text": "-forming toxin (PFT)-induced necroptosis simultaneously experienced caspase activation independently of RIPK3. MLKL deficient REC treated with a pan-c", "offsetInBeginSection": 217, "offsetInEndSection": 367, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33848465", "text": "uring necroptosis. We show that MLKL and phosphoMLKL, key for membrane permeabilization, are exclusively acylated during necroptosis. Reducing the lev", "offsetInBeginSection": 484, "offsetInEndSection": 634, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c3f3690f196b51000005", "type": "summary", "body": "What is the definition of dermatillomania?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25307926", "http://www.ncbi.nlm.nih.gov/pubmed/29463978", "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "http://www.ncbi.nlm.nih.gov/pubmed/24091067", "http://www.ncbi.nlm.nih.gov/pubmed/21323095", "http://www.ncbi.nlm.nih.gov/pubmed/27286530"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24091067", "text": "enticity of which was difficult to confirm. The diagnosis of comorbid factitious disorder with dermatillomania was retained. In view of reducing self-", "offsetInBeginSection": 538, "offsetInEndSection": 688, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "text": "Skin picking disorder, also termed dermatillomania is a condition that leads to repetitive\u00a0picking of their skin ending up in skin and soft tissue damage.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29463978", "text": "Dermatillomania is a rare disease that seldom affects the genitals. Genital dermatillomania has not yet been recognized as a separate entity within th", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21323095", "text": "Dermatillomania is a pathologic grooming disorder characterized by repetitive, ritualistic, impulsive skin picking without an underlying dermatologic condition.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25307926", "text": "Dermatillomania is a disorder in which a person habitually picks their skin, and this is a form of self-injury. It can involve any part of the body, b", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27286530", "text": "At least since the introduction of the official diagnosis Excoriation (Skin-Picking) Disorder in the DSM-5 [1], dermatillomania is an important and growing field of research.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eeeb70f36125a426000005", "type": "factoid", "body": "What disease can be treated with Glofitamab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24286607", "http://www.ncbi.nlm.nih.gov/pubmed/34263696", "http://www.ncbi.nlm.nih.gov/pubmed/9148449", "http://www.ncbi.nlm.nih.gov/pubmed/35626120", "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "http://www.ncbi.nlm.nih.gov/pubmed/36078155", "http://www.ncbi.nlm.nih.gov/pubmed/34953862", "http://www.ncbi.nlm.nih.gov/pubmed/34941996"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34953862", "text": "This is a novel PKPD-based approach for selection of FIH starting dose for a CD20xCD3 bispecific antibody in B-cell lymphoma, evidenced in the glofitamab study, NP30179 (NCT03075696).", "offsetInBeginSection": 1206, "offsetInEndSection": 1356, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34263696", "text": "Glofitamab appears to be a welcome addition to the treatment possibilities for patients with B-cell lymphomas who otherwise have limited therapeutic options.", "offsetInBeginSection": 809, "offsetInEndSection": 959, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36078155", "text": "We report two cases of patients with mantle cell lymphoma who relapsed after CAR T therapy and were treated with the bispecific CD20/CD3 T cell engaging antibody glofitamab.", "offsetInBeginSection": 602, "offsetInEndSection": 752, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35626120", "text": "Our data suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity.", "offsetInBeginSection": 1125, "offsetInEndSection": 1275, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34941996", "text": "30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma. Preclinical studies showed that glofitamab leads to T-cell ", "offsetInBeginSection": 110, "offsetInEndSection": 260, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "text": " I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, with obinutuzumab", "offsetInBeginSection": 174, "offsetInEndSection": 324, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "text": "CONCLUSION\nIn patients with predominantly refractory, aggressive B-NHL, glofitamab showed favorable activity with frequent and durable CRs and a predictable and manageable safety profile.", "offsetInBeginSection": 1742, "offsetInEndSection": 1892, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "text": "This trial included heavily pretreated patients with R/R B-NHL; most were refractory to prior therapy (155; 90.6%) and had received a median of three prior therapies.", "offsetInBeginSection": 839, "offsetInEndSection": 989, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9148449", "text": "The effectiveness of topical steroid application in relieving phimosis was studied in 41 boys treated with a potent steroid ointment. 35 patients show", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24286607", "text": "Osteoarthritis is becoming more problematic as the population ages. Recent reports suggest that the benefit of anti-inflammatory drugs is unimpressive", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}]}